Non-lysosomal glucosylceramidase inhibitors and uses thereof
Compounds specifically targeting non-lysosomal glucosylceramidase (GBA2) address the lack of selectivity in existing inhibitors, effectively treating neurological and liver diseases by modulating glucosylceramide levels and reducing inflammation.
Patent Information
- Application Number
- JP2021566468
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-10
- Filing Date
- 2020-05-07
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2040-05-07
AI Technical Summary
Current small molecule inhibitors of GBA2, such as N-butyldeoxynojirimycin and N-(5-adamantan-1-yl-methoxy)pentyl)-deoxynojirimycin, lack selectivity for GBA2 and inhibit other enzymes, and there is a need for compounds that can effectively modulate glucosylceramide and glycosphingolipid metabolism to treat a wide range of diseases including neurological disorders and liver diseases.
Development of compounds that specifically inhibit non-lysosomal glucosylceramidase (GBA2) with enhanced selectivity and permeability, capable of modulating glucosylceramide and glycosphingolipid levels, thereby treating conditions like Alzheimer's disease, Parkinson's disease, and liver diseases.
The compounds effectively inhibit GBA2 activity, reducing inflammation and alpha-synuclein protein aggregation, increasing glucosylceramide levels, and enhancing GCase activity, providing therapeutic benefits for neurological and liver diseases with improved selectivity and brain penetration.
Smart Images

Figure 0007594548000001 
Figure 0007594548000002 
Figure 0007594548000003
Abstract
Description
[Technical Field]
[0001] This application relates, in part, to compounds that inhibit glucosylceramidase and uses thereof. [Background technology]
[0002] Glucosylceramidase is a group of enzymes that catalyze the hydrolytic cleavage of the β-glucosidic linkage of the glycosphingolipid glucosylceramide (GlcCer, also known as glucocerebroside) to produce D-glucose and ceramide. In humans, there are three unique enzymes that process glucosylceramidase activity: lysosomal β-glucocerebrosidase (GCase or GBA1, EC 3.2.1.45), non-lysosomal glucosylceramidase (GBA2, EC 3.2.1.45), and cytosolic β-glucosidase (GBA3, EC 3.2.1.21). GCase is a lysosomal enzyme encoded by the gene GBA. Homozygous loss-of-function mutations in GBA cause Gaucher disease, a lysosomal storage disorder characterized by the pathological accumulation of glucosylceramide in lysosomes. 1 GBA2 is a membrane-bound protein located on the cytoplasmic side of the endoplasmic reticulum (ER) and Golgi membranes and is expressed at high levels in the central nervous system (CNS). 2,3 GBA3 is a cytosolic enzyme that is expressed primarily in the liver. 3,4
[0003] Glucosylceramidase plays a key role in regulating cellular levels of these substrate molecules, glucosylceramide, which is the simplest member and biosynthetic precursor of a broad class of cell membrane lipids, glycosphingolipids (GSLs). 3,5 Dysregulation of GSL metabolism and homeostasis is implicated in a wide range of diseases, including the neurological disorder Alzheimer's disease (AD); 6 Parkinson's disease (PD), 7 multiple sclerosis (MS), 8Huntington's disease (HD), 9 and amyotrophic lateral sclerosis (ALS); 10 Niemann-Pick disease type C (NPC), a lysosomal storage disorder 11 Mucolipidosis type IV (MLIV), 12 and Sandhoff disease; 13 and non-alcoholic fatty liver disease (NAFLD), a liver disease. 14 and nonalcoholic steatohepatitis (NASH) 14 Small molecule GBA2 inhibitors have been shown to extend lifespan and improve motor coordination in rodent models of NPC. 15、16 Similarly, evidence suggests that inhibition of GBA2 may be associated with MLIV 12 and Sandhoff disease 13 In a murine model of synucleinopathies, small molecule GBA2 inhibitors have been shown to reduce the accumulation of alpha-synuclein aggregates in the brain. 13 Reduction of GBA2 activity has also been demonstrated to ameliorate the clinical picture in a rodent model of Gaucher disease. 17 In addition, studies have shown that GBA2 is involved in regulating inflammatory responses. 2 and that reducing GBA2 activity reduces inflammation in a cell model of cystic fibrosis (CF). 18 Increased glucosylceramide levels are associated with nonalcoholic steatohepatitis (NASH). 19 ,hepatitis 20 , hepatocellular carcinoma (HCC) 21 , autoimmune cholangitis 22 , and drug-induced liver injury (DILI) 23 They have also demonstrated beneficial effects in rodent models of liver disease, including The enzymatic activity of GBA2 can be pharmacologically blocked by the iminosugars N-butyldeoxynojirimycin (NB-DNJ, miglustat) and N-(5-adamantan-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNM, Genz-529648), but these compounds are not selective for GBA2 and also exhibit inhibitory activity against other enzymes, including GCase, glucosylceramide synthase (GCS, EC 2.4.1.80), and intestinal α-glucosidase. 24
[0004] International Patent Application No. PCT / GB2003 / 003099, filed July 17, 2003, published January 22, 2004, under WO 2004 / 007453; International Patent Application No. PCT / GB2004 / 002450, filed June 9, 2004, published December 23, 2004, under WO 2004 / 111001; International Patent Application No. PCT / GB2004 / 002450, filed June 9, 2004, published December 23, 2004, under WO 2004 / 111002 International Patent Application No. PCT / GB2004 / 002451, filed January 11, 2005, published July 28, 2005, with WO 2005 / 068426; International Patent Application No. PCT / GB2005 / 000071, filed March 23, 2015, published October 1, 2015, with WO 2015 / 147639, are directed to small molecule inhibitors of GBA2. Summary of the Invention
[0005] The present invention provides, in part, compounds, prodrugs of compounds, uses of compounds and prodrugs for inhibiting non-lysosomal glucosylceramidase (GBA2), pharmaceutical compositions containing the compounds or prodrugs of the compounds, and methods for treating diseases and disorders modulated by dysregulation of GBA2 activity levels and / or glucosylceramide levels, and / or glycosphingolipid metabolism or homeostasis. In certain embodiments, the present invention provides compositions and methods for preventing and / or treating neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis, lysosomal storage diseases, including Gaucher disease, Niemann-Pick disease type C, mucolipidosis type IV, and Sandhoff disease, or liver diseases, including nonalcoholic steatohepatitis (NASH), by administering to a patient in need thereof an effective amount of one or more compounds or prodrugs of compounds described herein.
[0006] In one aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0007] [ka] (I)
[0008] In the formula, R 1 may be H, and R 2 may be CH3, CH2F, or CHF2, or R 1 may be CH3 or CH2F, R 2 may be H, R 3 is (CH2) n R 4 where n may be 1 or 2, and R 4are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which may be one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 optionally substituted with one to a maximum of alkoxy and / or CF3 substituents; R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents; or R 3is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth,
[0009] [ka] where R may be 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 and may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF3, and / or CF3 substituents.
[0010] In another embodiment, the present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof:
[0011] [ka] (Ia)
[0012] In the formula, R 2 may be CH3, CH2F, or CHF2; R 3 is (CH2) n R 4 where n may be 1 or 2, and R 4are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which may be one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 optionally substituted with one to a maximum of alkoxy and / or CF3 substituents; R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents; or R 3is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth,
[0013] [ka] where R may be 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 and may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF3, and / or CF3 substituents.
[0014] In another embodiment, the present invention provides a compound of formula (Ib) or a pharmaceutically acceptable salt thereof:
[0015] [ka] (Ib)
[0016] In the formula, R 1 may be CH3 or CH2F, R 3 is (CH2) n R 4 where n may be 1 or 2, and R 4are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which may be one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 optionally substituted with one to a maximum of alkoxy and / or CF3 substituents; R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents; or R 3is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth,
[0017] [ka] where R may be 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 and may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF3, and / or CF3 substituents.
[0018] In another embodiment, the present invention provides a compound of formula (Ic) or a pharmaceutically acceptable salt thereof:
[0019] [ka] (I C)
[0020] In the formula, R 3 is (CH2) n R 4 where n may be 1 or 2, and R 4are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which may be one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 optionally substituted with one to a maximum of alkoxy and / or CF3 substituents; R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents; or R 3is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth,
[0021] [ka] where R may be 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 and may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF3, and / or CF3 substituents.
[0022] In another embodiment, the present invention provides a compound of formula (Id) or a pharmaceutically acceptable salt thereof:
[0023] [ka] (Id)
[0024] In the formula, R 3 is (CH2) n R 4 where n may be 1 or 2, and R 4are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which may be one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 optionally substituted with one to a maximum of alkoxy and / or CF3 substituents; R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents; or R 3is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth,
[0025] [ka] where R may be 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 and may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF3, and / or CF3 substituents.
[0026] In another embodiment, the present invention provides a compound of formula (Ie) or a pharmaceutically acceptable salt thereof: [ka] (Ie)
[0027] In the formula, R 6 and R 7 are H, F, Cl, C 1-6 In some embodiments, R 6 may be H, and R 7may be CF, 2-fluoropropan-2-yl, isopropyl, or tert-butyl. 6 may be CF3, 2-fluoropropan-2-yl, isopropyl, or tert-butyl; R 7 may be H.
[0028] In another embodiment, the present invention provides a compound of formula (If) or a pharmaceutically acceptable salt thereof: [ka] (If)
[0029] In the formula, R 6 and R 7 are H, F, Cl, C 1-6 may be independently selected from the group consisting of alkyl, OCH3, phenyl, cyclopropyl, vinyl, methoxymethyl, 2-fluoropropan-2-yl, and / or CF3.
[0030] In another embodiment, the present invention provides a compound of formula (Ig) or a pharmaceutically acceptable salt thereof: [ka] (Ig)
[0031] In the formula, R 8 , R 9 , and R 10 are pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, H, F, Cl, C 1-6In some embodiments, R 8 , R 9 , and R 10 may be independently selected from the group consisting of H, F, Cl, tetrahydro-2H-pyran-4-yl, 4-morpholino, pyrrolidin-1-yl, and piperidin-1-yl.
[0032] In another embodiment, the present invention provides a compound of formula (Ih) or a pharmaceutically acceptable salt thereof: [ka] (Ih)
[0033] In the formula, R 8 , R 9 , and R 10 are H, F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 alkoxy, and / or CF3.
[0034] In another embodiment, the present invention provides a compound of formula (Ii) or a pharmaceutically acceptable salt thereof: [ka] (II) In the formula, R 8 , R 9 , and R 10 are H, F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 In some embodiments, R 8 , R 9 , and R 10 may be independently selected from the group consisting of H, F, and CF3.
[0035] In another embodiment, the present invention provides a compound of formula (Ij) or a pharmaceutically acceptable salt thereof: [ka] (Ij) In the formula, R 11 is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 It may be independently selected from the group consisting of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl.
[0036] In another embodiment, the present invention provides a compound of formula (Ik) or a pharmaceutically acceptable salt thereof: [ka] (Ik)
[0037] In the formula, R 12 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 In some embodiments, R may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each of which may be substituted with from one to a maximum of alkoxyl, OCF, and / or CF substituents. 12 may be selected from the group consisting of 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
[0038] In another embodiment, the present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof: [ka] (Il)
[0039] In the formula, R 12 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 In some embodiments, R may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each of which may be substituted with from one to a maximum of alkoxyl, OCF, and / or CF substituents. 12 may be selected from the group consisting of 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
[0040] In another embodiment, the present invention provides a compound of formula (Im) or a pharmaceutically acceptable salt thereof: [ka] (Im)
[0041] In the formula, R 12 is one or more of F, Cl, C 1-6 Alkyl, C 1-6In some embodiments, R may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each of which may be substituted with from one to a maximum of alkoxyl, OCF, and / or CF substituents. 12 may be selected from the group consisting of 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
[0042] In another embodiment, the present invention provides a compound of formula (In) or a pharmaceutically acceptable salt thereof: [ka] (In)
[0043] In the formula, R 12 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 In some embodiments, R may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each of which may be substituted with from one to a maximum of alkoxyl, OCF, and / or CF substituents. 12may be selected from the group consisting of 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
[0044] In another embodiment, the compound may be a prodrug, the compound may inhibit non-lysosomal glucosylceramidase (GBA2), the compound may inhibit GBA2 (e.g., mammalian GBA2), the compound may inhibit wild-type GBA2, or the compound may inhibit mutant GBA2. In another embodiment, the compounds according to Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Il), Formula (Im), or Formula (In) may exhibit enhanced selectivity and / or permeability.
[0045] In another embodiment, the compound according to Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Il), Formula (Im), or Formula (In) may exhibit enhanced selectivity and / or permeability. In another embodiment, the compounds according to Formula (Ie), Formula (Ig), Formula (Ik), Formula (Il), Formula (Im), or Formula (In) may exhibit enhanced selectivity and / or permeability.
[0046] In another embodiment, a compound according to Formula (Ic), Formula (Ie), or Formula (Ig), Formula (Ik), Formula (Il), Formula (Im), or Formula (In) can exhibit enhanced selectivity. In another embodiment, a compound according to Formula (Ie) can exhibit enhanced selectivity. In another embodiment, a compound according to Formula (Ig) can exhibit enhanced selectivity. In another embodiment, a compound according to Formula (Ik) or Formula (Il) can exhibit enhanced selectivity. In another embodiment, a compound according to Formula (Im) or Formula (In) can exhibit enhanced selectivity.
[0047] In another embodiment, a compound according to Formula (Ic), Formula (Ie), Formula (Ig), Formula (Ii), Formula (Ik), Formula (Il), Formula (Im), or Formula (In) can achieve high brain concentrations when administered in vivo. In another embodiment, a compound according to Formula (Ie) can achieve high brain concentrations when administered in vivo. In another embodiment, a compound according to Formula (Ig) can achieve high brain concentrations when administered in vivo. In another embodiment, a compound according to Formula (Ii) can achieve high brain concentrations when administered in vivo. In another embodiment, a compound according to Formula (Ik) or Formula (Il) can achieve high brain concentrations when administered in vivo. In another embodiment, a compound according to Formula (Im) or Formula (In) can achieve high brain concentrations when administered in vivo. In an alternative aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
[0048] In another aspect, the present invention provides a method for inhibiting GBA2 in a subject in need thereof, or for treating a neurological disease, or a lysosomal storage disease, or a liver disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (I), including any one or more of formulae (Ia) to (In) described herein, or a pharmaceutically acceptable salt thereof. Neurological disorders include, but are not limited to, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), addiction, anxiety, argyrophilic grain dementia, ataxia-telangiectasia (AT), attention-deficit / hyperactivity disorder (ADHD), autism spectrum disorder (ASD), Becker muscular dystrophy (BMD), bipolar disorder (BD), Bluit disease, cerebellar ataxia, Charcot-Marie-Tooth disease (CMT), chronic fatigue syndrome, corticobasal degeneration (CBD), dementia pugilistica (D). pugilistica, dementia with Lewy bodies (DLB), Dejerine-Sottas disease, diffuse neurofibrillary tangles with calcifications, Down syndrome, Duchenne muscular dystrophy (DMD), epilepsy, essential tremor (ET), familial British dementia, familial Danish dementia, fibromyalgia, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Friedreich's ataxia, Gerstmann-Sträussler-Scheinker disease, glaucoma, Guadeloupean parkinsonism, Guillain-Barré syndrome, Hallervorden-Spatz disease (neurodegeneration with brain iron accumulation type 1)1), insomnia, Lambert-Eaton myasthenic syndrome (LEMS), major depressive disorder (MDD), migraine, mild cognitive impairment (MCI), multi-infarct dementia, multiple system atrophy (MSA), myasthenia gravis, myotonic dystrophy (including DM1 and DM2), neuronal ceroid lipofuscinosis (including types 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10), neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), oculopharyngeal muscular dystrophy, pain, pallido-ponto-nigral degeneration, parkinsonism-dementia complex of Guam, Pick's disease (PiD), post-encephalitic parkinsonism parkinsonism (PEP), primary lateral sclerosis (PLS), prion diseases (including Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD), fatal familial insomnia, and kuru), progressive supercortical gliosis, progressive supranuclear palsy (PSP), Richardson syndrome, schizophrenia, seizures, spinal cord disorders, spinal muscular atrophy (SMA), spinocerebellar ataxias (including types 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, and 29), stroke, subacute sclerosing panencephalitis, tangle-only dementia The cause may be dementia, tardive dyskinesia, Tourette's syndrome (TS), vascular dementia, or Wilson's disease.
[0049] The lysosomal storage disease can be, but is not limited to, Gaucher disease (including types I, II, and III), Niemann-Pick disease (including types A, B, and C), mucolipidosis (including types I, II, III, IV, VI, and VII), cerebrotendineous xanthomatosis, Fabry disease, Farber disease, GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy (MLD), multiple sulfatase deficiency, Pompe disease, Sandhoff disease, or Tay-Sachs disease.
[0050] The liver disease can be, but is not limited to, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), Alagille syndrome, alcohol-related liver disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, autoimmune cholangitis, benign liver tumors, biliary atresia, cirrhosis, Crigler-Najjar syndrome, drug-induced liver injury (DILI), galactosemia, Gilbert syndrome, hemochromatosis, hepatic encephalopathy, hepatocellular carcinoma (HCC), intrahepatic cholestasis of pregnancy (ICP), lysosomal acid lipase deficiency (LAL-D), liver cysts, liver cancer, newborn jaundice, primary sclerosing cholangitis (PBC), primary biliary cholangitis (PSC), Reye's syndrome, glycogen storage disease type I, or viral hepatitis (including types A, B, C, D, and E).
[0051] In another embodiment, the present invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering to the subject an effective amount of any one or more compounds of Formula (Ic), Formula (Ie), Formula (Ig), Formula (Ii), Formula (Ik), Formula (Il), Formula (Im), or Formula (In), or a pharmaceutically acceptable salt thereof, as described herein. In another embodiment, the present invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (Ie), or a pharmaceutically acceptable salt thereof, as described herein. In another embodiment, the present invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (Ig), or a pharmaceutically acceptable salt thereof, as described herein. In another embodiment, the present invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (Ik), or a pharmaceutically acceptable salt thereof, as described herein. In another embodiment, the present invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (II) as described herein, or a pharmaceutically acceptable salt thereof. In another embodiment, the present invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (Im) as described herein, or a pharmaceutically acceptable salt thereof. In another embodiment, the present invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (In) as described herein, or a pharmaceutically acceptable salt thereof.
[0052] In another embodiment, administration can reduce the enzyme activity level of GBA2 in a subject. In another embodiment, administration can regulate the level of glucosylceramide and / or glycosphingolipid in a subject. In another embodiment, administration can increase the level of glucosylceramide in a subject. In another embodiment, administration can increase the level of ganglioside GM1 in a subject. In another embodiment, administration can regulate the level of ceramide, and / or glucosylsphingosine, and / or sphingosine, and / or sphingosine-1-phosphate in a subject. The subject may be a human.
[0053] In another embodiment, the present invention provides the use of an effective amount of a compound of Formula (I), including any one or more of Formulae (Ia)-(In) described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament, which may be for inhibiting GBA2, treating a condition modulated by GBA2, or treating a neurological disease, or a lysosomal storage disease, or a liver disease. This summary does not necessarily describe all features of the present invention. DETAILED DESCRIPTION OF THE INVENTION
[0054] The present invention provides, in part, compounds and uses thereof for inhibiting non-lysosomal glucosylceramidase (GBA2).
[0055] "Non-lysosomal glucosylceramidase" or "GBA2" refers to a non-lysosomal membrane-bound enzyme (EC 3.2.1.45) located on the cytoplasmic side of the ER and Golgi membranes, which has glucosylceramidase activity that catalyzes the hydrolytic cleavage of the β-glucosidic linkage of the glycolipid glucosylceramide. Alternative names for GBA2 include NLGase, glucosylceramidase β2, β-glucocerebrosidase 2, β-glucosidase 2, glucosylceramidase 2, bile acid β-glucosidase, "glucosidase, β (bile acid) 2," KIAA1605, DKFZp762K054, SPG46, and AD035. In some embodiments, the GBA2 can be mammalian GBA2, such as rat, mouse, or human GBA2. The GBA2 can be wild-type GBA2 or a mutant GBA2. In some embodiments, GBA2 can be a wild-type mammalian GBA2, such as a rat, mouse, or human wild-type GBA2. In some embodiments, GBA2 can be a mutant mammalian GBA2, such as a rat, mouse, or human mutant GBA2. In some embodiments, GBA2 can have the sequence set forth in any one of the following accession numbers: Q9HCG7, Q69ZF3, D3DRP2, Q5TCV6, Q96A51, Q96LY1, Q96SJ2, Q9H2L8, Q5M868, or O16581. In other embodiments, GBA2 can have an alternative splicing isoform sequence set forth in any one of the following accession numbers: Q9HCG7-1, Q9HCG7-2, or Q9HCG7-3.In another embodiment, GBA2 is selected from the group consisting of the following accession numbers: NP_065995.1, NP_001317589.1, NP_766280.2, NP_001013109.2, NM_020944, NM_172692, NM_001330660, XM_011517973, XP_005251583.1, XP_006716872.1, XP_011516275.1, XP_01 In another embodiment, the human GBA2 can have the sequence set forth below.
[0056]
number
[0057] In certain embodiments, one or more compounds of the present invention can inhibit the activity of GBA2, e.g., the ability to inhibit the cleavage of glucose from glucosylceramide or the ability to inhibit the cleavage of glucose from an appropriate substrate molecule, such as 4-methylumbelliferone-β-D glucopyranoside. "Inhibit," "inhibition," or "inhibiting" refers to a decrease in GBA2 activity by any value between about 10% and about 90%, or any value between about 30% and about 60%, or even greater than 100%, or a decrease of about 1-fold, 2-fold, 5-fold, 10-fold, or more, compared to a reference sample or compound, or compared to wild-type GBA2. It should be understood that inhibition does not require complete inhibition. In certain embodiments, the inhibition may be temporary, e.g., for a period of 5 minutes to 60 minutes, 1 hour to 5 hours, 1 hour to 12 hours, 1 hour to 24 hours, 24 hours to 48 hours, 1 day to 2 days, 1 day to 5 days, 1 day to 7 days, 1 day to 14 days, 1 day to 28 days, or any specific time within any of these ranges, e.g., 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 60 minutes, 1.5 hours, 2 hours, 2 The period of time for the inhibition of GBA2 may be 0.5 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 1.5 days, 2 days, 2.5 days, 3 days, 3.5 days, 4 days, 4.5 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days. In some embodiments, the inhibition may be localized. For example, one or more compounds of the present invention may inhibit GBA2 in a specific cellular compartment, such as the endoplasmic reticulum (ER) or Golgi apparatus (Golgi), or one or more compounds of the present invention may inhibit GBA2 in a specific tissue type, such as the brain or liver.
[0058] In certain embodiments, one or more compounds of the present invention may specifically bind to GBA2. In another embodiment, one or more compounds of the present invention may specifically bind to the active site of GBA2. In certain embodiments, one or more compounds of the present invention that specifically bind to the active site of GBA2 may also inhibit the activity of GBA2. In another embodiment, one or more compounds of the present invention may specifically bind to human non-lysosomal glucosylceramidase (GBA2) over human lysosomal glucosylceramidase (CCase) and / or human cytosolic glucosylceramidase (GBA3). In another embodiment, one or more compounds of the present invention may specifically bind to human non-lysosomal glucosylceramidase (GBA2) over human glucosylceramide synthase (GCS). In another embodiment, one or more compounds of the present invention can specifically bind to human non-lysosomal glucosylceramidase (GBA2) over intestinal alpha-glucosidase, where the intestinal alpha-glucosidase can be sucrase-isomaltase or maltase-glucoamylase. By "specifically bind," we mean a compound that binds to GBA2 but does not substantially bind to other molecules in a sample, such as lactase, sucrase, maltase, isomaltase, sucrase-isomaltase, glucoamylase, maltase-glucoamylase, glucosylceramide synthase, alpha-glucosidase II, ER alpha-glucosidase, intestinal alpha-glucosidase, glycogen phosphorylase, acid alpha-glucosidase, β-hexosaminidase, O-GlcNAcase, GCase, or GBA3.By "does not substantially bind" is meant a binding specificity in the range of about 5-fold to about 100,000-fold, or about 10-fold to about 100,000-fold, or about 100-fold to about 100,000-fold, or about 100-fold to about 100,000-fold, or about 1000-fold to about 100,000-fold, or at least about 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, 1000-fold, 1500-fold, 2000-fold, 2500-fold, 3000-fold, 3500-fold, 4000-fold, 4500-fold, 5000-fold, 6000-fold, 7000-fold, 10,000-fold, 25,000-fold, 50,000-fold, 75,000-fold, or any value within or near the recited range, where "binding specificity" is the ratio of the corresponding binding constants, i.e., Ki. (他の分子) / Ki (GBA2) means or corresponds to IC 50 The ratio of IC 50(他の分子) / I C 50(GBA2)Examples of compounds that exhibit enhanced binding specificity include, but are not limited to, the compounds of Examples 7, 9, 11, 12, 13, 20, 24, 45, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 70, 71, 73, 114, 115, 116, 117, 118, 119, 120, 129, 131, 136, 137, 138, 139, 140, 141, 142, 147, 151, or 152. In certain embodiments, one or more compounds of the invention may exhibit increased binding specificity or increased selectivity compared to a suitable reference compound, such as, for example, N-butyldeoxynojirimycin (NB-DNJ, miglustat) or N-(5-adamantan-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNM, Genz-529648). In certain embodiments, "enhanced specificity" or "enhanced selectivity" refers to any value between about 10% and about 100%, or any integer value between about 10% and about 100%, e.g., about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%, or an increase in binding specificity (as defined above) measured relative to a suitable reference compound, or in the range of about 1-fold to about 100,000-fold, or about 5-fold to about 100,000-fold, or about 10-fold to about 100,000-fold, or about "Increase" refers to an increase in the range of 1000-fold to about 100,000-fold, or at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, 450-fold, 500-fold, 1000-fold, 1500-fold, 2000-fold, 2500-fold, 3000-fold, 3500-fold, 4000-fold, 4500-fold, 5000-fold, 6000-fold, 7000-fold, 10,000-fold, 25,000-fold, 50,000-fold, 75,000-fold, 100,000-fold, or any value within or near the recited range or greater.
[0059] In certain embodiments, one or more compounds of the present invention can inhibit the cleavage of glucose from glucosylceramide by GBA2. In certain embodiments, one or more compounds of the present invention can inhibit the aggregation of α-synuclein protein and / or inhibit the formation of Lewy bodies. "Inhibit," "inhibition," or "inhibiting" refers to any value between about 10% and about 90%, or any value between about 30% and about 60%, or even a greater than 100% decrease, or about a 1-fold, 2-fold, 5-fold, 10-fold, or greater decrease, compared to a reference sample or compound, or compared to wild-type GBA2. It should be understood that inhibition does not require complete inhibition. In certain embodiments, inhibition can be temporary.
[0060] In certain embodiments, one or more compounds of the present invention can reduce CNS inflammation. In certain embodiments, one or more compounds of the present invention can reduce alpha-synuclein protein aggregation and / or Lewy body formation. By "decreasing" or "decrease" is meant any value between about 5% and about 90%, or any value between about 30% and about 60%, or even a decrease of more than 100%, or a decrease of about 1-fold, 2-fold, 5-fold, 10-fold, 15-fold, 25-fold, 50-fold, 100-fold, or more, compared to a reference sample or compound.
[0061] In certain embodiments, one or more compounds of the present invention can elevate glucosylceramide levels. In certain embodiments, one or more compounds of the present invention can elevate glycosphingolipid levels. In certain embodiments, one or more compounds of the present invention can elevate GM1 ganglioside levels. "Elevating" or "enhancing" or "increasing" refers to an increase of any value between about 5% and about 90%, or any value between about 30% and about 60%, or even greater than 100%, or an increase of about 1-fold, 2-fold, 5-fold, 10-fold, 15-fold, 25-fold, 50-fold, 100-fold, or more, compared to a reference sample or compound. In certain embodiments, one or more compounds of the present invention can elevate glucosylceramide levels, and / or glycosphingolipid levels, and / or GM1 ganglioside levels in the brain.
[0062] In certain embodiments, one or more compounds of the present invention can increase GCase activity levels and / or GCase protein levels in vivo and can be effective in treating conditions requiring or responsive to increased GCase activity. In certain embodiments, one or more compounds of the present invention can increase GCase activity levels and / or GCase protein levels in vivo, particularly through interaction with GBA2, and can be effective in treating conditions requiring or responsive to increased GCase activity. "Increasing" or "enhancing" or "increasing" refers to any increase between about 5% and about 100%, e.g., about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or even greater than 100%, or about a 1-fold, 2-fold, 5-fold, 10-fold, 15-fold, 25-fold, 50-fold, 100-fold, or greater increase, compared to a reference sample or compound, or compared to wild-type or mutant GCase.
[0063] In certain embodiments, one or more compounds of the present invention may exhibit enhanced permeability. Permeability can be assessed using a variety of standard experimental techniques, including, but not limited to, in situ perfusion, ex vivo tissue diffusion, in vitro cell monolayers (e.g., Caco-2 cells, MDCK cells, LLC-PK1 cells), and artificial cell membranes (e.g., PAMPA assay), and can be measured as effective permeability (P eff ) or apparent transmittance (P app Suitable techniques for measuring P are reviewed, for example, by Volpe in The AAPS Journal, 2010, 12(4), 670-678. In certain embodiments, one or more compounds of the present invention may be used to measure P eff or P app In some embodiments, a compound exhibiting enhanced permeability may exhibit increased oral absorption. In some embodiments, a compound exhibiting enhanced permeability may exhibit increased brain penetration when administered in vivo. In some embodiments, a compound exhibiting enhanced permeability may achieve high brain concentrations when administered in vivo. Examples of compounds that exhibit high brain concentrations when administered in vivo include, but are not limited to, the compounds of Examples 7, 12, 45, 49, 70, and 85. In some embodiments, a compound exhibiting enhanced permeability may exhibit high brain / plasma concentrations when administered in vivo. In some embodiments, "enhanced permeability" refers to a measured P relative to a suitable reference compound, such as N-butyldeoxynojirimycin (NB-DNJ, miglustat) or N-(5-adamantan-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNM, Genz-529648). eff or P appIn one embodiment, "enhanced permeability" refers to any value between about 10% and about 100%, or any integer value between about 10% and about 100%, e.g., about a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than a 100% increase in P. In one embodiment, "enhanced permeability" refers to an increase in P using an in vitro cell monolayer. app measurable P by an appropriate assay app In one embodiment, "enhanced permeability" refers to a P value (i.e., a value greater than 0) measured using an in vitro cell monolayer. app 2 x 10 -6 P exceeding cm / s app In another embodiment, "enhanced permeability" refers to a P value measured using an in vitro cell monolayer. app 2 x 10 -6 cm / s~40×10 -6 P in the cm / s range app In certain embodiments, "high brain concentration" refers to any value between about 10% and about 100%, or any integer value between about 10% and about 100%, e.g., about a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or greater than 100%, or about a 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, or 50-fold or greater increase in measured brain concentration when a compound is administered in vivo compared to a suitable reference compound, such as, for example, N-butyldeoxynojirimycin (NB-DNJ, miglustat) or N-(5-adamantan-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNM, Genz-529648).
[0064] The "reference compound" or "control" may be a carbohydrate mimetic iminosugar that is a GBA2 inhibitor and has been described in the literature. Examples of reference compounds or controls that are GBA2 inhibitors include, but are not limited to, N-butyldeoxynojirimycin (NB-DNJ, miglustat) and N-(5-adamantan-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNM, Genz-529648). 24
[0065] In certain embodiments, the present invention provides compounds generally described by formula (I), including any one or more of formulae (Ia)-(In), and salts, prodrugs, and enantiomeric forms thereof.
[0066] [ka] (I)
[0067] As described in formula (I), R 1 may be H, and R 2 may be CH3, CH2F, or CHF2, or R 1 may be CH3 or CH2F, R 2 may be H, R 3 is (CH2) n R 4 where n may be 1 or 2, and R 4are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which may be one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 optionally substituted with one to a maximum of alkoxy and / or CF3 substituents; R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents; or R 3is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth,
[0068] [ka] may be where R 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 and may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF3, and / or CF3 substituents.
[0069] In some embodiments, R according to formula (I) 1 may be H, CH, or CHF. In some embodiments, R 1 may be CH3. In some embodiments, R 1 may be CHF. In some embodiments, R 1 may be H, provided that R 2 The condition is that is not H.
[0070] In some embodiments, R according to formula (I) 2 may be H, CH, CHF, or CHF. In some embodiments, R 2may be CHF. In some embodiments, R 2 may be CHF2. In one embodiment, R 2 may be CH3. In some embodiments, R 2 may be H, provided that R 1 The condition is that is not H.
[0071] In some embodiments, R according to formula (I) 3 is (CH2) n R 4 where n may be 1 or 2, and R 4 are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which may be one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 alkoxy, and / or CF3, or R 3is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents; or R 3 is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 or (1-formylpiperidin-4-yl)methyl substituted at the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth,
[0072] [ka] where R may be 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 and may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF3, and / or CF3 substituents.
[0073] In one embodiment, R 3 is (CH2)n R 4 where n may be 1 or 2, and R 4 are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)methyl, ([1,1'-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which may be one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 It may be substituted with one to a maximum of alkoxy and / or CF3 substituents.
[0074] In one embodiment, R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6It may be phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents.
[0075] In one embodiment, R 3 is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7 It may be (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl.
[0076] In one embodiment, R 3 teeth, [ka] where R may be 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 In some embodiments, R may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF, and / or CF substituents. 3 (CH2) n R 4 where n may be 1, and R 4 is one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6It may also be cyclohexyl or 1-phenylpiperidin-4-yl, each optionally substituted with from one to a maximum number of alkoxy and / or CF3 substituents.
[0077] In one embodiment, R 3is cyclohexylmethyl, (4,4-dimethylcyclohexyl)methyl, (4,4-difluorocyclohexyl)methyl, (4,4-dichlorocyclohexyl)methyl, (4-ethylcyclohexyl)methyl, ((1s,4S)-4-vinylcyclohexyl)methyl, ((1s,4S)-4-isopropylcyclohexyl)methyl, ((1r,4R)-4-isopropylcyclohexyl)methyl, 4-(tert-butyl)cyclohexyl)methyl, ((1s,4S)-4-(tert-butyl)cyclohexyl)methyl, ( (1r,4R)-4-(tert-butyl)cyclohexyl)methyl, ((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl, ((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl, ((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((trans)-3-(trifluoromethyl)cyclohexyl)methyl, ((cis)-3-(trifluoromethyl)cyclo (1s,4S)-4-methoxycyclohexyl)methyl, (1r,4R)-4-methoxycyclohexyl)methyl, (4-(methoxymethyl)cyclohexyl)methyl, (1s,4S)-4-cyclopropylcyclohexyl)methyl, (1r,4R)-4-cyclopropylcyclohexyl)methyl, (4-phenylcyclohexyl)methyl, (spiro[2.5]octan-6-yl)methyl, (spiro[3.5]nonan-7-yl)methyl, (spiro[4.5]decan-8-yl)methyl, 2-cyclohexyl cyclohexylethyl, 2-(4,4-difluorocyclohexyl)ethyl, 2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-(adamantan-1-yl)ethyl, 3-cyclohexylpropyl, phenethyl, 2-methylphenethyl, 2-methoxyphenethyl, 2-fluorophenethyl, 2-chlorophenethyl, 2,3-difluorophenethyl, 2,4-difluorophenethyl, 2,5-difluorophenethyl, 3,4-Difluorophenethyl, 2-fluoro-4-methoxyphenethyl, 3-chloro-2-fluorophenethyl, 4-chloro-2-fluorophenethyl, 5-chloro-2-fluorophenethyl, 2,6-difluorophenethyl, 3-chloro-2,6-difluorophenethyl, 2,6-difluoro-4-(prop-1-en-2-yl)phenethyl, 2,6-difluoro-4-isopropylphenethyl, 2,6-difluoro 2,6-difluoro-4-(trifluoromethyl)phenethyl, 2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl, 2,6-difluoro-4-(piperidin-1-yl)phenethyl, 2,6-difluoro-4-morpholinophenethyl, 4-butoxy-2,6-difluorophenethyl, 4-(cyclopropylmethyl)phenethyl, 4-cyclopropylmethyl (R)-2-phenylpropyl, (S)-2-phenylpropyl, 4-((tetrahydrofuran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl, 4-phenoxyphenethyl, 4-((tetrahydrofuran-3-yl)methoxy)phenethyl, (R)-2-phenylpropyl, (S)-2-phenylpropyl 2-([1,1'-biphenyl]-4-yl)ethyl, 2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl, 2-(benzo[d][1,3]dioxol-5-yl)ethyl, 2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl, 2-(thiophen-2-yl)ethyl, 2-(thiophen-3-yl)ethyl, 2-(pyridin-2-yl)ethyl, 3-phenylpropyl, 3-(2-fluorophenyl)propyl, 3-(4-fluorophenyl)propyl, 3-(thiophen-2-yl)propyl, 3-(thiophen-3-yl)propyl, (1-phenylpiperidin-4-yl)methyl, (1-(2-fluorophenyl)piperidin-4-yl)methyl, (1-(3-fluorophenyl)piperidin-4-yl)methyl, (1-(4-fluorophenyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl, (4-methyl-1-phenylpiperidin-4-yl)methyl,
[0078] (4-fluoro-1-phenylpiperidin-4-yl)methyl, 2-(1-phenylpiperidin-4-yl)ethyl, (1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl, (1-isobutyrylpiperidin-4-yl)methyl, (1-pivaloylpiperidin-4-yl)methyl, (1-butyrylpiperidin-4-yl)methyl, (1-(3-methylbutanoyl)piperidin-4-yl)methyl, (1-(3,3-dimethylbutanoyl)piperidin-4-yl)methyl, (1-(2-cyclopentylacetyl)piperidin-4-yl)methyl methyl, (1-(cyclopropanecarbonyl)piperidin-4-yl)methyl, (1-(cyclobutanecarbonyl)piperidin-4-yl)methyl, (1-(cyclopentanecarbonyl)piperidin-4-yl)methyl, (1-(cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-((1s,4s)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-((1r,4r)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-methoxycyclohexa (1-(4-(trifluoromethyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-benzoylpiperidin-4-yl)methyl, (1-(3-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl, (1-(2-phenylacetyl)piperidin-4-yl)methyl, (1-(thiophene-3-carbonyl)piperidin-4-yl)methyl, ((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl, (1,2,3,4-tetrahydro naphthalen-2-yl)methyl, (2,3-dihydro-1H-inden-2-yl)methyl, 2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl, (1-(pyridin-3-yl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamoyl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamothioyl)piperidin-4-yl)methyl, (1-((1S,2R)-2-(trifluoromethyl)cyclohexyl)azetidin-3-yl)methyl, ((R)-1-phenylpyrrolidin-3-yl)methyl,((R)-1-(o-tolyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, (R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl, (R)-1-(3-fluorophenyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridine-2 -yl)pyrrolidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-methylpyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, (R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl, (S)-(1-(4-(trifluoromethyl)benzoyl)pyrrolidin-3-yl)methyl, ((R)-1-(o-thiazol-4-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 3-fluorophenethyl, 4-fluorophenethyl, 3,4-dichlorophenethyl, 3-(trifluoromethyl)phenethyl,4-(trifluoromethyl)phenethyl, ((R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 4-(3,5-dimethylisoxazol-4-yl)-2,6-difluorophenethyl, 4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,6-difluorophenethyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl (R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]oxazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-isopropylthiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1- (benzo[d]thiazol-4-yl)piperidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin (S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, or ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl.
[0079] In one embodiment, R 1 may be H, and R 2 may be CH3. In some embodiments, R 1 may be H, and R 2 may be CHF. In some embodiments, R1 may be H, and R 2 may be CHF2. In one embodiment, R 1 may be CH3, and R 2 may be H. In some embodiments, R 1 may be CHF, and R 2 may be H.
[0080] In one embodiment, R 1 may be H, and R 2 may be CH3, and R 3 (CH2) n R 4 where n may be 1, and R 4 is one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 It may also be cyclohexyl or 1-phenylpiperidin-4-yl, each optionally substituted with from one to a maximum number of alkoxy and / or CF3 substituents.
[0081] In one embodiment, R 1 may be H, and R 2 may be CH3, and R 3 is one or more of F, Cl, C 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6and 2-(4-phenylcyclohexyl)methyl, (4-(2-fluoropropan-2-yl)cyclohexyl)methyl, (4-(methoxymethyl)cyclohexyl)methyl, (spiro[2.5]octan-6-yl)methyl, (spiro[3.5]nonan-7-yl)methyl, (spiro[4.5]decan-8-yl)methyl, (2-adamantyl)ethyl, 2-(benzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl, 2-([1,1'-biphenyl]-4-yl)ethyl, 2-(pyridin-2-yl)ethyl, each of which may be substituted by one to a maximum number of alkoxy and / or CF3 substituents.
[0082] In one embodiment, R 1 may be H, and R 2 may be CH3, and R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 It may be phenylethyl optionally substituted with one to a maximum of alkyl, cyclopropyl, propen-2-yl, OCH3, and / or CF3 substituents.
[0083] In one embodiment, R 1 may be H, and R 2 may be CH3, and R 3 is one or more F, C 1-6 C, each optionally substituted with one to a maximum of alkyl, OCH3, and / or CF3 substituents; 1-6 Alkyl, C 3-7It may be (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl.
[0084] In one embodiment, R 1 may be H, and R 2 may be CH3, and R 3 teeth, [ka] where R may be 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 and may be selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted with from one to a maximum of alkoxy, OCF3, and / or CF3 substituents.
[0085] In one embodiment, R 1 may be H, and R 2 may be CH3, and R 3is (4-ethylcyclohexyl)methyl, ((1s,4S)-4-isopropylcyclohexyl)methyl, ((1r,4R)-4-isopropylcyclohexyl)methyl, ((1s,4S)-4-(tert-butyl)cyclohexyl)methyl, ((1r,4R)-4-(tert-butyl)cyclohexyl)methyl, ((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl, ((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl, ((1s,4S)-4-(2-fluoropropane -2-yl)cyclohexyl)methyl, ((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((1s,4S)-4-cyclopropylcyclohexyl)methyl, ((1r,4R)-4-cyclopropylcyclohexyl)methyl, 2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl, 2,5-difluorophenethyl, 3-chloro-2-fluorophenethyl, 5-chloro-2-fluoro Phenethyl, 2,6-difluorophenethyl, 3-chloro-2,6-difluorophenethyl, 2,6-difluoro-4-(prop-1-en-2-yl)phenethyl, 2,6-difluoro-4-isopropylphenethyl, 2,6-difluoro-3-isopropylphenethyl, 4-cyclopropyl-2,6-difluorophenethyl, 2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl, 2,6-difluoro-4-(piperidin-1-yl)phenethyl, 2,6-difluoro-4-morpholinophenethyl, 4-bromo- 2,6-difluorophenethyl, 4-(cyclopropylmethoxy)-2,6-difluorophenethyl, 2-([1,1'-biphenyl]-4-yl)ethyl, 2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl, 2-(benzo[d][1,3]dioxol-5-yl)ethyl, 2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl, (1-(2-fluorophenyl)piperidin-4-yl)methyl, (1-(3-fluorophenyl)piperidin-4-yl)methyl, (1-(4-fluorophenyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl, (2,3-dihydro-1H-inden-2-yl)methyl, (1,2,3,4-tetrahydronaphthalen-2-yl)methyl, ((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, ((R)-1-phenylpyrrolidin-3-yl)methyl, ((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1 -(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl, ((R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl, ((R)-1-(3-fluorophenyl)pyrrolidin-3-yl)methyl, ((R)-1-(o-tolyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl, ((R)- 1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidine- 3-yl)methyl, ((R)-1-(o-tolyl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, 2,6-Difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrimidin-3-yl)methyl It may be ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, or ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl.
[0086] In certain embodiments of the present invention, compounds according to Formula (I) include those set forth in Table 1.
[0087] [Table 1] TIFF0007594548000028.tif203155 TIFF0007594548000029.tif203155 TIFF0007594548000030.tif203156 TIFF0007594548000031.tif197154 TIFF0007594548000032.tif182153 TIFF0007594548000033.tif203156 TIFF0007594548000034.tif197154 TIFF0007594548000035.tif192154 TIFF0007594548000036.tif197154 TIFF0007594548000037.tif192155 TIFF0007594548000038.tif197156 TIFF0007594548000039.tif203158 TIFF0007594548000040.tif192166 TIFF0007594548000041.tif187159 TIFF0007594548000042.tif203169 TIFF0007594548000043.tif203164 TIFF0007594548000044.tif187158 TIFF0007594548000045.tif187154 TIFF0007594548000046.tif197155 TIFF0007594548000047.tif208157 TIFF0007594548000048.tif213158 TIFF0007594548000049.tif109152
[0088] As will be appreciated by those skilled in the art, formula (I) above can alternatively be represented as follows: [ka] (I)
[0089] As used herein, the singular forms "a," "and," and "the" include plural references unless the context clearly dictates otherwise. For example, "a compound" refers to one or more such compounds, and "the enzyme" includes not only the specific enzyme but also other family member equivalents known to those of skill in the art.
[0090] Throughout this application, the term "compound" or "compounds" refers to the compounds discussed herein, including precursors and derivatives of the compounds, including acyl-protected derivatives and pharmaceutically acceptable salts of the compounds, precursors, and derivatives. The invention also includes prodrugs of the compounds, compositions comprising the compounds and a pharmaceutically acceptable carrier, and pharmaceutical compositions comprising the prodrugs of the compounds and a pharmaceutically acceptable carrier.
[0091] The compounds of the present invention may contain one or more additional asymmetric centers beyond those specified in Formula (I), including any one or more of Formulae (Ia) through (In), and thus may occur as single enantiomers, diastereomeric mixtures, and individual diastereomers. Such additional asymmetric centers may exist depending on the nature of the various substituents on the molecule. Each such additional asymmetric center independently produces two optical isomers, and all such possible enantiomers and diastereomers in mixtures, as well as pure or partially purified compounds, are intended to be included within the scope of the present invention. Any formula, structure, or name of a compound described herein that does not specify the specific stereochemistry of an additional asymmetric center is intended to encompass all of the existing isomers described above and mixtures thereof, in any proportion. When the stereochemistry of an additional asymmetric center is specified, the present invention is intended to encompass that specific isomer in pure form or as part of a mixture with other isomers, in any proportion.
[0092] "Alkyl" refers to a straight or branched hydrocarbon chain group composed solely of carbon and hydrogen atoms and containing no unsaturation, e.g., containing 1 to 10 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, attached to the remainder of the molecule by a single bond. In another embodiment, an alkyl group can contain 1 to 8 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. In another embodiment, an alkyl group can contain 1 to 6 carbon atoms, e.g., 1, 2, 3, 4, 5, or 6 carbon atoms. Unless specifically stated herein, alkyl groups can be substituted with one or more substituents described herein. It is understood that substitution can occur at any substituent of an alkyl group unless specifically stated herein. "Cycloalkyl" refers to a stable monovalent monocyclic, bicyclic, or tricyclic hydrocarbon radical, composed solely of carbon and hydrogen atoms, e.g., having from 3 to 15 carbon atoms, saturated, and attached to the remainder of the molecule by a single bond. In another embodiment, a cycloalkyl group can contain from 3 to 6 carbon atoms, e.g., 3, 4, 5, or 6 carbon atoms. Unless specifically stated otherwise herein, the term "cycloalkyl" is intended to include cycloalkyl groups that are optionally substituted as described herein. "Alkoxy" means a group of the formula -OR a where R a are independently selected from the group consisting of C 1-10 Alkyl, or C 1-6 Alkyl, or C 1-5 An alkoxy group may be optionally substituted as described herein.
[0093] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where the event or circumstance occurs one or more times, or not at all. For example, "optionally substituted alkyl" means that the alkyl group may or may not be substituted, and that the description includes both substituted and unsubstituted alkyl groups, and that the alkyl group may be substituted one or more times. Examples of optionally substituted alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, and the like. Examples of suitable optional substituents include, but are not limited to, H, F, Cl, CH, OH, OCH, CF, CHF, CHF, and CN.
[0094] Treatment indications The present invention provides, in part, methods for treating conditions directly or indirectly regulated by the GBA2 enzyme or GBA2 enzyme activity level, such as conditions that would benefit from inhibiting the GBA2 enzyme or reducing GBA2 enzyme activity level. Such conditions may include, but are not limited to, neurological diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis (ALS); lysosomal storage diseases such as Gaucher disease, Niemann-Pick disease type C, mucolipidosis type IV, and Sandhoff disease; and liver diseases such as nonalcoholic steatohepatitis (NASH). Thus, one or more compounds of the present invention can be used to treat subjects at risk of developing or who have already been diagnosed with various neurological or other diseases. The term "treating" as used herein may include treatment, prevention, and / or amelioration.
[0095] In another embodiment, one or more compounds of the present invention may be useful for treating diseases or disorders associated with GBA2 deficiency or overexpression, or with glycosylceramide accumulation or depletion, or any disease or disorder that responds to glycosidase inhibitor therapy or glycosidase inhibitor therapy. Such diseases and disorders include, but are not limited to, neurological diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis (ALS), lysosomal storage diseases such as Gaucher disease, Niemann-Pick disease type C, mucolipidosis type IV, and Sandhoff disease, and liver diseases such as nonalcoholic steatohepatitis (NASH). Such diseases and disorders may also include diseases or disorders associated with accumulation or deficiency of the enzyme glucosylceramide synthase, or dysregulation of glycosphingolipid metabolism and / or homeostasis. Also included are methods of protecting or treating target cells expressing GBA2, the dysregulation of which may result in disease or pathology.
[0096] In another embodiment, the present invention provides a method for reducing the level of GBA2 enzyme activity in an animal subject, e.g., livestock or a human subject, which reduction in GBA2 activity may be useful for preventing or treating neurological or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis (ALS)), providing neuroprotection, preventing damage to dopaminergic neurons, preventing or treating lysosomal storage diseases (e.g., Gaucher disease, Niemann-Pick disease type C, mucolipidosis type IV, and Sandhoff disease), and preventing or treating liver diseases (e.g., nonalcoholic steatohepatitis (NASH)). In another embodiment, the present invention provides methods of inhibiting the GBA2 enzyme in animal subjects, including livestock and human subjects.
[0097] In another embodiment, the present invention provides a method for reducing CNS inflammation in animal subjects, such as livestock and human subjects. Disease conditions of interest may include neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis (ALS), whose etiology is associated with neuroinflammation. In some embodiments, the compounds of the present invention can be used to reduce GBA2 enzyme activity levels, thereby preventing, treating, or ameliorating neuroinflammation, thereby providing therapeutic benefits.
[0098] In another embodiment, the present invention provides a method for inhibiting the aggregation of alpha-synuclein protein or inhibiting the formation of Lewy bodies in animal subjects, e.g., livestock and human subjects. Disease states of interest may include Parkinson's disease (PD) and related neurodegenerative synucleinopathies, the etiology of which is linked to the abnormal aggregation of alpha-synuclein protein. In certain embodiments, compounds of the present invention can be used to provide a therapeutic benefit by reducing GBA2 enzyme activity levels to block the abnormal aggregation of alpha-synuclein protein.
[0099] Neurological disorders that may be treated by the compounds of the present invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), addiction, anxiety, argyrophilic grain dementia, ataxia-telangiectasia (AT), attention-deficit / hyperactivity disorder (ADHD), autism spectrum disorder (ASD), Becker muscular dystrophy (BMD), bipolar disorder (BD), vascular bruit disease, cerebellar ataxia, Charcot-Marie-Tooth disease (CMT), chronic fatigue syndrome, cerebral ataxia, and the like. Corticobasal degeneration (CBD), dementia pugilistica, dementia with Lewy bodies (DLB), Dejerine-Sottas disease, diffuse neurofibrillary tangles with calcifications, Down syndrome, Duchenne muscular dystrophy (DMD), epilepsy, essential tremor (ET), familial British dementia, familial Danish dementia, fibromyalgia, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Friedreich's ataxia, Gerstmann-Sträussler-Scheinker disease, glaucoma, Guadeloupe parkinsonism, Guillain-Barré syndrome, Hazel disease, Lavorden-Spatz syndrome (neurodegeneration with brain iron accumulation type 1), insomnia, Lambert-Eaton myasthenic syndrome (LEMS), major depressive disorder (MDD), migraine, mild cognitive impairment (MCI), multi-infarct dementia, multiple system atrophy (MSA), myasthenia gravis, myotonic dystrophy (including DM1 and DM2), neuronal ceroid lipofuscinosis (including types 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10), neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), oculopharyngeal muscular dystrophy, pain, pallidopontonigral degeneration Neuropathy, Guam Parkinsonism-Dementia Complex, Pick's Disease (PiD), Postencephalitic Parkinsonism (PEP), Primary Lateral Sclerosis (PLS), Prion Diseases (including Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Fatal Familial Insomnia, and Kuru), Progressive Transcortical Gliosis, Progressive Supranuclear Palsy (PSP), Richardson Syndrome, Schizophrenia, Seizures, Spinal Cord Disorders, Spinal Muscular Atrophy (SMA), Spinocerebellar Ataxia (1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 16, 17, 18, 19,20, 21, 22, 23, 25, 26, 27, 28, and 29), stroke, subacute sclerosing panencephalitis, fibrillary tangle-predominant dementia, tardive dyskinesia, Tourette's syndrome (TS), vascular dementia, or Wilson's disease.
[0100] Lysosomal storage diseases that may be treated by the compounds of the invention may include, but are not limited to, Gaucher disease (including types I, II, and III), Niemann-Pick disease (including types A, B, and C), mucolipidosis (including types I, II, III, IV, VI, and VII), cerebrotendinous xanthomatosis, Fabry disease, Farber disease, GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy (MLD), multiple sulfatase deficiency, Pompe disease, Sandhoff disease, or Tay-Sachs disease.
[0101] Liver diseases that may be treated by the compounds of the present invention may include, but are not limited to, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), Alagille syndrome, alcohol-related liver disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, autoimmune cholangitis, benign liver tumors, biliary atresia, cirrhosis, Crigler-Najjar syndrome, drug-induced liver injury (DILI), galactosemia, Gilbert syndrome, hemochromatosis, hepatic encephalopathy, hepatocellular carcinoma (HCC), intrahepatic cholestasis of pregnancy (ICP), lysosomal acid lipase deficiency (LAL-D), liver cysts, liver cancer, neonatal jaundice, primary sclerosing cholangitis (PBC), primary biliary cholangitis (PSC), Reye's syndrome, glycogen storage disease type I, or viral hepatitis (including types A, B, C, D, and E). In certain embodiments, the compounds of the present invention may be useful in the treatment of disorders in which modulation of GBA2 enzyme activity levels is implicated, or any of the conditions described herein. Other conditions that may be treated using one or more compounds of the present invention are conditions that are induced by, affected by, or otherwise correlated with the level of GBA2 enzyme activity. It is expected that one or more compounds of the present invention may be useful in treating such conditions, particularly, but not limited to, Parkinson's disease, Gaucher's disease, Niemann-Pick disease type C, mucolipidosis type IV, and Sandhoff's disease.
[0102] Pharmaceutical and veterinary compositions, dosages, and administration Pharmaceutical compositions comprising compounds of the invention or for use in accordance with the invention are considered within the scope of the invention. In one embodiment, a pharmaceutical composition is provided that comprises an effective amount of a compound of formula (I), including any one or more of formulae (Ia)-(In).
[0103] Compounds of formula (I), including any one or more of formulas (Ia)-(In), and pharmaceutically acceptable salts, enantiomers, solvates, or derivatives thereof, may be useful because they may have pharmacological activity in animals, particularly humans. In certain embodiments, one or more compounds of the present invention may be stable in plasma when administered to a subject, for example, a human. Generally, the compounds of the present invention can be administered to a subject in need thereof, or contacted with a cell or sample, by a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), for example, including any one or more of formulae (Ia)-(In).
[0104] In certain embodiments, the compounds of the present invention or compounds used in accordance with the present invention may be provided in combination with any other active agent or pharmaceutical composition, and such combination therapy may be useful for inhibiting GBA2 activity levels to treat, for example, neurological disorders, or lysosomal storage diseases, or liver diseases, or any of the conditions described herein. In certain embodiments, the compounds of the present invention or compounds used in accordance with the present invention may be provided in combination with one or more agents useful for the prevention or treatment of Parkinson's disease. Examples of such agents may include, but are not limited to, the following: Levodopa (L-DOPA), Peripheral DOPA decarboxylase inhibitors (DDCIs), such as carbidopa (Lodosyn®), Carbidopa / levodopa combination drugs (Kinson®, Sinemet®, Parcopa®, Atamet®), Carbidopa / levodopa / entacapone combination (Stalevo®), amantadine (Symmetrel®), Dopamine antagonists, for example bromocriptine (Cycloset®, Parlodel®), pergolide (Permax®), pramipexole (Mirapexin®, Sifrol®, Mirapex®), ropinirole (Ronirol®, Adartrel®, Requip®), piribedil (Trivastal®) Retard®, Trastal®, Trivastan®, Clarium®, Pronoran®), cabergoline (Cabaser®, Dostinex®), apomorphine (Ixense®, Spontane®, Uprima®, Apokyn®), Lisuride® (Dopergin®, Proclacam®, Revanil®), rotigotine (Neupro®), Ciladopa® (AY-27, 1 10), Dihydrexidine (DAR-0100), Dinapsoline (registered trademark), Doxanthrine (registered trademark), epicriptine (β-dihydroergocryptine), Nn-propylnorapomorphine (NPA), quinagolide (Norprolac (registered trademark)), Roxindole (registered trademark) (EMD-49,980), Sumanirole (registered trademark) (PNU-95,666), pardoprunox, aplindore, etc. Monoamine oxidase B (MAO-B) inhibitors, such as selegiline (Anipryl®, L-deprenyl®, Eldepryl®, Emsam®, Zelapar®), rasagiline (Azilect®, AGN1135), safinamide, etc. anticholinergic drugs, such as benzatropine (benztropine, Cogentin®), diphenhydramine (Benadryl®, Dimedrol®, Daedalon®, Nytol®), orphenadrine (Norflex®, Mephenamin®, Disipal®, Banflex®, Flexon®, Biorphen®, Brocasipal®, Dolan®, Norgesic®, OrfenAce®), trihexyphenidyl (Artane®, Apo-Trihex®, Parkin®, Pacitane®, benzhexol, trihex), etc. Catechol-O-methyltransferase (COMT) inhibitors, such as entacapone (COMTan®), tolcapone (Tasmar®), nitecapone, nebicapone, etc. Adenosine A 2A Receptor antagonists, such as istradefylline (KW-6002), preladenant, fipamezole (JP-1730), SCH-420814, BIIA-014, Lu AA4707, etc. Metabotropic glutamate receptor 5 (mgluR5) modulators, such as dipraglurant, AMPA receptor antagonists, such as perampanel (Fycompa®), anticonvulsants, such as zonisamide (Tremode®); Nicotinic acetylcholine receptor (nAChR) agonists, such as nicotine, ABT-418, WAY-317,538 (SEN-12333), EVP-6124, MEM 3454, and nefiracetam; Acetylcholinesterase inhibitors (AChEIs), such as Aricept® (Donepezil), Exelon® (Rivastigmine), Razadyne® (Razadyne ER®, Reminyl®, Nivalin®, galantamine), Cognex® (tacrine), Huperzine A, phenserine, Debio-9902 SR (ZT-1 SR), Zanapezil (TAK0147), ganstigmine, NP7557, etc. atypical antipsychotics, such as clozapine, or Modafinil (Alertec®, Modavigil®, Provigil®).
[0105] Combinations of compounds according to or used according to the present invention with drugs useful for treating Parkinson's disease are not limited to the examples described herein and may include combinations with any drug useful for treating Parkinson's disease. Combinations of compounds according to or used according to the present invention with drugs useful for treating Parkinson's disease may be administered separately or together. Administration of one drug may occur before, simultaneously with, or after administration of the other drug.
[0106] In certain embodiments, the compounds of the invention or used in accordance with the invention may be provided in combination with one or more agents useful in the prevention or treatment of Gaucher disease. Examples of such agents may include, but are not limited to: combination human GCase enzyme replacement therapy, such as imiglucerase (Cerezyme®), velaglucerase alfa (VPRIV®), taliglucerase alfa (Elelyso®), etc. Glucosylceramide synthase inhibitors, such as EXEL-0346, Genz-123346, Eliglustat® (Genz-112638), etc. Bisphosphonates, such as zoledronate (Zometa®, Zomera®, Aclasta®, Reclast®), alendronate sodium (Fosamax®), etidronate (Didronel®), clodronate (Bonefos®, Loron®), tiludronate (Skelid®), pamidronate (APD®, Aredia®), neridronate (Nerixia®), olpadronate, ibandronate (Boniva®), risedronate (Actonel®), etc. Antiepileptic drugs, such as Tegretol® (Carbatrol®, carbamazepine), Zarontin® (ethosuximide), Felbatol® (felbamate), Gabitril® (tiagabine), Keppra® (levetiracetam), Lamictal® (lamotrigine), Lyrica® (pregabalin), Neurontin® (gabapentin), Dilantin® ®) (phenytoin), Topamax® (topiramate), Trileptal® (oxcarbazepine), Depakene® (Depakote®, valproate, valproic acid), Zonegran® (zonisamide), Valium® (diazepam), Ativan® (lorazepam), Klonopin® (clonazepam), Fycompa® (perampanel), Oxtellar XR® (oxcarbazepine), and the like; · Gene therapy.
[0107] Combinations of compounds according to or for use according to the present invention with drugs useful for treating Gaucher disease are not limited to the examples described herein and may include combinations with any drug useful for treating Gaucher disease. Combinations of compounds according to or for use according to the present invention with drugs useful for treating Gaucher disease may be administered separately or together. Administration of one drug may be before, simultaneously with, or after administration of the other drug.
[0108] In another embodiment, the compounds of the present invention may be applied in a "prodrug" or protected form, which releases the compound after administration to a subject. For example, the compound may have a protecting group that is cleaved by hydrolysis in a body fluid, such as the bloodstream, thereby releasing the active compound, or that is oxidized or reduced in a body fluid to release the compound. Thus, a "prodrug" is intended to refer to a compound that can be converted into a biologically active compound of the present invention under physiological conditions or by solvolysis. Thus, the term "prodrug" refers to a pharmaceutically acceptable metabolic precursor of a compound of the present invention. A prodrug may be inactive when administered to a subject in need thereof, but can be converted into an active compound of the present invention in vivo. A prodrug is typically rapidly transformed in vivo, for example, by hydrolysis in the blood, to produce the parent compound of the present invention. Prodrug compounds often offer advantages of solubility, tissue compatibility, or delayed release in a subject. The term "prodrug" is also intended to include any covalently bonded carrier that releases an active compound of the present invention in vivo when such prodrug is administered to a subject. Prodrugs of the compounds of the present invention can be prepared by modifying functional groups present in the compounds of the present invention such that the modifications are cleaved from the parent compound either by routine manipulation or in vivo. Prodrugs include compounds of the present invention in which a hydroxy, amino, or mercapto group is bonded to any group that is cleaved to form a free hydroxy, free amino, or free mercapto group, respectively, when the prodrug of the compound of the present invention is administered to a mammalian subject. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohols, and acetamide, formamide, and benzamide derivatives of amine functional groups in one or more of the compounds of the present invention.
[0109] For a discussion of prodrugs, see "Smith and Williams' Introduction to the Principles of Drug Design," H.J. Smith, Wright, Second Edition, London (1988); Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam); The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Chapter 31, (Academic Press, 1996); A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Chapter 5, pgs. 113-191 (Harwood Academic Publishers, 1991); Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," ACS Symposium Series, Vol. 14; or Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
[0110] One or more prodrug forms of the compounds of the present invention may be those in which one or more OH groups according to formula (I), including any one or more of formulas (Ia)-(In), are optionally protected as OC(O)R, and R is substituted C 1-6In some embodiments, the ester group may be an alkyl group. In these cases, the ester group may be hydrolyzed in vivo (e.g., in body fluids) to liberate the OH group and release the active compound. Preferred prodrug embodiments of the present invention include compounds of Formula (I), including any one or more of Formulas (Ia)-(In), in which one or more OH groups may be protected with acetate, e.g., OC(O)CH3.
[0111] The compounds of the present invention, or compounds used according to the present invention, can be provided alone or in combination with other compounds in the presence of liposomes, nanoparticles, adjuvants, or any pharmaceutically acceptable carrier, diluent, or excipient, in a form suitable for administration to a subject, for example, a mammal, e.g., a human, cow, sheep, etc. If desired, treatment with the compounds of the present invention can be combined with traditional, existing therapies for the therapeutic indications described herein. The compounds of the present invention can be provided chronically or intermittently. "Chronic" administration refers to administration of the compound in a continuous manner as opposed to an acute manner, so that the initial therapeutic effect (activity) is maintained over an extended period of time. "Intermittent" administration is treatment that is not continuous without interruption, but rather is cyclic in nature. The terms "administration," "administrable," or "administering," as used herein, should be understood to mean providing a compound of the present invention to a subject in need of treatment.
[0112] A "pharmaceutically acceptable carrier, diluent, or excipient" may include, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing, suspending agent, stabilizing, isotonic agent, solvent, or emulsifying agent approved by the U.S. Food and Drug Administration or other government agency as acceptable for use in humans or domestic animals. The compounds of the present invention can be administered in the form of pharmaceutically acceptable salts.In such cases, the pharmaceutical compositions according to the present invention can contain salts of such compounds, preferably physiologically acceptable salts, as known in the art.In one embodiment, the term "pharmaceutically acceptable salts" as used herein refers to active ingredients, including compounds of formula (I), including any one or more of formulas (Ia) to (In), used in salt form, and in particular, these salt forms provide the active ingredients with improved pharmacokinetic properties compared to the free form or other previously disclosed salt forms of the active ingredients.
[0113] "Pharmaceutically acceptable salts" can include both acid and base addition salts. "Pharmaceutically acceptable acid addition salts" refers to salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which can be formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
[0114] "Pharmaceutically acceptable base addition salts" refer to salts that can retain biological effectiveness and properties and may not be biologically or otherwise undesirable. These salts can be prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases can include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Preferred inorganic salts can be ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases may include, but are not limited to, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Particularly preferred organic bases may be isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
[0115] Thus, the term "pharmaceutically acceptable salt" includes acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methyl bromide, bromide, methyl nitrite, calcium edetate, methyl sulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, lysate, lysozyme ...
[0033] The term "antioxidant" encompasses all acceptable salts, including, but not limited to, phosphate / diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate, hexylresorcinate, monoacetate, hydradamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, isethionate, triethiodide, lactate, panoate, valerate, and the like. Pharmaceutically acceptable salts of the compounds of the present invention can be used as dosages to modify solubility or hydrolysis characteristics, or can be used in sustained-release or prodrug formulations. Pharmaceutically acceptable salts of the compounds of the present invention can also include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, and zinc, as well as those formed from bases such as ammonia, ethylenediamine, N-methylglutamine, lysine, arginine, ornithine, choline, N,N-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.
[0116] Pharmaceutical compositions typically include one or more carriers acceptable for the mode of administration of the formulation, such as injection, inhalation, topical administration, irrigation, or other mode appropriate for the selected treatment. Suitable carriers may be those known in the art for use in such modes of administration.
[0117] Suitable pharmaceutical compositions can be formulated by methods known in the art, and their mode of administration and dosage can be determined by a skilled practitioner. For parenteral administration, the compound can be dissolved in sterile water, saline, or a pharmaceutically acceptable vehicle used to administer water-insoluble compounds, such as those used for vitamin K. For enteral administration, the compound can be administered in tablet, capsule, or dissolved in liquid form. The tablet or capsule can be enterically coated or formulated for sustained release. Many suitable formulations are known, including polymer or protein microparticles, ointments, gels, hydrogels, or solutions encapsulating the compound to be released, which can be used topically or locally to administer the compound. Sustained-release patches or implants can be used to provide release over an extended period of time. Many techniques known to the skilled practitioner are described in Remington: The Science & Practice of Pharmacy by Alfonso Gennaro, 20th ed., Williams & Wilkins, (2000). Formulations for parenteral administration may contain, for example, excipients such as polyalkylene glycols, such as polyethylene glycol, vegetable oils, or hydrogenated naphthalene. Biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene-polyoxypropylene copolymers can be used to control the release of the compound. Other potentially useful parenteral delivery systems for regulating compounds may include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion pump systems, and liposomes. Formulations for inhalation may contain excipients such as lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate, and deoxycholate, or may be oily solutions administered in the form of nasal drops or as gels.
[0118] The compounds or pharmaceutical compositions of the present invention can be administered orally or parenterally, for example, intramuscularly, intraperitoneally, intravenously, intracisternally, subcutaneously, transdermally, or transmucosally. In some embodiments, the compounds or pharmaceutical compositions according to or used in the present invention can be administered via a medical device or apparatus, such as an implant, graft, prosthesis, stent, or the like. Implants intended to contain and release such compounds or compositions are contemplated. An example is an implant made of a polymeric material adapted to release the compound over an extended period of time. The compounds can be administered alone or in admixture with a pharmaceutically acceptable carrier, for example, in solid formulations such as tablets, capsules, granules, powders, and the like; liquid formulations such as syrups, injections, and the like; injections, drops, suppositories, and pessaries. In certain embodiments, the compounds or pharmaceutical compositions according to or used in the present invention may be administered by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes and may be formulated into appropriate dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles appropriate for each route of administration, either alone or together.
[0119] The compounds of the present invention can be used to treat animals, including mice, rats, horses, cattle, sheep, dogs, cats, and monkeys. However, the compounds of the present invention can also be used in other organisms, such as birds (e.g., chickens). One or more compounds of the present invention may also be effective for use in humans. The term "subject" or alternatively referred to herein as "patient" is intended to refer to an animal, preferably a mammal, most preferably a human, for whom treatment, observation, or experimentation is the object of treatment. However, one or more compounds, methods, and pharmaceutical compositions of the present invention can be used to treat animals. Thus, as used herein, a "subject" can be a human, non-human primate, rat, mouse, cattle, horse, pig, sheep, goat, dog, cat, etc. A subject can be suspected of having or at risk of having a condition that may require inhibition of GBA2 activity.
[0120] An "effective amount" of a compound of the present invention may include a therapeutically effective amount or a prophylactically effective amount. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result, e.g., inhibiting GBA2, reducing GBA2 enzyme activity levels, inhibiting α-synuclein protein aggregation, or any of the conditions described herein. A therapeutically effective amount of a compound may vary according to factors such as the individual's disease state, age, sex, and weight, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide an optimal therapeutic response. A therapeutically effective amount may also be one in which any toxic or adverse effects of the compound are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" may refer to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result, e.g., inhibiting GBA2, reducing GBA2 enzyme activity levels, inhibiting α-synuclein protein aggregation, or any of the conditions described herein. Typically, a prophylactic dose is used in subjects prior to or at an early stage of disease, such that the prophylactically effective amount may be less than the therapeutically effective amount. A suitable range for a therapeutically or prophylactically effective amount of a compound may be any integer between 0.1 nM and 0.1 M, 0.1 nM and 0.05 M, 0.05 nM and 15 μM, or 0.01 nM and 10 μM.
[0121] In another embodiment, for the treatment or prevention of conditions that may require inhibition of GBA2 activity, appropriate dosage levels may generally be about 0.01 to 500 mg per kg of subject body weight per day, which may be administered in single or multiple doses. In certain embodiments, dosage levels may be about 0.1 to about 250 mg / kg per day. It is understood that the specific dose level and frequency of administration for any particular patient may vary and may depend on a variety of factors, including the activity of the particular compound used, the metabolic stability and duration of action of that compound, age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combinations, the severity of the particular condition, and any therapies the patient is receiving.
[0122] It should be noted that dosage values may vary depending on the severity of the condition being alleviated. For any particular subject, a specific dosage regimen may be adjusted over time according to the individual's needs and the professional judgment of the person administering or supervising the administration of the composition. The dosage ranges set forth herein are merely exemplary and do not limit the dosage range that may be selected by a physician. The amount of active compound in the composition may vary depending on factors such as the disease state, age, sex, and weight of the subject. The dosage regimen may be adjusted to provide the optimal therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be reduced or increased as dictated by the exigencies of the therapeutic situation. It may be advantageous to formulate parenteral compositions in unit dosage form for ease of administration and uniformity of dosage. Generally, the compounds of the present invention should be used without causing substantial toxicity, and one or more compounds may exhibit a safety profile suitable for therapeutic use, as described herein. The toxicity of the compounds of the invention can be determined using standard techniques, for example, in cell cultures or experimental animals, to determine the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). However, in some situations, for example, in severe disease states, it may be necessary to administer substantial excesses of the composition.
[0123] In compounds of general formula (I) containing one or more of formulas (Ia) to (In), atoms may exhibit natural isotopic abundance, or one or more atoms may be artificially enriched in a particular isotope having the same atomic number but an atomic mass or mass number different from that predominantly found in nature. The present invention is intended to include all appropriate isotopic variations of compounds of general formula (I) containing one or more of formulas (Ia) to (In). For example, different isotopic forms of hydrogen (H) include protium ( 1 H), deuterium ( 2 H), and tritium ( 3H). Protium is the predominant hydrogen isotope found in nature. Enrichment to deuterium can confer certain therapeutic benefits, such as increased in vivo half-life or reduced dosage requirements, or can provide compounds useful as standards for characterization of biological samples. Isotopically enriched compounds within the scope of general formula (I), including any one or more of formulas (Ia)-(In), can be prepared by conventional techniques known to those skilled in the art, or by methods analogous to those described in the schemes and examples herein using appropriately isotopically enriched reagents and / or intermediates.
[0124] Other uses In another embodiment, one or more compounds of the present invention may be used to study the physiological role of GBA2 at the cellular and organismal levels. In certain embodiments, one or more compounds may be useful in developing animal models to study diseases or disorders that may be associated with GBA2 deficiency, GBA2 overexpression, glucosylceramide accumulation, glucosylceramide depletion, glycosphingolipid accumulation, or glycosphingolipid depletion, as well as to study the treatment of diseases and disorders that may be associated with GBA2 deficiency or overexpression, glucosylceramide accumulation or depletion, or glycosphingolipid accumulation or depletion. Such diseases and disorders may include, but are not limited to, neurological disorders including Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis (ALS); lysosomal storage diseases including Gaucher disease, Niemann-Pick disease type C, mucolipidosis type IV, and Sandhoff disease; and liver diseases including nonalcoholic steatohepatitis (NASH).
[0125] The efficacy of a compound to treat a pathology associated with a lysosomal storage disease (e.g., Gaucher disease, Niemann-Pick disease type C, mucolipidosis type IV, or Sandhoff disease) can be confirmed by testing the compound's ability to prevent, treat, or ameliorate symptoms of the disease in, for example, established cellular and / or transgenic animal disease models using standard techniques. 12,13,15,16,25 Various alternative embodiments and examples of the present invention are described herein, which are illustrative and should not be construed as limiting the scope of the invention. [Example]
[0126] The following examples are intended to illustrate the invention and are not intended to be construed as limiting. Abbreviation ABCN = 1,1'-azobis(cyclohexanecarbonitrile) BzCl = benzoyl chloride DAST = diethylaminosulfur trifluoride DCM = dichloromethane DIAD = diisopropyl azodicarboxylate DIPEA = diisopropylethylamine DMA = dimethylacetamide DMAP = 4-dimethylaminopyridine DMF = N,N-dimethylformamide DMP = Dess-Martin periodinane Et2O = diethyl ether HOAc = acetic acid LAH = lithium aluminum hydride MeOH = methanol MsCl = methanesulfonyl chloride RT=room temperature TBDMSCl = tert-butyldimethylsilyl chloride TFA = 2,2,2-trifluoroacetic acid THF = tetrahydrofuran
[0127] Example 1 (2R,3R,4R,5S)-1-(cyclohexylmethyl)-2-methylpiperidine-3,4,5-triol [ka]
[0128] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (43 mg, 0.10 mmol) and cyclohexanecarboxaldehyde (23 mg, 0.20 mmol) in anhydrous MeOH (5 mL) was added HOAc (0.10 mL, 1.75 mmol), and the mixture was stirred for 30 minutes. NaBHCN (13 mg, 0.20 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(cyclohexylmethyl)-2-methylpiperidine as an oil (49 mg, 95%). ESI MS m / z 514.32 [M+H] + .
[0129] To a stirred solution of the above material (49 mg, 0.096 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.70 mL, 0.70 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 h and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 min. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(cyclohexylmethyl)-2-methylpiperidine-3,4,5-triol as a white solid (15 mg, 64%). 1H NMR (400 MHz, CD3OD) δ 3.52-3.42 (m, 1H), 3.12 (t, J = 9.0 Hz, 1H), 3.03 (dd, J = 11.4, 4.8 Hz, 1H), 2.96 (t, J = 9.1 Hz, 1H), 2.57 (dd, J = 12.8, 8.9 Hz, 1H), 2.11-1.85 (m, 4H), 1.79-1.63 (m, 4H), 1.58-1.43 (m, 1H), 1.39-1.20 (m, 3H), 1.19 (d, J = 6.1 Hz, 3H), 1.01-0.79 (m, 2H); ESI MS m / z 244.18 [M + H] + .
[0130] Example 2 (2R,3R,4R,5S)-1-((4,4-dimethylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of spiro[2.5]octan-6-ylmethanol (100 mg, 0.71 mmol) in HOAc (5 mL) was added PtO2 (48 mg, 0.21 mmol). The mixture was treated with hydrogen (40 psi) for 18 h. The catalyst was filtered off through Celite, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography to give (4,4-dimethylcyclohexyl)methanol as an oil (51 mg, 51%). 1 H NMR (400 MHz, CDCl3) δ 3.50 (d, J = 6.4 Hz, 2H), 1.70-1.55 (m, 3H), 1.49-1.37 (m, 3H), 1.29-1.08 (m, 4H), 0.93 (s, 3H), 0.90 (s, 3H).
[0131] To a solution of the above material (50 mg, 0.35 mmol) in anhydrous DCM (10 mL) at 0 °C, DMP (194 mg, 0.46 mmol) was added, and the mixture was stirred at 0 °C for 2 h. The mixture was slowly quenched with NaSO solution. The mixture was extracted with DCM (3 × 10 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 4,4-dimethylcyclohexanecarbaldehyde as an oil (30 mg, not pure).
[0132] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (30 mg, 0.072 mmol) and 4,4-dimethylcyclohexanecarbaldehyde (30 mg, 0.21 mmol) in anhydrous DCM (5 mL) was added HOAc (0.10 mL, 1.75 mmol), and the mixture was stirred for 30 minutes. NaBHCN (13 mg, 0.20 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-((4,4-dimethylcyclohexyl)methyl)-2-methylpiperidine as an oil (10 mg, 26%). ESI MS m / z 542.34 [M+H] + .
[0133] To a stirred solution of the above material (10 mg, 0.018 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.50 mL, 0.50 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 h and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 min. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-((4,4-dimethylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (4 mg, 82%). 1 H NMR (400 MHz, CD3OD) δ 3.52-3.43 (m, 1H), 3.12 (t, J = 9.0 Hz, 1H), 3.03 (dd, J = 11.4, 4.8 Hz, 1H), 2.96 (t, J = 9.1 Hz, 1H), 2.62 (dd, J = 12.8, 8.9 Hz, 1H), 2.11-1.93 (m, 3H), 1.77-1.67 (m, 1H), 1.57-1.48 (m, 1H), 1.47-1.37 (m, 3H), 1.33-1.01 (m, 7H), 0.92 (d, J = 5.4 Hz, 6H); ESI MS m / z 272.20 [M + H] + .
[0134] Example 3 (2R,3R,4R,5S)-1-((4,4-difluorocyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.090 g, 0.22 mmol), 4,4-difluorocyclohexanecarbaldehyde (0.080 g, 0.54 mmol), and NaBH(OAc) (0.13 g, 0.60 mmol) in DCM (8 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (10 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:9 to 1:6) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-((4,4-difluorocyclohexyl)methyl)-2-methylpiperidine as a clear oil (0.10 g, 84%); ESI MS m / z 550.309 [M+H] + .
[0135] A mixture of the above material (0.015 g, 0.027 mmol) and Pd(OH) / C (20% Pd by mass, 0.015 g, 0.028 mmol) and aqueous HCl (5 N, 1 drop) in MeOH (3 mL) was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash chromatography on silica gel (1 M NHMeOH / DCM, 1:7) to give (2R,3R,4R,5S)-1-((4,4-difluorocyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol (0.0067 g, 89%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 3.44 (ddd, J = 10.5, 9.0, 4.8 Hz, 1H), 3.10 (t, J = 9.0 Hz, 1H), 3.01 (dd, J = 11.3, 4.8 Hz, 1H), 2.92 (t, J = 9.0 Hz, 1H), 2.59 (dd, J = 12.9, 9.2 Hz, 1H), 2.05-1.93 (m, 6H), 1.77-1.66 (m, 3H), 1.63-1.58 (m, 1H), 1.30-1.10 (m, 5H, 1.17 (d, J = 6.1 Hz, 3H); ESI MS m / z 280.162 [M + H] + .
[0136] Example 4 (2R,3R,4R,5S)-1-((4,4-dichlorocyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka]
[0137] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-((4,4-difluorocyclohexyl)methyl)-2-methylpiperidine (0.10 g, 0.18 mmol) in anhydrous DCM (8 mL) at −78° C. and N2, BCl3 (1.0 M in DCM, 1.5 mL, 1.5 mmol) was added and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with a few drops of saturated aqueous NaHCO3 and purified by flash chromatography on silica gel (1M NH3 in MeOH / DCM, 1:7) to give (2R,3R,4R,5S)-1-((4,4-dichlorocyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.046 g, 80%). 1H NMR (500 MHz, DMSO-d6) δ 4.69-4.65 (m, 3H), 3.25-3.18 (m, 1H), 2.89 (td, J = 8.8, 4.3 Hz, 1H), 2.83 (dd, J = 11.2, 4.7 Hz, 1H), 2.69 (td. (d, J = 6.0 Hz, 3H); ESI MS m / z 312.105 [M + H] + .
[0138] Example 5 (2R,3R,4R,5S)-1-((4-ethylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(((1s,4S)-4-vinylcyclohexyl)methyl)piperidine (0.180 g, 0.333 mmol) and Pd(OH) / C (20% Pd by mass, 0.20 g, 0.38 mmol) and 5 drops of concentrated HCl in MeOH (25 mL) was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness under reduced pressure. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NHMeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-((4-ethylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.083 g, 92%). 1 1 H NMR showed that the solid contained a mixture of cis and trans isomers in a ratio of cis:trans=0.65:0.35). 1H NMR (400 MHz, DMSO-d6) δ 4.74-4.59 (m, 3H), 3.26-3.14 (m, 1H), 2.94-2.78 (m, 2H), 2.76-2.57 (m, 1.65H), 2.40 (dd, J = 12.6, 9.2 Hz, 0.35H), 1.90-1.80 (m, 1.65H), 1.79-1.69 (m, 2H), 1.64-1.56 (m, 1H), 1.51-1.11 (m, 9H), 1.06 (d, J = 6.0 Hz, 1.65 H), 1.03 (d, J = 6.0Hz, 1.35H), 0.90-0.69 (m, 4.35H); ESI MS m / z 272.228 [M + H] + .
[0139] Example 6 (2R,3R,4R,5S)-2-Methyl-1-(((1s,4S)-4-vinylcyclohexyl)methyl)piperidine-3,4,5-triol [ka]
[0140] To a solution of cis-4-(hydroxymethyl)cyclohexanecarboxylic acid (1.00 g, 6.32 mmol) in anhydrous MeOH (25 mL), SOCl (1.55 g, 13.0 mmol) was added dropwise, and the mixture was stirred at room temperature for 4 hours. The solvent was then removed under reduced pressure, and the residue was diluted with saturated aqueous NaHCO (30 mL). After extraction with DCM (3 × 30 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure to give a clear liquid. The liquid was dissolved in anhydrous DMF (20 mL), and to this was added imidazole (1.36 g, 20.0 mmol) and TBDMSCl (1.51 g, 10.0 mmol) at 0 °C. After stirring at room temperature for 16 hours, the reaction mixture was diluted with brine (60 mL) and extracted with EtOAc (3 × 30 mL). The combined extracts were washed with brine (2 × 50 mL) and dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:9) to give (1s,4s)-methyl 4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexanecarboxylate as a clear liquid (1.60 g, 88%, 2 steps).
[0141] To a solution of the above material (1.60 g, 5.58 mmol) in anhydrous THF (25 mL) at 0 °C under N2, LAH (0.380 g, 10.0 mmol) was added, and the mixture was stirred at 0 °C for 2 h. Wet sodium sulfate heptahydrate (50 g) was added to quench the reaction, and the suspension was stirred for 30 min. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4 to 1:2) to give a clear liquid. The liquid was dissolved in DCM (40 mL), and DMP (4.50 g, 10.6 mmol) was added. The reaction mixture was stirred at room temperature for 1.5 h to form a white suspension. Hexane (50 mL) was added, and the suspension was filtered through a Celite cake. The filtrate was collected and concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:20 to 1:9) to give (1s,4s)-4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexanecarbaldehyde as a clear liquid (0.98 g, 68%, two steps). 1 H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 3.37 (d, J = 6.6 Hz, 2H), 2.44-2.39 (m, 1H), 2.16-2.06 (m, 2H), 1.70-1.45 (m, 5H), 1.11-0.96 (m, 2H), 0.87 (s, 9H), 0.02 (s, 6H).
[0142] To a solution of methyltriphenylphosphonium bromide (1.30 g, 3.61 mmol) in anhydrous THF (40 mL) at 0 °C, KO tBu (0.390 g, 3.50 mmol) was added, and the mixture was stirred at 0 °C for 20 min. A solution of (1s,4s)-4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexanecarbaldehyde (0.620 g, 2.41 mmol) in anhydrous THF (10 mL) was added, and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with saturated aqueous NH4Cl (30 mL) and then extracted with EtOAc (2 × 30 mL). The combined extracts were dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was dissolved in anhydrous THF (20 mL) and cooled at 0 °C. TBAF (1.0 M in THF, 5.0 mL, 5.0 mmol) was added, and the mixture was stirred at room temperature for 1 h. After dilution with brine (30 mL), the mixture was extracted with EtOAc (3 × 20 mL), and the combined extracts were dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4 to 1:2) to give ((1s,4s)-4-vinylcyclohexyl)methanol as a clear oil (0.26 g, 77%, two steps).
[0143] A mixture of the above material (0.260 g, 1.85 mmol) and DMP (1.10 g, 2.59 mmol) in DCM (40 mL) was stirred at room temperature for 1 hour to form a white suspension. Hexane (20 mL) was added, and the suspension was filtered through a Celite cake. The filtrate was collected and concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:5) to give (1s,4s)-4-vinylcyclohexanecarbaldehyde as a clear liquid (0.190 g, 74%). 1 H NMR (400 MHz, CDCl3) δ 9.69 (s, 1H), 5.75 (ddd, J = 17.1, 10.4, 6.3 Hz, 1H), 5.00-4.89 (m, 2H), 2.42-2.37 (m, 1H), 2.17-2.00 (m, 3H), 1.73-1.55 (m, 4H), 1.33-1.21 (m, 2H).
[0144] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.417 g, 1.00 mmol), (1s,4s)-4-vinylcyclohexanecarbaldehyde (0.19 g, 1.4 mmol), and NaBH(OAc) (0.45 g, 2.1 mmol) in DCM (40 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (30 mL) and extracted with DCM (3 × 20 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:13 to 1:9) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(((1s,4S)-4-vinylcyclohexyl)methyl)piperidine as a clear oil (0.39 g, 72%).
[0145] To a solution of the above material (0.180 g, 0.333 mmol) in anhydrous DCM (6 mL) at −78° C. and N was added BCl (1.0 M in DCM, 3.0 mL, 3.0 mmol), and the mixture was stirred at 0° C. for 3 hours. The reaction mixture was cooled at −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash chromatography on silica gel (1 M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-2-methyl-1-(((1s,4S)-4-vinylcyclohexyl)methyl)piperidine-3,4,5-triol as a white solid (0.078 g, 87%). 1H NMR (400 MHz, CD3OD) δ 5.88 (ddd, J = 17.4, 10.5, 6.3 Hz, 1H), 5.02-4.93 (m, 2H), 3.45 (ddd, J = 10.5, 9.0, 4.8 Hz, 1H), 3.10 (t, J = 9.0 Hz, 1H), 3.02 (dd, J = 11.3, 4.8 Hz, 1H), 2.94 (t, J = 9.1 Hz, 1H), 2.75 (dd, J = 12.9, 9.2 Hz, 1H), 2.21-2.18 (m, 1H), 2.06-2.00 (m, 1H), 1.96-1.91 (m, 2H), 1.71-1.67 (m, 1H), 1.62-1.35 (m, 8H), 1.18 (d, J = 6.1 Hz, 3H); ESI MS m / z 270.213 [M + H] + .
[0146] Examples 7 and 8 (2R,3R,4R,5S)-1-(((1s,4S)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol and (2R,3R,4R,5S)-1-(((1r,4R)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.18 g, 0.43 mmol), 4-isopropylcyclohexanecarbaldehyde (0.10 g, 0.65 mmol), and NaBH(OAc) (0.16 g, 0.75 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (15 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:16 to 1:10) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1s,4S)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine as a clear oil (0.099 g, 41%) and (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1r,4R)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine as a clear oil (0.027 g, 11%).
[0147] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1s,4S)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine (0.098 g, 0.18 mmol) in anhydrous DCM (6 mL) at −78° C. and N2, BCl3 (1.0 M in DCM, 1.5 mL, 1.5 mmol) was added and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(((1s,4S)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.045 g, 88%). 1H NMR (400 MHz, DMSO-d6) δ 4.67-4.64 (m, 3H), 3.24-3.16 (m, 1H), 2.89 (td, J = 8.8, 4.3 Hz, 1H), 2.83 (dd, J = 11.2, 4.8 Hz, 1H), 2.75-2.67 (m, 2H), 1.92-1.84 (m, 1H), 1.76-1.67 (m, 3H), 1.51-1.33 (m, 7H), 1.30-1.21 (m, 2H), 1.07 (d, J = 6.0 Hz, 3H), 1.04-1.01 (m, 1H), 0.83 (d, J = 6.7 Hz, 6H); ESI MS m / z 286.225 [M + H] + .
[0148] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1r,4R)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine (0.027 g, 0.049 mmol) in anhydrous DCM (5 mL) at −78° C. and N2, BCl3 (1.0 M in DCM, 1.0 mL, 1.0 mmol) was added and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(((1r,4R)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.013 g, 92%). 1H NMR (400 MHz, CD3OD) δ 3.49-3.42 (m, 1H), 3.10 (t, J = 9.1 Hz, 1H), 3.02 (dd, J = 11.3, 4.8 Hz, 1H), 2.95 (t, J = 9.1 Hz, 1H), 2.53 (dd, J = 12.8, 8.8 Hz, 1H), 2.07-1.91 (m, 4H), 1.77-1.71 (m, 3H), 1.50-1.35 (m, 3H), 1.17 (d, J = 6.1 Hz, 3H), 1.02-0.80 (m, 10H, 0.88 (including d, J = 6.8 Hz, 6H); ESI MS m / z 286.226 [M + H] + .
[0149] Examples 9 and 10 (2R,3R,4R,5S)-1-(((1s,4S)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol and (2R,3R,4R,5S)-1-(((1r,4R)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka]
[0150] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.18 g, 0.43 mmol), 4-(tert-butyl)cyclohexanecarbaldehyde (0.15 g, 0.89 mmol), and NaBH(OAc) (0.16 g, 0.75 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (15 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:16 to 1:10) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1s,4S)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine as a clear oil (0.080 g, 33%) and (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1r,4R)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine as a clear oil (0.088 g, 36%).
[0151] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1s,4S)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine (0.080 g, 0.14 mmol) in anhydrous DCM (8 mL) at −78° C. and N2, BCl3 (1.0 M in DCM, 1.5 mL, 1.5 mmol) was added and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(((1s,4S)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.038 g, 91%). 1H NMR (400 MHz, DMSO-d6) δ 4.67-4.64 (m, 3H), 3.24-3.16 (m, 1H), 2.92-2.81 (m, 3H), 2.74-2.68 (m, 1H), 1.92-1.85 (m, 1H), 1.79-1.68 (m, 4H), 1.55-1.42 (m, 4H), 1.28-1.18 (m, 1H), 1.07 (d, J = 6.0 Hz, 3H), 1.05-0.91 (m, 3H), 0.81 (s, 9H); ESI MS m / z 300.244 [M+H] + .
[0152] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1r,4R)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine (0.088 g, 0.15 mmol) in anhydrous DCM (8 mL) at −78° C. and N2, BCl3 (1.0 M in DCM, 1.5 mL, 1.5 mmol) was added and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(((1r,4R)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.043 g, 93%). 1H NMR (400 MHz, DMSO-d6) δ 4.66-4.63 (m, 3H), 3.24-3.16 (m, 1H), 2.88 (td, J = 8.8, 4.3 Hz, 1H), 2.82 (dd, J = 11.2, 4.7 Hz, 1H), 2.73-2.67 (m, 1H), 2.39 (dd, J = 12.5, 9.1 Hz, 1H), 1.90-1.65 (m, 7H), 1.35-1.24 (m, 1H), 1.03 (d, J = 6.0 Hz, 3H), 0.95-0.82 (m, 4H), 0.82 (s, 9H), 0.77-0.68 (m, 1H),); ESI MS m / z 300.245 [M + H] + .
[0153] Examples 11 and 12 (2R,3R,4R,5S)-2-Methyl-1-(((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol and (2R,3R,4R,5S)-2-methyl-1-(((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol [ka] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.195 g, 0.467 mmol), 4-(trifluoromethyl)cyclohexanecarbaldehyde (0.150 g, 0.842 mmol), and NaBH(OAc) (0.212 g, 1.00 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (15 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:12 to 1:7) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine as a clear oil (0.101 g, 37%) and (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine as a clear oil (0.047 g, 17%); ESI MS m / z 582.303 [M+H] + .
[0154] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine (0.10 g, 0.17 mmol) in anhydrous DCM (5 mL) at −78° C. and N2, BCl3 (1.0 M in DCM, 1.5 mL, 1.5 mmol) was added and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-2-methyl-1-(((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol as a white solid (0.047 g, 89%). 1H NMR (400 MHz, DMSO-d6) δ 4.67-4.65 (m, 3H), 3.25-3.18 (m, 1H), 2.90 (td, J = 8.8, 4.3 Hz, 1H), 2.83 (dd, J = 11.2, 4.8 Hz, 1H), 2.78-2.68 (m, 2H), 2.30-2.22 (m, 1H), 1.93-1.86 (m, 1H), 1.79-1.72 (m, 3H), 1.65-1.50 (m, 4H), 1.46-1.34 (m, 4H), 1.07 (d, J = 6.0 Hz, 3H); ESI MS m / z 312.170 [M + H] + .
[0155] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine (0.047 g, 0.081 mmol) in anhydrous DCM (3 mL) at −78° C. and N2, BCl3 (1.0 M in DCM, 1.5 mL, 1.5 mmol) was added and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-2-methyl-1-(((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol as a white solid (0.021 g, 84%). 1H NMR (400 MHz, DMSO-d6) δ 4.67-4.64 (m, 3H), 3.25-3.18 (m, 1H), 2.90 (td, J = 8.8, 4.3 Hz, 1H), 2.83 (dd, J = 11.2, 4.7 Hz, 1H), 2.70 (td, J = 8.8, 5.4 Hz, 1H), 2.42 (dd, J = 11.7, 9.3 Hz, 1H), 2.22-2.10 (m, 1H), 1.93-1.67 (m, 7H), 1.45-1.35 (m, 1H), 1.30-1.14 (m, 2H), 1.04 (d, J = 6.0 Hz, 3H), 0.97-0.87 (m, 1H), 0.85-0.75 (m, 1H); ESI MS m / z 312.164 [M + H] + .
[0156] Examples 13 and 14 (2R,3R,4R,5S)-1-(((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol and (2R,3R,4R,5S)-1-(((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka]
[0157] To a solution of 4-(hydroxymethyl)cyclohexanecarboxylic acid (1.00 g, 6.32 mmol) in anhydrous MeOH (25 mL), SOCl (1.55 g, 13.0 mmol) was added dropwise, and the mixture was stirred at room temperature for 4 hours. The solvent was then removed under reduced pressure, and the residue was diluted with saturated aqueous NaHCO (30 mL). After extraction with DCM (3 × 30 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure to give a clear liquid. The liquid was dissolved in anhydrous THF (40 mL), and to this was added MeMgBr (3.0 M in EtO, 10 mL, 30 mmol) at 0 °C. After stirring at room temperature for 16 hours, the reaction mixture was diluted with saturated aqueous NH Cl (50 mL) and extracted with EtOAc (5 × 50 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc) to give 2-(4-(hydroxymethyl)cyclohexyl)propan-2-ol as a white solid (1.05 g, 96%, 2 steps). 1 1 H NMR showed that the solid contained a mixture of cis and trans isomers in a ratio of cis:trans=0.82:0.18).
[0158] To a solution of the above material (1.05 g, 6.09 mmol) in anhydrous DCM (30 mL) at 0 °C and N was added DIPEA (1.41 g, 10.9 mol), DMAP (0.24 g, 2.0 mmol), and BzCl (1.29 g, 9.18 mmol). The mixture was stirred at room temperature for 16 h and then diluted with saturated aqueous NaHCO (50 mL). After extraction with DCM (3 × 50 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4 to 1:1) to give methyl (4-(2-hydroxypropan-2-yl)cyclohexyl)benzoate as a clear oil (1.68 g, 100%). 1 H NMR showed that the oil contained a mixture of cis and trans isomers in a ratio of cis:trans = 0.82:0.18).
[0159] To a solution of the above material (1.65 g, 5.97 mmol) in anhydrous DCM (30 mL) was added DAST (1.45 g, 9.06 mmol) at −78° C. under N2, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was cooled at −78° C. and quenched with saturated aqueous NaHCO3 (50 mL). The organic layer was collected, and the aqueous was extracted with DCM (3 × 40 mL). The combined extracts were dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:19) to give methyl (4-(2-fluoropropan-2-yl)cyclohexyl)benzoate as a clear oil (1.07 g, 66%). 1 H NMR showed that the oil contained a mixture of cis and trans isomers in a ratio of cis:trans = 0.82:0.18).
[0160] A mixture of the above material (0.850 g, 3.05 mmol) and K2CO3 (0.80 g, 0.58 mmol) in MeOH (60 mL) was stirred at room temperature for 4 hours. The solvent was removed under reduced pressure, and the residue was diluted with saturated aqueous NaHCO3 (40 mL). After extraction with DCM (3 × 40 mL), the combined extracts were dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:1 to 3:2) to give (4-(2-fluoropropan-2-yl)cyclohexyl)methanol as a clear oil (0.49 g, 92%). 1 H NMR showed that the oil contained a mixture of cis and trans isomers in a ratio of cis:trans = 0.82:0.18).
[0161] A mixture of the above material (0.47 g, 2.7 mmol) and DMP (1.7 g, 4.0 mmol) in DCM (30 mL) was stirred at room temperature for 1.5 hours to form a white suspension. Hexane (20 mL) was added, and the suspension was filtered through a Celite cake. The filtrate was collected and concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:13 to 1:9) to give cis-4-(2-fluoropropan-2-yl)cyclohexanecarbaldehyde as a clear liquid (0.21 g, 44%). 1 H NMR (400 MHz, CDCl) δ 9.72 (s, 1H), 2.50-2.43 (m, 1H), 2.37-2.27 (m, 2H), 1.78-1.67 (m, 2H), 1.62-1.45 (m, 3H), 1.27 (s, 3H), 1.21 (s, 3H), 1.07-0.96 (m, 2H). trans-4-(2-Fluoropropan-2-yl)cyclohexanecarbaldehyde was also isolated as a white solid (impure, estimated 0.045 g, estimated 10%).
[0162] A mixture of cis-4-(2-fluoropropan-2-yl)cyclohexanecarbaldehyde (0.10 g, 0.58 mmol), (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.20 g, 0.48 mmol), and NaBH(OAc) (0.17 g, 0.80 mmol) in DCM (6 mL) under N was stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:12 to 1:8) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine as a clear oil (0.24 g, 87%).
[0163] A mixture of the above material (0.24 g, 0.42 mmol) and Pd(OH) / C (20% Pd by mass, 0.080 g, 0.15 mmol) in MeOH (20 mL) and 4 drops of concentrated HCl was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was dissolved in anhydrous pyridine (3 mL), and to this was added AcO (0.5 mL) at 0 °C. The mixture was stirred at room temperature for 16 hours and diluted with saturated aqueous NaHCO (20 mL). After extraction with EtOAc (2 × 20 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was treated with 1 M NH in MeOH (5 mL) at room temperature for 16 hours. After concentration under reduced pressure, the residue was purified by flash chromatography on silica gel (1M NHMeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol (0.098 g, 77%, 3 steps) as a white solid. 1 H NMR (400 MHz, CD3OD) δ 3.45 (ddd, J = 10.6, 9.1, 4.8 Hz, 1H), 3.11 (t, J = 9.0 Hz, 1H), 3.04-2.92 (m, 3H), 2.10-2.03 (m, 1H), 1.95-1.86 (m, 4H), 1.66-1.37 (m, 6H), 1.29 (s, 3H), 1.24 (s, 3H), 1.24-1.15 (including m, 5H, 1.20 (d, J = 6.1 Hz, 3H)); ESI MS m / z 304.226 [M+H] + .
[0164] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.16 g, 0.38 mmol), trans-4-(2-fluoropropan-2-yl)cyclohexanecarbaldehyde (0.040 g, approximately 90% pure, 0.20 mmol), and NaBH(OAc) (0.17 g, 0.80 mmol) in DCM (6 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:12 to 1:8) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine as a clear oil (0.061 g, 51%).
[0165] A mixture of the above material (0.0600 g, 0.105 mmol), Pd(OH) / C (20% Pd by mass, 0.050 g, 0.094 mmol), and 2 drops of concentrated HCl in MeOH (15 mL) was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was dissolved in anhydrous pyridine (3 mL), and to it was added AcO (0.5 mL) at 0 °C. The mixture was stirred at room temperature for 16 h and diluted with saturated aqueous NaHCO (20 mL). After extraction with EtOAc (2 × 20 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:6 to 1:4) to give a white foam. The white foam was treated with 1M NH in MeOH (5 mL) at room temperature for 16 hours. After concentration under reduced pressure, the residue was purified by flash chromatography on silica gel (1M NHMeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol (0.0037 g, 12%, 3 steps) as a white solid. 1 H NMR (400 MHz, CD3OD) δ 3.46 (ddd, J = 10.6, 9.1, 4.8 Hz, 1H), 3.10 (t, J = 9.0 Hz, 1H), 3.02 (dd, J = 11.4, 4.8 Hz, 1H), 2.94 (t, J = 9.1 Hz, 1H), 2.55 (dd, J = 12.9, 9.0 Hz, 1H), 2.10-1.95 (m, 4H), 1.87-1.75 (m, 3H), 1.52-1.42 (m, 2H), 1.29 (s, 3H), 1.24 (s, 3H), 1.17 (d, J = 6.1 Hz, 3H), 1.17-1.02 (m, 2H), 0.99-0.80 (m, 2H); ESI MS m / z 304.230 [M + H] + .
[0166] Example 15 (2R,3R,4R,5S)-2-Methyl-1-(((trans)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol [ka] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(piperidin-4-ylmethyl)piperidine (186 mg, 0.36 mmol), trans-3-(trifluoromethyl)cyclohexanecarbaldehyde (100 mg, 0.55 mmol), and HOAc (3 drops) in anhydrous MeOH (5 mL) under Ar was added NaBHCN (40 mg, 95%, 0.60 mmol). The mixture was stirred at room temperature for 18 hours, saturated aqueous NaHCO (30 mL) was added, and the mixture was extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel using 20% EtOAc in hexanes to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-((3-(trifluoromethyl)cyclohexyl)methyl)piperidine as a white foam (140 mg, 67%). 1 1 H NMR showed this material to be a mixture of two stereoisomers.
[0167] To a solution of the above material (140 mg, 0.24 mmol) in anhydrous DCM (2 mL) under Ar at −78° C., BCl solution (2.4 mL, 1 M in DCM, 2.40 mmol) was added. The mixture was stirred at −78° C. for 1 h and at 0° C. for 4 h; MeOH (20 mL) was added. The mixture was stirred at 0° C. for an additional 2 h and evaporated to dryness under reduced pressure. The residue was purified by flash chromatography on silica gel (dry load) using 10% MeOH and 2% NH in DCM to give a mixture of (2R,3R,4R,5S)-2-methyl-1-(((1S,3S)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol and (2R,3R,4R,5S)-2-methyl-1-(((1R,3R)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol (16) as a white foam (46 mg, 61%). 1 H NMR (400 MHz, DMSO) δ 4.70-4.66 (m, 3H), 3.24-3.18 (m, 1H), 3.04-2.59 (m, 4H), 2.30-2.78 (m, 1H), 2.12-1.66 (m, 5H), 1.65-1.17 (m, 7H), 1.16-0.90 (m, 3H); ESI MS m / z 312.16 [M + H] + .
[0168] Example 16 (2R,3R,4R,5S)-2-Methyl-1-(((cis)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol [ka] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(piperidin-4-ylmethyl)piperidine (186 mg, 0.36 mmol), cis-3-(trifluoromethyl)cyclohexanecarbaldehyde (98 mg, 0.54 mmol), and HOAc (3 drops) in anhydrous MeOH (5 mL) under Ar was added NaBHCN (36 mg, 95%, 0.54 mmol). The mixture was stirred at room temperature for 18 h, saturated aqueous NaHCO (30 mL) was added, and the mixture was extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel using 20% EtOAc in hexanes to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-((3-(trifluoromethyl)cyclohexyl)methyl)piperidine as a white foam (100 mg, 48%). 1 1 H NMR showed this material to be a mixture of two stereoisomers.
[0169] To a solution of the above material (100 mg, 0.17 mmol) in anhydrous DCM (2 mL) under Ar at −78° C. was added BCl solution (1.7 mL, 1 M in DCM, 1.70 mmol). The mixture was stirred at −78° C. for 1 h and at 0° C. for 4 h; MeOH (20 mL) was added. The mixture was stirred at 0° C. for an additional 2 h and evaporated to dryness under reduced pressure. The residue was purified by flash chromatography on silica gel (dry load) using 10% MeOH and 2% NH in DCM to give a mixture of (2R,3R,4R,5S)-2-methyl-1-(((1R,3S)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol and (2R,3R,4R,5S)-2-methyl-1-(((1S,3R)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol as a white foam (38 mg, 67%). 1H NMR (400 MHz, DMSO) δ 4.68-4.57 (m, 3H), 3.23-3.19 (m, 1H), 2.96-2.78 (m, 2H), 2.77-2.65 (m, 1H), 2.48-2.44 (m, 1H), 2.27-2.21 (m, 1H), 2.15-1.44 (m, 8H), 1.42-1.10 (m, 2H), 1.05 (d, J = 6.0 Hz, 3H), 0.85-0.50 (m, 2H); ESI MS m / z 312.16 [M + H] + .
[0170] Examples 17 and 18 (2R,3R,4R,5S)-1-(((1s,4S)-4-methoxycyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol and (2R,3R,4R,5S)-1-(((1r,4R)-4-methoxycyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of 4-methoxycyclohexanecarboxylic acid (340 mg, 2.15 mmol) in anhydrous THF (10 mL) at 0 °C was added LAH (245 mg, 6.45 mmol), and the mixture was stirred at 0 °C for 1 h. The mixture was slowly quenched with saturated aqueous NaSO and filtered. The solid was washed with EtOAc. The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure to give crude (4-methoxycyclohexyl)methanol as an oil (320 mg).
[0171] To a solution of the above material (180 mg, 1.25 mmol) in anhydrous DCM (10 mL) at 0° C., DMP (689 mg, 1.63 mmol) was added, and the mixture was stirred at 0° C. for 2 hours. The mixture was slowly quenched with NaSO solution. The mixture was extracted with DCM (3×20 mL). The combined organic layers were washed with water (2×10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give (1s,4s)-4-methoxycyclohexanecarbaldehyde as an oil (67 mg, 38%); 1 H NMR (400 MHz, CDCl3) δ 9.64 (d, J = 1.3 Hz, 1H), 3.39 (dq, J = 5.7, 2.9 Hz, 1H), 3.33 (s, 3H), 2.28 (ttd, J = 8.9, 4.2, 1.2 Hz, 1H), 1.93-1.74 (m, 4H), 1.73-1.55 (m, 4H). (1r,4r)-4-Methoxycyclohexanecarbaldehyde was also isolated as an oil (20 mg, 11%); 1 H NMR (400 MHz, CDCl3) δ 9.67 (d, J = 1.3 Hz, 1H), 3.38 (s, 3H), 3.20-3.08 (m, 1H), 2.31-2.20 (m, 1H), 2.16-2.00 (m, 4H), 1.45-1.25 (m, 4H).
[0172] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (80 mg, 0.19 mmol) and (1s,4s)-4-methoxycyclohexanecarbaldehyde (55 mg, 0.39 mmol) in anhydrous MeOH (5 mL) was added HOAc (0.10 mL, 1.75 mmol) and stirred for 30 minutes. NaBHCN (24 mg, 0.39 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1s,4S)-4-methoxycyclohexyl)methyl)-2-methylpiperidine as an oil (92 mg, 95%). 1 H NMR (400 MHz, CDCl3) δ 7.40-7.26 (m, 15H), 4.97 (dd, J = 13.3, 10.9 Hz, 2H), 4.85 (d, J = 11.0 Hz, 1H), 4.78-4.57 (m, 3H), 3.59 (td, J = 9.8, 4.5 Hz, 1H), 3.51 (t, J = 9.0 Hz, 1H), 3.43 (s, 1H), 3.33 (s, 3H), 3.16-2.98 (m, 2H), 2.57 (dd, J = 12.8, 8.6 Hz, 1H), 2.26 (dd, J = 9.3, 6.0 Hz, 1H), 2.10-1.93 (m, 2H), 1.90-1.80 (m, 2H), 1.62-1.22 (m, 7H), 1.19 (d, J = 6.1 Hz, 3H).
[0173] To a solution of the above material (90 mg, 0.16 mmol) in EtOH (10 mL) was added Pd(OH) / C (20% by weight, 8.6 mg, 0.012 mmol) and 6 N HCl (0.1 mL). The mixture was treated with hydrogen (1 atmosphere) for 18 h. The catalyst was filtered off through Celite, and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(((1s,4S)-4-methoxycyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (30 mg, 67%). 1 H NMR (400 MHz, CD3OD) δ 3.51-3.43 (m, 2H), 3.32 (s, 3H), 3.12 (t, J = 9.0 Hz, 1H), 3.03 (dd, J = 11.4, 4.8 Hz, 1H), 2.95 (t, J = 9.1 Hz, 1H), 2.63 (dd, J = 12.8, 8.9 Hz, 1H), 2.09-2.01 (m, 1H), 2.00-1.92 (m, 2H), 1.91-1.82 (m, 2H), 1.67-1.41 (m, 5H), 1.36-1.23 (m, 2H), 1.19 (d, J = 6.1 Hz, 3H); ESI MS m / z 274.20 [M + H] + .
[0174] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (40 mg, 0.096 mmol) and (1r,4r)-4-methoxycyclohexanecarbaldehyde (20 mg, 0.14 mmol) in anhydrous MeOH (5 mL), HOAc (0.10 mL, 1.75 mmol) was added and stirred for 30 minutes. NaBHCN (12 mg, 0.19 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1r,4R)-4-methoxycyclohexyl)methyl)-2-methylpiperidine as an oil (34 mg, 65%).
[0175] To a solution of the above material (30 mg, 0.055 mmol) in EtOH (10 mL) was added Pd(OH) / C (20% by weight, 8.6 mg, 0.012 mmol) and 6 N HCl (0.1 mL). The mixture was treated with hydrogen (1 atm) for 18 h. The catalyst was filtered off through Celite, and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(((1r,4R)-4-methoxycyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (12 mg, 80%). 1H NMR (400 MHz, CD3OD) δ 3.51-3.43 (m, 1H), 3.36 (s, 3H), 3.21-3.08 (m, 2H), 3.03 (dd, J = 11.4, 4.8 Hz, 1H), 2.95 (t, J = 9.1 Hz, 1H), 2.55 (dd, J = 12.8, 8.9 Hz, 1H), 2.15-1.92 (m, 6H), 1.81-1.72 (m, 1H), 1.54-1.40 (m, 1H), 1.27-1.08 (m, 5H), 1.05-0.83 (m, 2H); ESI MS m / z 274.20 [M + H] + .
[0176] Example 19 (2R,3R,4R,5S)-1-((4-(methoxymethyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(piperidin-4-ylmethyl)piperidine (82 mg, 0.19 mmol) and 4-(methoxymethyl)cyclohexanecarbaldehyde (33 mg, 0.21 mmol) in anhydrous DCM (5 mL) under Ar was added NaBH(OAc) (84 mg, 0.39 mmol). The mixture was stirred at room temperature for 18 h, saturated aqueous NaHCO (30 mL) was added, and the mixture was extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel using 20% EtOAc in hexanes to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-((4-(methoxymethyl)cyclohexyl)methyl)-2-methylpiperidine as a mixture of cis and trans isomers (92 mg, 85%).
[0177] To a solution of the above material (92 mg, 0.17 mmol) in anhydrous DCM (5 mL) under Ar at −78° C. was added BCl solution (1.3 mL, 1 M in DCM, 1.3 mmol). The mixture was stirred at −78° C. for 1 h and at 0° C. for 4 h; MeOH (20 mL) was added. The mixture was stirred at 0° C. for an additional 2 h and evaporated to dryness. The residue was purified by flash chromatography on silica gel using 10% MeOH and 2% NH in DCM to give a mixture of (2R,3R,4R,5S)-1-((4-(methoxymethyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol as a white foam (35 mg, 74%); this material was isolated as a mixture of cis and trans isomers. 1 H NMR (400 MHz, CD3OD) δ 3.57-3.40 (m, 1H), 3.35-3.31 (m, 3.5H), 3.22 (d, J = 6.4 Hz, 1.5H), 3.18-3.09 (m, 1H), 3.04 (dd, J = 11.3, 4.8 Hz, 1H), 2.97 (t, J = 9.1 Hz, 1H), 2.81 (dd, J = 12.9, 9.3 Hz, 0.25H), 2.81 (dd, J = 12.9, 9.3 Hz, 0.75H), 2.17-1.90 (m, 4H), 1.87-1.69 (m, 2H), 1.56-1.33 (m, 4H), 1.57-1.54 (m, 3H), 1.11-0.75 (m, 3H); ESI MS m / z 288.2 [M + H] + .
[0178] Example 20 (2R,3R,4R,5S)-1-(((1s,4S)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of cis-cyclohexane-1,4-dicarboxylic acid monomethyl ester (3.7 g, 19.8 mmol) in THF (100 mL) was added borane-dimethyl sulfide complex (2.25 g, 29.7 mmol) under ice-cooling, and the mixture was stirred for 15 minutes and at room temperature for 4 hours. MeOH (5 mL) was added, and the contents were evaporated under reduced pressure. 1 M NaOH (20 mL) was added to the residue, and the mixture was extracted with EtOAc. The organics were washed with brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (1s,4s)-methyl 4-(hydroxymethyl)cyclohexanecarboxylate (2.35 g, 69%) as an oil. 1 H NMR (500 MHz, CDCl3) δ 3.65 (s, 3H), 3.45 (dd, J = 6.3, 0.9 Hz, 2H), 2.56-2.53 (m, 1H), 2.01-1.94 (m, 2H), 1.89-1.85 (m, 1H), 1.63-1.49 (m, 5H), 1.31-1.21 (m, 2H).
[0179] To a stirred solution of the above material (0.78 g, 4.52 mmol) in dry DCM (35 mL) at 0 °C was added DMP (2.8 g, 6.7 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with a 1:1 mixture of 1 M NaSO:saturated NaHCO solution (20 mL) and further stirred for 30 min before diluting with DCM (40 mL). The organics were separated, dried over anhydrous NaSO, and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (1s,4s)-methyl 4-formylcyclohexanecarboxylate (0.57 g, 74%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 9.61 (s, 1H), 3.61 (s, 3H), 2.45-2.37 (m, 1H), 2.35-2.29 (m, 1H), 1.94-1.85 (m, 2H), 1.75-1.59 (m, 6H).
[0180] To a mixture of methyltriphenylphosphonium bromide (1.5 g, 4.4 mmol) in anhydrous THF (15 mL) at 0 °C was added KOtBu (0.5 g, 4.4 mmol). The mixture was stirred for 30 minutes, and then (1s,4s)-methyl 4-formylcyclohexanecarboxylate (0.5 g, 2.9 mmol) predissolved in anhydrous THF (10 mL) was slowly added. The mixture was warmed to room temperature, stirred for 2 hours, and then concentrated under reduced pressure. The resulting crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (1s,4s)-methyl 4-vinylcyclohexanecarboxylate (0.5 g, 68%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 5.78 (ddd, J = 17.1, 10.5, 6.3 Hz, 1H), 4.98-4.89 (m, 2H), 3.65 (s, 3H), 2.50 (ddd, J = 10.4, 5.9, 4.4 Hz, 1H), 2.16-2.05 (m, 1H), 2.03-1.92 (m, 2H), 1.63-1.51 (m, 4H), 1.46-1.36 (m, 2H).
[0181] To a mixture of the above material (0.20 g, 1.18 mmol) in DCE (8 mL) at 0 °C, diethylzinc (1.0 M in hexane, 3.5 mL, 3.5 mmol) was added, followed by chloroiodomethane (0.51 mL, 7.08 mmol). The mixture was stirred at 0 °C for 2 h and then at room temperature for 2 h before being quenched with saturated aqueous NH4Cl. The reaction mixture was partitioned between DCM and water, and the organics were separated, dried over anhydrous Na2SO4, and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (1s,4s)-methyl 4-cyclopropylcyclohexanecarboxylate (0.18 g, 83.6%) as an oil. 1H NMR (400 MHz, CDCl3) δ 3.67 (s, 3H), 2.48 (tt, J = 6.3, 4.3 Hz, 1H), 2.02-1.92 (m, 2H), 1.64-1.49 (m, 4H), 1.48-1.38 (m, 2H), 0.71-0.62 (m, 1H), 0.61-0.51 (m, 1H), 0.41-0.32 (m, 2H), 0.04-0.03 (m, 2H).
[0182] To a cooled (0 °C) solution of the above material (0.19 g, 1.04 mmol) in 5 mL of anhydrous THF, 0.11 g (3.12 mmol) of LAH was added portionwise with stirring under Ar. The mixture was stirred at 0 °C for 2.5 h and then at reflux for 5 h until the starting material disappeared. The mixture was diluted with EtOAc and washed with 1.0 M HCl, water, and brine. The organics were dried over anhydrous NaSO and concentrated to afford ((1s,4s)-4-cyclopropylcyclohexyl)methanol (0.13 g, 84%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 3.54 (d, J = 6.8 Hz, 2H), 1.62 (ttd, J = 10.2, 6.8, 3.0 Hz, 1H), 1.57-1.48 (m, 7H), 1.48-1.39 (m, 2H), 0.80-0.71 (m, 1H), 0.68-0.60 (m, 1H), 0.42-0.35 (m, 2H), 0.04-0.01 (m, 2H).
[0183] To a stirred solution of the above material (0.135 g, 0.87 mmol) in dry DCM (6 mL) at 0 °C was added DMP (0.55 g, 1.3 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with a 1:1 mixture of 1 M NaSO:saturated NaHCO solution (20 mL) and further stirred for 30 min before diluting with DCM (40 mL). The organics were separated, dried over anhydrous NaSO, and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:9) to give (1s,4s)-4-cyclopropylcyclohexanecarbaldehyde (0.06 g, 45%) as an oil. 1 H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H), 2.37-2.33 (m, 1H), 2.09-2.01 (m, 2H), 1.69-1.60 (m, 2H), 1.59-1.51 (m, 2H), 1.29-1.20 (m, 2H), 0.57-0.50 (m, 2H), 0.40-0.33 (m, 2H), 0.04-0.02 (m, 2H).
[0184] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.2 g, 0.5 mmol) and (1s,4s)-4-cyclopropylcyclohexanecarbaldehyde (0.06 g, 0.40 mmol) in anhydrous MeOH (5 mL) was added AcOH (a few drops) and the mixture was stirred at room temperature for 10 minutes. Sodium cyanoborohydride (0.032 g, 0.50 mmol) was added and the reaction was stirred at room temperature overnight. The mixture was concentrated and diluted with EtOAc (30 mL), and the organics were washed with saturated NaHCO solution. The organics were dried over anhydrous Na2SO4, concentrated, and the crude residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:9) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1s,4S)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine (0.11 g, 50.9%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.39-7.27 (m, 15H), 4.98 (dd, J = 16.1, 10.9 Hz, 2H), 4.85 (d, J = 11.0 Hz, 1H), 4.77-4.65 (m, 2H), 4.63 (d, J = 10.8 Hz, 1H), 3.64-3.58 (m, 1H), 3.57-3.49 (m, 1H), 3.16-3.04 (m, 2H), 2.69 (dd, J = 12.8, 9.0 Hz, 1H), 2.29 (dq, J = 12.4, 6.2 Hz, 1H), 2.08-1.97 (m, 2H), 1.60-1.45 (m, 8H), 1.41-1.29 (m, 2H), 1.24-1.19 (m, 2H), 0.81-0.72 (m, 1H), 0.68-0.61 (m, 1H), 0.45-0.38 (m, 2H), 0.09-0.03 (m, 2H); ESI MS m / z 554.349 [M + H] + .
[0185] To a solution of the above material (0.1 g, 0.18 mmol) in DCM (5 mL) under Ar at −78° C., BCl (1.0 M in DCM, 0.95 mL, 0.95 mmol) was added, and the mixture was stirred for 2 h, during which time the bath temperature reached 0° C. The mixture was further stirred at 0° C. for 2 h and then quenched by the slow addition of MeOH (2 mL). After stirring at room temperature for 30 min, the mixture was concentrated under reduced pressure. The resulting residue was dissolved in a mixture of AcO / pyridine (4.5 mL, 1:9), stirred overnight, and then evaporated under reduced pressure. 2 M NH / MeOH solution (8 mL) was then added to the crude, and the mixture was stirred overnight and concentrated to dryness. The residue was purified and separated by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-(((1s,4S)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol (0.02 g, 39.2%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 3.51-3.43 (m, 1H), 3.15-3.09 (m, 1H), 3.05 (dd, J = 11.3, 4.8 Hz, 1H), 3.00-2.94 (m, 1H), 2.80 (dd, J = 12.9, 9.2 Hz, 1H), 2.10-2.04 (m, 1H), 2.02-1.94 (m, 2H), 1.75-1.63 (m, 1H), 1.63-1.48 (m, 6H), 1.47-1.38 (m, 2H), 1.22 (d, J = 6.1 Hz, 3H), 0.83-0.74 (m, 1H), 0.67-0.59 (m, 1H), 0.46-0.39 (m, 2H), 0.07-0.02 (m, 2H); ESI MS m / z 284.218 [M + H] + .
[0186] Example 21 (2R,3R,4R,5S)-1-(((1r,4R)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of trans-1,4-cyclohexanedicarboxylic acid monomethyl ester (1.86 g, 10 mmol) in THF (60 mL) and EtN (1.5 mL, 10.8 mmol) at −5° C. was added methyl chloroformate (1.0 mL, 10.8 mmol) while maintaining the temperature between −5° C. and 0° C. After 1 h, the mixture was added via cannula to a solution of NaBH (0.8 g, 21.6 mmol) in water (30 mL) at 10° C. The reaction mixture was further stirred at 10° C. for 30 min and then quenched with 1 N HCl until pH = 1. The mixture was partitioned with EtOAc, and the organics were washed with brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:9) to give (1r,4r)-methyl 4-(hydroxymethyl)cyclohexanecarboxylate (1.34 g, 77.8%) as an oil. 1H NMR (400 MHz, CDCl3) 3.66 (s, 3H), 3.64-3.46 (m, 2H), 2.35-2.20 (m, 1H), 2.13-1.97 (m, 2H), 1.93-1.79 (m, 1H), 1.60-1.33 (m, 4H), 1.05 (m, 2H).
[0187] To a stirred solution of the above material (0.6 g, 3.48 mmol) in dry DCM (10 mL) at 0 °C was added DMP (2.2 g, 5.2 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with a 1:1 mixture of 1 M NaSO:saturated NaHCO solution (20 mL) and further stirred for 30 min before diluting with DCM (40 mL). The organics were separated, dried over anhydrous NaSO, and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (1r,4r)-methyl 4-formylcyclohexanecarboxylate (0.36 g, 60.7%) as an oil. 1 H NMR (500 MHz, CDCl3) δ 9.50 (s, 1H), 3.54 (s, 3H), 2.24-2.08 (m, 2H), 2.0-1.9 (m, 4H), 1.37 (qt, J = 13.6, 3.4 Hz, 2H), 1.18 (qt, J = 12.6, 3.4 Hz, 2H).
[0188] To a mixture of methyltriphenylphosphonium bromide (1.14 g, 3.2 mmol) in anhydrous THF (8 mL) at 0 °C was added KOtBu (0.36 g, 3.2 mmol). The mixture was stirred for 30 minutes, and then (1r,4r)-methyl 4-formylcyclohexanecarboxylate (0.36 g, 2.12 mmol) predissolved in anhydrous THF (8 mL) was slowly added. The mixture was warmed to room temperature, stirred for 2 hours, and then concentrated under reduced pressure. The resulting crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (1r,4r)-methyl 4-vinylcyclohexanecarboxylate (0.25 g, 70%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 5.71 (ddd, J = 17.1, 10.4, 6.4 Hz, 1H), 4.99-4.81 (m, 2H), 3.62 (s, 3H), 2.20 (tt, J = 12.3, 3.6 Hz, 1H), 2.02-1.85 (m, 3H), 1.85-1.73 (m, 2H), 1.48-1.37 (m, 2H), 1.13-1.02 (m, 2H).
[0189] To a mixture of the above material (0.25 g, 1.48 mmol) in DCE (8 mL) at 0 °C, diethylzinc (1.0 M in hexane, 4.4 mL, 4.4 mmol) was added, followed by chloroiodomethane (0.65 mL, 8.88 mmol). The mixture was stirred at 0 °C for 2 h and then at room temperature for 2 h before being quenched with saturated aqueous NH4Cl. The reaction mixture was partitioned between DCM and water, and the organics were separated, dried over anhydrous Na2SO4, and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (1r,4r)-methyl 4-cyclopropylcyclohexanecarboxylate (0.24 g, 88.9%) as an oil. 1H NMR (400 MHz, CDCl3) δ 3.63 (s, 3H), 2.21 (tt, J = 12.2, 3.6 Hz, 1H), 1.99-1.90 (m, 2H), 1.89-1.81 (m, 2H), 1.33 (tdd, J = 13.1, 12.0, 3.4 Hz, 2H), 1.13-1.00 (m, 2H), 0.50-0.38 (m, 2H), 0.38-0.30 (m, 2H), 0.05-0.03 (m, 2H).
[0190] To a cooled (0 °C) solution of the above material (0.24 g, 1.31 mmol) in 5 mL of anhydrous THF, 0.15 g (3.95 mmol) of LAH was added portionwise with stirring under Ar. The mixture was stirred at 0 °C for 2.5 h and then at reflux for 5 h until the starting material disappeared. The mixture was diluted with EtOAc and washed with 1.0 M HCl, water, and brine. The organics were dried over anhydrous NaSO and concentrated to afford ((1r,4r)-4-cyclopropylcyclohexyl)methanol (0.19 g, 94%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 3.44 (d, J = 6.4 Hz, 2H), 1.91-1.70 (m, 4H), 1.45 (tdt, J = 12.0, 6.4, 3.2 Hz, 1H), 1.10 (qd, J = 13.1, 12.7, 3.2 Hz, 2H), 0.88 (qd, J = 12.7, 3.2 Hz, 2H), 0.46 (dddd, J = 13.1, 11.3, 7.6, 3.8 Hz, 2H), 0.39-0.32 (m, 2H), 0.08-0.00 (m, 2H).
[0191] To a stirred solution of the above material (0.19 g, 1.23 mmol) in dry DCM (5 mL) at 0 °C was added DMP (0.78 g, 1.84 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with a 1:1 mixture of 1 M NaSO:saturated NaHCO solution (20 mL) and further stirred for 30 min before diluting with DCM (40 mL). The organics were separated, dried over anhydrous NaSO, and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:9) to give (1r,4r)-4-cyclopropylcyclohexanecarbaldehyde (0.14 g, 74.7%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 9.59 (s, 1H), 2.22-2.11 (m, 1H), 2.06-1.84 (m, 4H), 1.27-1.04 (m, 4H), 0.52-0.40 (m, 2H), 0.40-0.33 (m, 2H), 0.04 (m, 2H).
[0192] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.23 g, 0.55 mmol) and (1r,4r)-4-cyclopropylcyclohexanecarbaldehyde (0.07 g, 0.46 mmol) in anhydrous MeOH (8 mL) was added AcOH (a few drops) and the mixture was stirred at room temperature for 10 minutes. Sodium cyanoborohydride (0.034 g, 0.55 mmol) was added and the reaction was stirred at room temperature overnight. The mixture was concentrated, diluted with EtOAc (30 mL), and the organics were washed with saturated aqueous NaHCO3. The organics were dried over anhydrous Na2SO4 and concentrated, and the crude residue was then purified by flash chromatography on silica gel (EtOAc / hexanes, 1:9) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(((1r,4R)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine (0.1 g, 39.2%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.39-7.26 (m, 15H), 4.97 (dd, J = 14.9, 10.9 Hz, 2H), 4.85 (d, J = 11.0 Hz, 1H), 4.78-4.58 (m, 3H), 3.59 (td, J = 9.7, 4.5 Hz, 1H), 3.51 (t, J = 9.0 Hz, 1H), 3.16-2.99 (m, 2H), 2.44 (dd, J = 12.8, 8.7 Hz, 1H), 2.29-2.21 (m, 1H), 2.09-1.92 (m, 2H), 1.90-1.77 (m, 3H), 1.73-1.61 (m, 1H), 1.39-1.28 (m, 1H), 1.18 (d, J = 6.1 Hz, 3H), 1.15-0.99 (m, 2H), 0.87-0.65 (m, 2H), 0.54-0.41 (m, 2H), 0.40-0.33 (m, 2H), 0.08-0.04 (m, 2H); ESI MS m / z 554.354 [M + H] + .
[0193] To a solution of the above material (0.1 g, 0.18 mmol) in DCM (5 mL) under Ar at −78° C., BCl (1.0 M in DCM, 0.9 mL, 0.9 mmol) was added, and the mixture was stirred for 2 h, during which time the bath temperature reached 0° C. The mixture was further stirred at 0° C. for 2 h and then quenched by the slow addition of MeOH (2 mL). After stirring at room temperature for 30 min, the mixture was concentrated under reduced pressure. The resulting residue was neutralized with NHOH (0.5 mL) and concentrated again under reduced pressure. The crude residue was purified by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-(((1r,4R)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol (0.039 g, 77%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 3.55 (td, J = 9.9, 4.5 Hz, 1H), 3.23-3.13 (m, 2H), 3.07 (t, J = 9.0 Hz, 1H), 2.77-2.68 (m, 1H), 2.39-2.14 (m, 3H), 2.01-1.84 (m, 3H), 1.75 (dt, J = 12.7, 3.1 Hz, 1H), 1.61-1.50 (m, 1H), 1.26 (d, J = 6.2 Hz, 3H), 1.23-1.07 (m, 2H), 1.02-0.80 (m, 2H), 0.54-0.43 (m, 2H), 0.41-0.36 (m, 2H), 0.09-0.03 (m, 2H); ESI MS m / z 284.218 [M + H] + .
[0194] Example 22 (2R,3R,4R,5S)-2-Methyl-1-((4-phenylcyclohexyl)methyl)piperidine-3,4,5-triol [ka]
[0195] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.2 g, 0.5 mmol) in DCM (8 mL) was added 4-phenylcyclohexanecarbaldehyde (0.18 g, 1.0 mmol) and Na(OAc)BH (0.2 g, 1.0 mmol) mL, 0.77 mmol). The reaction was stirred at room temperature overnight and then diluted with DCM (25 mL). The organics were washed with saturated aqueous NaHCO, brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:9) to give a 1:1 cis / trans mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-((4-phenylcyclohexyl)methyl)piperidine (0.19 g, 64%) as an oil. ESI MS m / z 590.329 [M+H]+ .
[0196] To a solution of the above material (0.1 g, 0.17 mmol) in DCM (5 mL) under Ar at −78° C., BCl (1.0 M in DCM, 1.7 mL, 1.7 mmol) was added, and the mixture was stirred for 2 h, during which the bath temperature was warmed to 0° C. The mixture was stirred at 0° C. for the next 2 h and then quenched by the slow addition of MeOH (2 mL). After stirring at room temperature for 30 min, the mixture was concentrated under reduced pressure. The resulting residue was neutralized with NHOH (0.5 mL) and concentrated again under reduced pressure. The crude residue was purified and separated by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-2-methyl-1-((4-phenylcyclohexyl)methyl)piperidine-3,4,5-triol (0.047 g, 86.5%) as a white solid. 1 H NMR analysis showed this material to be an approximately 1:1 mixture of cis / trans isomers; ESI MS m / z 320.21 [M+H] + .
[0197] Example 23 (2R,3R,4R,5S)-2-Methyl-1-(spiro[2.5]octan-6-ylmethyl)piperidine-3,4,5-triol [ka] To a stirred solution of methyltriphenylphosphonium bromide (10.7 g, 300 mmol) in anhydrous THF (100 mL) was added KO tBu (3.36 g, 300 mmol) was added at 0 °C under N2 and stirred for 30 min. Then, ethyl 4-oxocyclohexanecarboxylate (3.4 g, 200 mmol) was dissolved in 20 mL of THF and added dropwise to the mixture under N2 and allowed to react at room temperature for 3 h. The reaction was quenched with saturated aqueous NaHCO3 at 0 °C. The mixture was extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give ethyl 4-methylenecyclohexanecarboxylate as an oil (2.25 g, 67%). 1 H NMR (400 MHz, CDCl3) δ 4.67 (d, J = 1.5 Hz, 2H), 4.15 (q, J = 7.1 Hz, 2H), 2.46 (tt, J = 11.0, 3.6 Hz, 1H), 2.36 (dt, J = 12.7, 3.7 Hz, 2H), 2.15-1.94 (m, 4H), 1.69-1.50 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H).
[0198] To a stirred solution of diethylzinc (16.5 mL, 1 M in hexane, 16.5 mmol) in anhydrous DCM (25 mL) was added TFA (1.1 mL, 16.4 mmol) under N at 0 °C, and the mixture was stirred for 60 min. Then, ethyl 4-methylenecyclohexanecarboxylate (1.1 g, 6.54 mmol) was dissolved in 3 mL of DCM and added dropwise to the mixture under N at 0 °C for 2 h. The reaction was quenched with water at 0 °C. The mixture was extracted with DCM (3 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over Na SO . After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give ethyl spiro[2.5]octane-6-carboxylate as an oil (0.90 g, 76%). 1H NMR (400 MHz, CDCl3) δ 4.15 (q, J = 7.1 Hz, 2H), 2.33 (tt, J = 10.8, 3.7 Hz, 1H), 1.91 (dt, J = 11.5, 3.1 Hz, 2H), 1.77-1.52 (m, 4H), 1.28 (t, J = 7.1 Hz, 3H), 1.06-0.96 (m, 2H), 0.35-0.18 (m, 4H).
[0199] To a solution of the above material (800 mg, 4.39 mmol) in anhydrous THF (10 mL) at 0 °C, LAH (500 mg, 13.2 mmol) was added, and the mixture was stirred at 0 °C for 1 h. The mixture was slowly quenched with saturated aqueous NaSO and filtered. The solid was washed with EtOAc. The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure to give crude spiro[2.5]octan-6-ylmethanol as an oil (725 mg). 1 H NMR (400 MHz, CDCl3) δ 3.52 (dd, J = 6.4, 1.0 Hz, 2H), 1.75 (ddd, J = 13.3, 8.2, 4.2 Hz, 4H), 1.60-1.41 (m, 2H), 1.25-1.07 (m, 2H), 1.01-0.87 (m, 2H), 0.43-0.11 (m, 4H).
[0200] To a solution of the above material (190 mg, 1.36 mmol) in anhydrous DCM (20 mL) at 0 °C, DMP (748 mg, 1.76 mmol) was added, and the mixture was stirred at 0 °C for 2 h. The mixture was slowly quenched with NaSO solution. The mixture was extracted with DCM (3 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give spiro[2.5]octane-6-carbaldehyde as an oil (63 mg, 34%). 1H NMR (400 MHz, CDCl3) δ 9.69 (d, J = 1.4 Hz, 1H), 2.30 (ddtd, J = 10.4, 7.3, 3.7, 1.3 Hz, 1H), 1.92 (ddd, J = 12.3, 6.2, 2.5 Hz, 2H), 1.72-1.46 (m, 4H), 1.10 (dt, J = 13.0, 3.9 Hz, 2H), 0.41-0.14 (m, 4H).
[0201] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (92 mg, 0.22 mmol) and spiro[2.5]octane-6-carbaldehyde (60 g, 0.43 mmol) in anhydrous MeOH (5 mL) was added HOAc (0.10 mL, 1.75 mmol), and the mixture was stirred for 30 minutes. NaBHCN (27 mg, 0.43 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(spiro[2.5]octan-6-ylmethyl)piperidine as an oil (59 mg, 50%). ESI MS m / z 540.32 [M+H] + .
[0202] To a stirred solution of the above material (55 mg, 0.10 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.80 mL, 0.80 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-2-methyl-1-(spiro[2.5]octan-6-ylmethyl)piperidine-3,4,5-triol as a white solid (17 mg, 63%). 1 H NMR (400 MHz, CD3OD) δ 3.52-3.43 (m, 1H), 3.12 (t, J = 9.0 Hz, 1H), 3.06 (dd, J = 11.4, 4.8 Hz, 1H), 2.96 (t, J = 9.1 Hz, 1H), 2.63 (dd, J = 12.8, 8.9 Hz, 1H), 2.11-1.93 (m, 3H), 1.92-1.83 (m, 1H), 1.82-1.61 (m, 3H), 1.61-1.47 (m, 1H), 1.19 (d, J = 6.1 Hz, 3H), 1.18-0.99 (m, 2H), 0.98 -0.88 (m, 2H), 0.32-0.16 (m, 4H); ESI MS m / z 270.19 [M + H] + .
[0203] Example 24 (2R,3R,4R,5S)-2-Methyl-1-(spiro[3.5]nonan-7-ylmethyl)piperidine-3,4,5-triol [ka] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(piperidin-4-ylmethyl)piperidine (491 mg, 1.1 mmol) and spiro[3.5]nonane-7-carbaldehyde (179 mg, 1.12 mmol) in anhydrous DCM (10 mL) under Ar was added NaBH(OAc) (499 mg, 2.3 mmol). The mixture was stirred at room temperature for 18 h, saturated aqueous NaHCO (30 mL) was added, and the mixture was extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel using 20% EtOAc in hexanes to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(spiro[3.5]nonan-7-ylmethyl)piperidine as a white form (203 mg, 31%).
[0204] To a solution of the above material (203 mg, 0.37 mmol) in anhydrous DCM (15 mL) at −78° C. under Ar was added BCl solution (10 mL, 1 M in DCM, 10 mmol). The mixture was stirred at −78° C. for 1 h and at 0° C. for 4 h; MeOH (20 mL) was added. The mixture was stirred at 0° C. for an additional 2 h and evaporated to dryness on a rotary evaporator. The residue was purified by flash chromatography on silica gel using 10% MeOH and 2% NH in DCM to give (2R,3R,4R,5S)-2-methyl-1-(spiro[3.5]nonan-7-ylmethyl)piperidine-3,4,5-triol as a white solid (88 mg, 85%). 1H NMR (400 MHz, CD3OD) δ 3.70-3.50 (m, 1H), 3.24 (t, J = 9.0 Hz, 2H), 3.16 (d, J = 9.1 Hz, 1H), 2.84 (bs, 1H), 2.50-2.45 (b, 3H), 1.97-1.66 (m, 9H), 1.64-1.47 (m, 2H), 1.44-1.21 (m, 5H), 1.15-0.89 (m, 2H); ESI MS m / z 284.2 [M + H] + .
[0205] Example 25 (2R,3R,4R,5S)-2-Methyl-1-(spiro[4.5]decan-8-ylmethyl)piperidine-3,4,5-triol [ka] To a suspension of LAH (1.80 g, 48.3 mmol) in anhydrous THF (60 mL) at 0 °C, a solution of 2,2'-(cyclopentane-1,1-diyl)diacetic acid (1.50 g, 8.05 mmol) was slowly added, and the mixture was refluxed for 2 h. The mixture was slowly quenched with saturated aqueous NaSO and filtered. The solid was washed with EtOAc. The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 2,2'-(cyclopentane-1,1-diyl)diethanol as a white solid (1.01 g, 79%). 1 H NMR (400 MHz, CDCl3) δ 3.76 (t, J = 6.9 Hz, 4H), 1.89 (s, 2H), 1.74-1.62 (m, 8H), 1.51-1.38 (m, 4H).
[0206] To a solution of the above material (500 mg, 3.16 mmol) in anhydrous pyridine (8 mL) at 0 °C, p-toluenesulfonyl chloride (1.27 g, 6.64 mmol) was added, and the mixture was stirred at room temperature for 18 hours. The mixture was slowly quenched with saturated aqueous Na2CO3 at 0 °C. The mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give cyclopentane-1,1-diylbis(ethane-2,1-diyl)bis(4-methylbenzenesulfonate) as a white solid (660 mg, 45%). 1 H NMR (400 MHz, CDCl3) δ 7.81-7.72 (m, 4H), 7.44-7.33 (m, 4H), 4.03 (t, J = 7.1 Hz, 4H), 2.48 (s, 6H), 1.65 (t, J = 7.1 Hz, 4H), 1.59-1.54 (m, 4H), 1.42-1.32 (m, 4H).
[0207] To a suspension of NaH (227 mg, 5.68 mmol) in anhydrous THF (10 mL) at 0 °C, a solution of dimethyl malonate (0.94 mL, 7.10 mmol) in THF (5 mL) was slowly added, and the mixture was stirred at 0 °C for 10 min. A solution of cyclopentane-1,1-diylbis(ethane-2,1-diyl)bis(4-methylbenzenesulfonate) (660 mg, 1.42 mmol) in THF (5 mL) was slowly added and stirred at 0 °C for 1 h. The mixture was refluxed for 20 h and then slowly quenched with saturated aqueous NH Cl. The mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over Na SO . After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give dimethyl spiro[4.5]decane-8,8-dicarboxylate as a clear oil (250 mg, 69%). 1H NMR (400 MHz, CDCl3) δ 3.74 (s, 6H), 2.04 (dd, J = 7.6, 4.7 Hz, 4H), 1.68-1.54 (m, 4H), 1.47-1.35 (m, 8H).
[0208] To a solution of the above material (250 mg, 0.98 mmol) in DMSO (5 mL) at room temperature, LiCl (166 mg, 3.92 mmol) and water (0.04 mL) were added, and the mixture was stirred at 185° C. for 5 h. The mixture was slowly quenched with saturated aqueous NaCO at 0° C. The mixture was extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (2×10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give methyl spiro[4.5]decane-8-carboxylate as a clear oil (123 mg, 64%). 1 H NMR (400 MHz, CDCl3) δ 3.69 (s, 3H), 2.34-2.21 (m, 1H), 1.88-1.78 (m, 2H), 1.66-1.51 (m, 8H), 1.44 (t, J = 6.9 Hz, 2H), 1.37 (t, J = 7.1 Hz, 2H), 1.33-1.24 (m, 2H).
[0209] To a solution of the above material (120 mg, 0.61 mmol) in anhydrous THF (5 mL) at 0 °C, LAH (93 mg, 2.45 mmol) was added, and the mixture was stirred at 0 °C for 2 h. The mixture was slowly quenched with saturated aqueous NaSO and filtered. The solid was washed with EtOAc. The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give spiro[4.5]decan-8-ylmethanol as a clear oil (101 mg, 99%). 1H NMR (400 MHz, CDCl3) δ 3.48 (d, J = 6.4 Hz, 2H), 1.69-1.34 (m, 14H), 1.29 (td, J = 13.1, 3.6 Hz, 2H), 1.15-1.01 (m, 2H).
[0210] To a solution of the above material (110 mg, 0.65 mmol) in anhydrous DCM (10 mL) at 0 °C, DMP (361 mg, 0.85 mmol) was added, and the mixture was stirred at 0 °C for 2 h. The mixture was slowly quenched with NaSO solution. The mixture was extracted with DCM (3 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give spiro[4.5]decane-8-carbaldehyde as an oil (60 mg, 55%).
[0211] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (97 mg, 0.23 mmol) and spiro[4.5]decane-8-carbaldehyde (58 mg, 0.35 mmol) in anhydrous DCM (5 mL) was added HOAc (0.10 mL, 1.75 mmol) and stirred for 30 minutes. Na(OAc)BH (74 mg, 0.35 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R(2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(spiro[4.5]decan-8-ylmethyl)piperidine as an oil (115 mg, 88%). ESI MS m / z 568.37 [M+H] + .
[0212] To a stirred solution of the above material (87 mg, 0.16 mmol) in anhydrous DCM (5 mL) was added BCl solution (1 M in DCM, 1.27 mL, 1.27 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-2-methyl-1-(spiro[4.5]decan-8-ylmethyl)piperidine-3,4,5-triol as a white solid (35 mg, 77%). 1 H NMR (400 MHz, CD3OD) δ 3.51-3.43 (m, 1H), 3.12 (t, J = 9.0 Hz, 1H), 3.04 (dd, J = 11.3, 4.8 Hz, 1H) 2.96 (t, J = 9.1 Hz, 1H), 2.58 (dd, J = 12.8, 8.8 Hz, 1H), 2.09-1.92 (m, 3H), 1.82-1.74 (m, 1H), 1.68-1.41 (m, 10H), 1.41-1.22 (m, 4H), 1.19 (d, J = 6.1 Hz, 3H), 1.14-0.92 (m, 2H); ESI MS m / z 298.24 [M + H] + .
[0213] Example 26 (2R,3R,4R,5S)-1-(((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of ((5s,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methanol (Bioorg. Med. Chem. Lett. 2019, 29, 373) (0.37 g, 1.86 mmol) in dry DCM (8 mL) at 0 °C was added DMP (1.19 g, 2.82 mmol). After stirring at 0 °C for 30 min, the reaction mixture was warmed to room temperature over 1.5 h. The reaction mixture was diluted with a 1:1 mixture of 1 M NaSO and saturated NaHCO (50 mL) and stirred for 30 min. DCM (30 mL) was added, and the organics were separated, dried over anhydrous NaSO, and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:1) to give (5s,8s)-3,3-dimethyl-2-oxaspiro[4.5]decane-8-carbaldehyde (0.25 g, 70.7%) as a gummy solid. 1 H NMR (500 MHz, CDCl3) δ 9.60 (s, 1H), 3.59 (s, 2H), 2.24-2.13 (m, 1H), 1.86-1.82 (m, 2H), 1.76-1.74 (m, 2H), 1.58 (d, J = 1.8 Hz, 2H), 1.48-1.32 (m, 4H), 1.23 (d, J = 2.2 Hz, 6H).
[0214] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.18 g, 0.43 mmol) in MeOH (5 mL) was added (5s,8s)-3,3-dimethyl-2-oxaspiro[4.5]decane-8-carbaldehyde (0.08 g, 0.43 mmol) and acetic acid (0.3 mL). After stirring at room temperature for 10 minutes, NaCNBH (0.04 g, 0.66 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated and then diluted with DCM (25 mL). The organics were washed with saturated aqueous NaHCO, brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:9) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-((3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl)-2-methylpiperidine (0.17 g, 66%) as an oil. 1 H NMR (500 MHz, CDCl3) δ 7.40-7.23 (m, 15H), 4.96 (dd, J = 16.8, 10.9 Hz, 2H), 4.84 (d, J = 11.0 Hz, 1H), 4.74 (d, J = 11.6 Hz, 1H), 4.64 (dd, J = 26.8, 11.2 Hz, 2H), 3.65 (d, J = 1.8 Hz, 2H), 3.61-3.54 (m, 1H), 3.50 (t, J = 9.0 Hz, 1H), 3.09 (t, J = 9.0 Hz, 1H), 3.03 (dd, J = 11.5, 4.7Hz, 1H), 2.46 (dd, J = 12.8, 8.9 Hz, 1H), 2.24 (dq, J = 12.1, 6.2 Hz, 1H), 2.07-1.94 (m, 2H), 1.81-1.67 (m, 3H), 1.64-1.52 (m, 3H), 1.40-1.30 (m, 3H), 1.27 (m, 6H), 1.20-1.14 (m, 3H), 0.96-0.74 (m, 2H); ESI MS m / z 598.394 [M + H] + .
[0215] A mixture of the above material (0.17 g, 0.28 mmol) and Pd(OH) / C (20 wt%, 0.02 g) in EtOH / 2N HCl (25 / 1 mL) was stirred overnight under 50 psi hydrogen pressure. The mixture was then filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. To the residue was added NHOH solution (3 mL), and the mixture was concentrated again. The crude residue was redissolved in pyridine (6 mL) and treated with AcO (0.6 mL). After stirring overnight at room temperature, the mixture was concentrated and purified by flash chromatography on silica gel (EtOAc / hexanes, 1:1) to give (2R,3R,4R,5S)-1-((3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl)-2-methylpiperidine-3,4,5-trityl triacetate, which was hydrolyzed by stirring overnight with a 1 M solution of NH in MeOH (10 mL). The crude residue was purified by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-((3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl)-2-methylpiperidine-3,4,5-triol (0.052 g, 56%) as a white solid. 1 H NMR (400 MHz, CD3OD) δ 3.69 (s, 2H), 3.46 (ddd, J = 10.5, 9.0, 4.7 Hz, 1H), 3.11 (t, J = 9.0 Hz, 1H), 3.02 (dd, J = 11.3, 4.8 Hz, 1H), 2.95 (t, J = 9.1 Hz, 1H), 2.58 (dd, J = 12.9, 8.8 Hz, 1H), 2.09-1.92 (m, 3H), 1.88-1.72 (m, 3H), 1.67-1.59 (m, 3H), 1.53-1.31 (m, 3H), 1.26 (s, 6H), 1.19 (d, J = 6.1 Hz, 3H), 1.05-0.84 (m, 2H); ESI MS m / z 328.245 [M + H] + .
[0216] Example 27 (2R,3R,4R,5S)-2-Methyl-1-((1,2,3,4-tetrahydronaphthalen-2-yl)methyl)piperidine-3,4,5-triol [ka]
[0217] To a solution of 1,2,3,4-tetrahydro-2-naphthoic acid (120 mg, 0.68 mmol) in anhydrous THF (5 mL) at 0 °C, LAH (78 mg, 2.04 mmol) was added, and the mixture was stirred at 0 °C for 2 h. The mixture was slowly quenched with saturated aqueous NaSO and filtered. The solid was washed with EtOAc. The combined organic layers were washed with HO (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure to give crude (1,2,3,4-tetrahydronaphthalen-2-yl)methanol as a clear oil. To a solution of the obtained oil in anhydrous DCM (5 mL) at 0 °C, DMP (375 mg, 0.88 mmol) was added, and the mixture was stirred at 0 °C for 2 h. The mixture was slowly quenched with NaSO solution. The mixture was extracted with DCM (3 × 20 mL). The combined organic layers were washed with HO (2×10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 1,2,3,4-tetrahydronaphthalene-2-carbaldehyde as an oil (44 mg, 40%).
[0218] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (80 mg, 0.19 mmol) and 1,2,3,4-tetrahydronaphthalene-2-carbaldehyde (40 mg, 0.25 mmol) in anhydrous DCM (5 mL) was added HOAc (0.10 mL, 1.75 mmol) and stirred for 30 minutes. NaBH(OAc) (52 mg, 0.25 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with HO (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-((1,2,3,4-tetrahydronaphthalen-2-yl)methyl)piperidine as an oil (90 mg, 84%). ESI MS m / z 562.71 [M+H] + .
[0219] To a solution of the above material (90 mg, 0.16 mmol) in anhydrous DCM (5 mL) was added BCl (1 M in DCM, 0.97 mL, 0.97 mmol) at −78° C. under N. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-2-methyl-1-((1,2,3,4-tetrahydronaphthalen-2-yl)methyl)piperidine-3,4,5-triol as a white solid (15 mg, 32%). This material was purified by 1 Based on 1 H NMR analysis, it was isolated as an approximately 1:1.2 mixture of diastereomers. 1H NMR (400 MHz, CD3OD) δ 7.06-7.03 (m, 4H), 3.60-3.47 (m, 1H), 3.23-3.07 (m, 2H), 3.04-2.69 (m, 5H), 2.49-2.34 (m, 1H), 2.21-1.83 (m, 5H), 1.46-1.29 (m, 1H), 1.24-1.16 (m, 3H); ESI MS m / z 292.19 [M + H] + .
[0220] Example 28 (2R,3R,4R,5S)-1-((2,3-dihydro-1H-inden-2-yl)methyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of 2-indanecarboxylic acid (200 mg, 1.23 mmol) in anhydrous THF (8 mL) at 0 °C was added LAH (141 mg, 3.70 mmol), and the mixture was stirred at 0 °C for 2 h. The mixture was slowly quenched with saturated aqueous NaSO and filtered. The solid was washed with EtOAc. The combined organic layers were washed with HO (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give (2,3-dihydro-1H-inden-2-yl)methanol as a clear oil (180 mg, 99%).
[0221] To a solution of the above material (180 mg, 1.22 mmol) in anhydrous DCM (10 mL) at 0 °C, DMP (678 mg, 1.60 mmol) was added, and the mixture was stirred at 0 °C for 2 h. The mixture was slowly quenched with NaSO solution. The mixture was extracted with DCM (3 × 20 mL). The combined organic layers were washed with HO (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 2,3-dihydro-1H-indene-2-carbaldehyde as an oil (130 mg, 72%).
[0222] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (80 mg, 0.19 mmol) and 2,3-dihydro-1H-indene-2-carbaldehyde (42 mg, 0.29 mmol) in anhydrous DCM (5 mL) was added HOAc (0.10 mL, 1.75 mmol) and stirred for 30 minutes. NaBH(OAc) (61 mg, 0.29 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with HO (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-((2,3-dihydro-1H-inden-2-yl)methyl)-2-methylpiperidine as an oil (89 mg, 86%). ESI MS m / z 548.69 [M+H] + .
[0223] To a solution of the above material (89 mg, 0.16 mmol) in anhydrous DCM (5 mL) was added BCl (1 M in DCM, 0.97 mL, 0.97 mmol) at −78° C. under N. The mixture was stirred at 0° C. for 2 h and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 min. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-((2,3-dihydro-1H-inden-2-yl)methyl)-2-methylpiperidine-3,4,5-triol as a white solid (21 mg, 47%). 1H NMR (400 MHz, CD3OD) δ 7.20-7.14 (m, 2H), 7.12-7.06 (m, 2H), 3.56-3.47 (m, 1H), 3.18-3.11 (m, 2H), 3.10-2.95 (m, 3H), 2.85-2.65 (m, 3H), 2.59 (dd, J = 15.4, 6.5 Hz, 1H), 2.35 (dd, J = 12.5, 4.7 Hz, 1H), 2.16-2.04 (m, 2H), 1.17 (d, J = 6.1 Hz, 3H); ESI MS m / z 278.17 [M+H] + .
[0224] Example 29 (2R,3R,4R,5S)-1-(2-cyclohexylethyl)-2-methylpiperidine-3,4,5-triol [ka]
[0225] To a solution of ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)piperidin-2-yl)methanol (0.2 g, 0.46 mmol) (J. Carb. Chem. 2017, 36, 295) in DMF (4 mL) and DIPEA (0.64 mL, 3.68 mmol) was added 2-cyclohexylethyl bromide (0.36 mL, 2.3 mmol). The reaction mixture was heated at 85 °C overnight and then diluted with EtOAc (30 mL). The organics were washed with brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:4) to give ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-cyclohexylethyl)piperidin-2-yl)methanol (0.156 g, 62%) as a gummy solid. 1H NMR (500 MHz, CDCl3) δ 7.38-7.27 (m, 15H), 4.98 (dd, J = 11.0, 5.1 Hz, 2H), 4.86 (d, J = 11.0 Hz, 1H), 4.76-4.65 (m, 3H), 3.79 (s, 2H), 3.63-3.49 (m, 3H), 3.10 (dd, J = 11.3, 4.6 Hz, 1H), 2.76 (ddd, J = 13.3, 10.5, 5.8 Hz, 1H), 2.50 (ddd, J = 13.3, 10.3, 5.2 Hz, 1H), 2.32-2.22 (m, 2H), 1.73-1.61 (m, 5H), 1.38-1.25 (m, 7H), 0.97-0.83 (m, 2H); ESI MS m / z 544.34 [M + H] + .
[0226] To a stirred solution of the above material (0.15 g, 0.28 mmol) in dry DCM (15 mL) at 0 °C was added PhP (0.15 g, 0.57 mmol), followed by CBr (0.19 g, 0.57). After stirring at 0 °C for 2 h, the reaction mixture was diluted with DCM (30 mL) and washed with saturated aqueous NaHCO. The organics were dried over anhydrous NaSO and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-(bromomethyl)-1-(2-cyclohexylethyl)piperidine (0.13 g, 74.6%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.38-7.27 (m, 15H), 5.01 (dd, J = 14.3, 10.9 Hz, 2H), 4.84 (d, J = 11.0 Hz, 1H), 4.75 (d, J = 10.8 Hz, 1H), 4.74-4.66 (m, 2H), 3.95 (dd, J = 11.5, 1.7 Hz, 1H), 3.72-3.50 (m, 4H), 3.15 (dd, J = 11.2, 4.9 Hz, 1H), 2.74 (q, J = 9.2, 5.1 Hz, 1H), 2.69-2.57 (m, 1H), 2.39-2.27 (m, 2H), 1.76-1.54 (m, 5H), 1.39 (dp, J = 11.2, 5.5 Hz, 1H), 1.31-1.11 (m, 5H), 0.92 (m, 2H); ESI MS m / z 606.25 [M + H] + .
[0227] To a stirred solution of the above material (0.13 g, 0.21 mmol) in dry toluene (7 mL) was added BuSnH (0.085 mL, 0.31 mmol), followed by ABCN (0.024 g, 0.1 mmol). The reaction mixture was heated at 100 °C overnight, then cooled and concentrated. The resulting crude mixture was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-cyclohexylethyl)-2-methylpiperidine (0.69 g, 40.6%) as a yellow solid. ESI MS m / z 528.34 [M+H] + .
[0228] To a solution of the above material (0.045 g, 0.085 mmol) in DCM (5 mL) under Ar at −78° C., BCl (1.0 M in DCM, 0.85 mL, 0.85 mmol) was added, and the mixture was stirred for 4 h, during which time the bath temperature reached room temperature. The mixture was then cooled at −78° C., and MeOH (2 mL) was carefully added. After stirring at room temperature for 30 min, the mixture was concentrated under reduced pressure. The resulting residue was neutralized with NHOH (0.5 mL) and concentrated again under reduced pressure. The crude residue was purified by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-(2-cyclohexylethyl)-2-methylpiperidine-3,4,5-triol (0.0053 g, 24%) as a white solid. 1 H NMR (400 MHz, CD3OD) δ 3.52 (ddd, J = 10.4, 9.1, 4.9 Hz, 1H), 3.14 (t, J = 8.9 Hz, 1H), 3.06-2.98 (m, 2H), 2.90-2.80 (m, 1H), 2.65-2.61 (m, 1H), 2.31-2.18 (m, 2H), 1.80-1.64 (m, 5H), 1.43-1.37 (m, 2H), 1.34-1.27 (m, 2H), 1.26-1.18 (m, 2H), 1.25 (d, J = 6.1 Hz, 3H), 1.06-0.91 (m, 2H); ESI MS m / z 258.20 [M + H] + .
[0229] Example 30 (2R,3R,4R,5S)-1-(2-(4,4-difluorocyclohexyl)ethyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of (methoxymethyl)triphenylphosphonium chloride (1.3 g, 3.8 mmol) in anhydrous DMF (20 mL) at 0 °C, KO tBu (0.43 g, 3.8 mmol) and 4,4-difluorocyclohexanecarbaldehyde (0.28 g, 1.9 mmol) were added, and the mixture was stirred at room temperature for 64 h. The reaction mixture was diluted with saturated aqueous NaHCO3 (20 mL) and extracted with EtOAc (3 × 20 mL). The combined extracts were washed with brine (30 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was dissolved in a mixture of THF (10 mL) and aqueous HCl (5 N, 10 mL). After stirring at reflux for 5 h, the mixture was cooled and diluted with saturated aqueous NaHCO3 (30 mL). After extraction with EtOAc (2 × 30 mL), the combined extracts were washed with brine (50 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:13 to 1:6) to give 2-(4,4-difluorocyclohexyl)acetaldehyde as a clear oil (0.21 g, 68%). 1 H NMR (500 MHz, CDCl3) δ 9.77 (t, J = 1.7 Hz, 1H), 2.40 (dd, J = 6.7, 1.7 Hz, 2H), 2.12-1.95 (m, 4H), 1.86-1.67 (m, 3H), 1.43-1.27 (m, 2H).
[0230] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.10 g, 0.24 mmol), 2-(4,4-difluorocyclohexyl)acetaldehyde (0.081 g, 0.50 mmol), and NaBH(OAc) (0.15 g, 0.71 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (10 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:5 to 1:3) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-(4,4-difluorocyclohexyl)ethyl)-2-methylpiperidine as a clear oil (0.084 g, 62%); ESI MS m / z 564.316 [M+H] + .
[0231] A mixture of the above material (0.080 g, 0.14 mmol) and Pd(OH) / C (20% Pd by mass, 0.030 g, 0.056 mmol) in MeOH (15 mL) and 1 drop of concentrated HCl was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash chromatography on silica gel (1 M NHMeOH / DCM, 1:7) to give (2R,3R,4R,5S)-1-(2-(4,4-difluorocyclohexyl)ethyl)-2-methylpiperidine-3,4,5-triol (0.030 g, 73%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 4.67-4.64 (m, 3H), 3.25-3.18 (m, 1H), 2.87 (td, J = 8.8, 4.3 Hz, 1H), 2.77 (dd, J = 11.1, 4.9 Hz, 1H), 2.72-2.61 (m, 2H), 2.32-2.25 (m, 1H), 2.01-1.87 (m, 4H), 1.82-1.66 (m, 4H), 1.33-1.23 (m, 3H), 1.19-1.10 (m, 2H), 1.05 (d, J = 6.0 Hz, 3H); ESI MS m / z 294.177 [M + H] + .
[0232] Examples 31 and 32 (2R,3R,4R,5S)-2-Methyl-1-(2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol and (2R,3R,4R,5S)-2-methyl-1-(2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol [ka]
[0233] To a solution of (methoxymethyl)triphenylphosphonium chloride (0.77 g, 2.5 mmol) in anhydrous DMF (20 mL) at 0 °C, KO tBu (0.28 g, 2.5 mmol) and 4-(trifluoromethyl)cyclohexanecarbaldehyde (0.27 g, 1.5 mmol) were added, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (20 mL) and then extracted with EtOAc (3 x 30 mL). The combined extracts were washed with brine (30 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was dissolved in a mixture of THF (10 mL) and aqueous HCl (5N, 10 mL). After stirring at reflux for 4 hours, the mixture was cooled and diluted with saturated aqueous NaHCO3 (30 mL). After extraction with EtOAc (2 x 30 mL), the combined extracts were washed with brine (50 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:13 to 1:7) to give mixed cis and trans isomers of 2-(4-(trifluoromethyl)cyclohexyl)acetaldehyde as a clear oil (0.087 g, 29%).
[0234] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.150 g, 0.359 mmol), 2-(4-(trifluoromethyl)cyclohexyl)acetaldehyde (0.087 g, 0.45 mmol) from above, and NaBH(OAc) (0.15 g, 0.71 mmol) in DCM (5 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (15 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:7 to 1:3) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine as a clear oil (0.083 g, 39%) and (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine as a clear oil (0.042 g, 17%); ESI MS m / z 596.313 [M+H] + .
[0235] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine (0.081 g, 0.14 mmol) and Pd(OH) / C (20% Pd by mass, 0.050 g, 0.094 mmol) and 1 drop of concentrated HCl in MeOH (10 mL) was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NHMeOH / DCM, 1:6) to give (2R,3R,4R,5S)-2-methyl-1-(2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol (0.036 g, 79%) as a white solid.1 H NMR (400 MHz, CD3OD) δ 3.47 (ddd, J = 101.6, 9.1, 4.9 Hz, 1H), 3.09 (t, J = 9.0 Hz, 1H), 2.98-2.93 (m, 2H), 2.83-2.76 (m, 1H), 2.56-2.48 (m, 1H), 2.18-2.02 (m, 3H), 2.00-1.80 (m, 5H), 1.20 (d, J = 6.1 Hz, 3H), 1.09-0.96 (m, 2H),); ESI MS m / z 326.172 [M + H] + .
[0236] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine (0.040 g, 0.067 mmol) and Pd(OH) / C (20% Pd by mass, 0.030 g, 0.056 mmol) and 1 drop of concentrated HCl in MeOH (10 mL) was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1M NH in MeOH and purified by flash chromatography on silica gel (1M NHMeOH / DCM, 1:6) to give (2R,3R,4R,5S)-2-methyl-1-(2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol (0.016 g, 73%) as a white solid. 1 H NMR (400 MHz, CD3OD) δ 3.48 (ddd, J = 10.6, 9.0, 4.9 Hz, 1H), 3.10 (t, J = 9.0 Hz, 1H), 3.00-2.93 (m, 2H), 2.78-2.74 (m, 1H), 2.52-2.45 (m, 1H), 2.19-2.12 (m, 3H), 1.71-1.50 (m, 11H), 1.22 (d, J = 6.1 Hz, 3H); ESI MS m / z 326.171 [M + H] + .
[0237] Example 33 (2R,3R,4R,5S)-1-((2-adamantan-1-yl)ethyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of 2-((3r,5r,7r)-adamantan-1-yl)ethanol (200 mg, 1.11 mmol) in anhydrous DCM (10 mL) at 0° C. was added DMP (612 mg, 1.44 mmol), and the mixture was stirred at 0° C. for 2 h. The mixture was slowly quenched with NaSO solution. The mixture was extracted with DCM (3×20 mL). The combined organic layers were washed with water (2×10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 2-((3r,5r,7r)-adamantan-1-yl)acetaldehyde as an oil (128 mg, 64%).
[0238] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (76 mg, 0.18 mmol) and 2-((3r,5r,7r)-adamantan-1-yl)acetaldehyde (65 mg, 0.37 mmol) in anhydrous MeOH (5 mL) was added HOAc (0.10 mL, 1.75 mmol) and stirred for 30 min. NaBHCN (23 mg, 0.37 mmol) was added and the resulting mixture was stirred at room temperature for 18 h. The reaction was quenched with saturated aqueous NaHCO at 0 °C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-1-(2-((3R,5R,7R)-adamantan-1-yl)ethyl)-3,4,5-tris(benzyloxy)-2-methylpiperidine as an oil (88 mg, 84%). ESI MS m / z 580.36 [M+H] + .
[0239] To a stirred solution of the above material (150 mg, 0.26 mmol) in anhydrous DCM (8 mL) was added BCl solution (1 M in DCM, 2.07 mL, 2.07 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The formed solid was collected by filtration to give (2R,3R,4R,5S)-1-((2-adamantan-1-yl)ethyl)-2-methylpiperidine-3,4,5-triol as the HCl salt (38 mg, 42%). 1 H NMR (400 MHz, CD3OD) δ 3.76-3.64 (m, 1H), 3.52-3.42 (m, 1H), 3.41-3.24 (m, 3H), 3.25-3.06 (m, 2H), 2.96 (t, J = 11.8 Hz, 1H), 2.05-1.96 (m, 3H), 1.85-1.68 (m, 6H), 1.67-1.52 (m, 7H), 1.52-1.40 (m, 4H); ESI MS m / z 310.23 [M + H] + .
[0240] Example 34 (2R,3R,4R,5S)-1-(3-cyclohexylpropyl)-2-methylpiperidine-3,4,5-triol [ka] A mixture of ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)piperidin-2-yl)methanol (0.17 g, 0.39 mmol), (3-bromopropyl)cyclohexane (0.30 g, 1.5 mmol), and DIPEA (0.22 g, 1.7 mmol) in anhydrous DMF (4 mL) in a sealed tube was stirred at 90 °C for 16 h. The reaction mixture was cooled at room temperature and diluted with saturated aqueous NaHCO (20 mL). After extraction with EtOAc (3 × 20 mL), the combined extracts were washed with brine (2 × 20 mL) and dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:4 to 1:3) to give ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(3-cyclohexylpropyl)piperidin-2-yl)methanol as a pale yellow oil (0.21 g, 97%); ESI MS m / z 558.386 [M+H] + .
[0241] To a solution of the above material (0.21 g, 0.38 mmol) in anhydrous DCM (15 mL) at 0 °C, PPh (0.20 g, 0.76 mmol) and CBr (0.20 g, 0.60 mmol) were added, and the mixture was stirred at room temperature for 16 h. The solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:9 to 1:7) to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-(bromomethyl)-1-(3-cyclohexylpropyl)piperidine as a clear oil (0.17 g, 72%); ESI MS m / z 620.299 and 622.297 [M+H]. + .
[0242] A mixture of the above material (0.17 g, 0.27 mmol), BuSnH (0.22 g, 0.75 mmol), and ABCN (0.015 g, 0.063 mmol) in anhydrous toluene (15 mL) was stirred at 95° C. for 4 h. After cooling, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:5 to 2:3) to give a mixture containing (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(3-cyclohexylpropyl)-2-methylpiperidine and its partially protected analog with two benzyl groups.
[0243] To a solution of the above mixture in anhydrous DCM (5 mL) at −78° C. and N2, BCl3 (1.0 M in DCM, 1.0 mL, 1.0 mmol) was added, and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled at −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified by flash chromatography on silica gel (1 M NH3 in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(3-cyclohexylpropyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.018 g, 25%, two steps). 1 H NMR (500 MHz, CD3OD) δ 3.48 (td, J = 9.3, 4.4 Hz, 1H), 3.11 (t, J = 9.3 Hz, 1H), 3.01-2.95 (m, 2H), 2.75-2.69 (m, 1H), 2.50-2.44 (m, ESI MS m / z 272.219 [M + H] + .
[0244] Example 35 (2R,3R,4R,5S)-2-Methyl-1-phenethylpiperidine-3,4,5-triol [ka] K2CO3 (1.64 g, 11.8 mmol) was added to a solution of ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)piperidin-2-yl)methanol (641 mg, 1.48 mmol) and (2-bromoethyl)benzene (1.09 g, 5.92 mmol) in DMF (20 mL) in a sealed tube. The mixture was stirred at 80 °C for 18 h and cooled to ambient temperature. The reaction mixture was poured into ice-water (50 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-phenethylpiperidin-2-yl)methanol as a clear oil (615 mg, 77%). ESI MS m / z 538.29 [M+H] + .
[0245] To a stirred solution of the above material (336 mg, 0.63 mmol) in pyridine (5 mL) was added MsCl (0.10 mL, 1.25 mmol) slowly at 0 °C. The reaction mixture was stirred at 50 °C for 1 h and quenched with saturated aqueous NaHCO (20 mL). The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-(chloromethyl)-1-phenethylpiperidine as an oil (182 mg, 52%). ESI MS m / z 556.27, 558.27 [M+H] + .
[0246] A mixture of the above material (90 mg, 0.24 mmol), Bu3SnH (0.065 mL, 0.24 mmol), and ABCN (20 mg, 0.08 mmol) in anhydrous toluene (10 mL) was stirred at 100° C. for 16 h. After cooling, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel flash chromatography to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-phenethylpiperidine as an oil (18 mg, 20%). ESI MS m / z 522.30 [M+H] + .
[0247] To a solution of the above material (18 mg, 0.035 mmol) in EtOH (10 mL) was added Pd(OH) / C (20% by weight, 8.6 mg, 0.012 mmol) and 6 N HCl (0.05 mL). The mixture was treated with hydrogen (1 atm) for 18 h. The catalyst was filtered off through Celite, and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-2-methyl-1-phenethylpiperidine-3,4,5-triol as a white solid (3 mg, 35%). 1 H NMR (400 MHz, CD3OD) δ 7.33 -7.25 (m, 2H), 7.23 -7.16 (m, 3H), 3.57 -3.48 (m, 1H), 3.15 (t, J = 8.8 Hz, 1H), 3.09 (dd, J = 11.2, 4.9 Hz, ESI MS m / z 252.16 [M + H] + .
[0248] Example 36 (2R,3R,4R,5S)-2-Methyl-1-(2-methylphenethyl)piperidine-3,4,5-triol [ka] DIPEA (0.17 mL, 0.96 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (52 mg, 0.12 mmol) and 1-(2-bromoethyl)-2-methylbenzene (124 mg, 0.62 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h and cooled to ambient temperature. The reaction mixture was poured into ice-water (30 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel flash chromatography to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(2-methylphenethyl)piperidine as a white solid (38 mg, 59%). ESI MS m / z 536.31 [M+H] + .
[0249] To a stirred solution of the above material (39 mg, 0.070 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.50 mL, 0.50 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-2-methyl-1-(2-methylphenethyl)piperidine-3,4,5-triol as a white solid (8.0 mg, 43%). 1H NMR (400 MHz, DMSO-d6) δ 7.15-7.05 (m, 4H), 4.73-4.68 (m, 3H), 3.31-3.23 (m, 1H), 2.96-2.88 (m, 2H), 2.77-2.56 (m, 5H), 2.28 (s, ESI MS m / z 266.17 [M + H] + .
[0250] Example 37 (2R,3R,4R,5S)-1-(2-methoxyphenethyl)-2-methylpiperidine-3,4,5-triol [ka] DIPEA (0.18 mL, 1.04 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (55 mg, 0.13 mmol) and 1-(2-bromoethyl)-2-methoxybenzene (141 mg, 0.66 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h and cooled to ambient temperature. The reaction mixture was poured into ice-water (30 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-methoxyphenethyl)-2-methylpiperidine as a white solid (40 mg, 56%). ESI MS m / z 552.30 [M+H] + .
[0251] To a solution of the above material (40 mg, 0.072 mmol) in EtOH (10 mL) was added Pd(OH) / C (20% by weight, 8.6 mg, 0.012 mmol) and 6 N HCl (0.1 mL). The mixture was treated with hydrogen (1 atm) for 18 h. The catalyst was filtered off through Celite, and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2-methoxyphenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (20 mg, 98%). 1 H NMR (400 MHz, CD3OD) δ 7.29-7.23 (m, 1H), 7.21 (dd, J = 7.4, 1.7 Hz, 1H), 6.99 (d, J = 8.2 Hz, 1H), 6.92 (td, J = 7.4, 1.0 Hz, 1H), 3.88 ESI MS m / z 282.16 [M + H] + .
[0252] Example 38 (2R,3R,4R,5S)-1-(2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] K2CO3 (630 g, 5.52 mmol) was added to a solution of ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)piperidin-2-yl)methanol (300 mg, 0.69 mmol) and 1-(2-bromoethyl)-2-fluorobenzene (582 mg, 3.45 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80 °C for 18 h and cooled to ambient temperature. The reaction mixture was poured into ice-water (50 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give ethyl ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-fluorophenethyl)piperidin-2-yl)methanol as a clear oil (225 mg, 59%). ESI MS m / z 556.30 [M+H] + .
[0253] To a stirred solution of the above material (68 mg, 0.12 mmol) in anhydrous DCM (5 mL) was added PPh (81 mg, 0.31 mmol), imdidazole (21 mg, 0.31 mmol), and iodine (30 mg, 0.24 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 2 h and then quenched with saturated aqueous NaSO at 0 °C. The mixture was diluted with DCM and washed with saturated aqueous NaHCO, and the organic phase was separated and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-fluorophenethyl)-2-(iodomethyl)piperidine as an oil (crude). ESI MS m / z 666.18 [M+H] + .
[0254] A mixture of the above material (0.12 mmol), Bu3SnH (0.048 mL, 0.18 mmol), and ABCN (15 mg, 0.06 mmol) in anhydrous toluene (10 mL) was stirred at 100° C. for 16 h. After cooling, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel flash chromatography to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-fluorophenethyl)-2-methylpiperidine as an oil (25 mg, 38% over two steps). ESI MS m / z 540.28 [M+H] + .
[0255] To a stirred solution of the above material (22 mg, 0.040 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.50 mL, 0.50 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (9 mg, 83%). 1 H NMR (400 MHz, CD3OD) δ 7.29-7.19 (m, 2H), 7.11 (td, J = 7.5, 1.3 Hz, 1H), 7.05 (ddd, J = 10.5, 8.1, 1.2 Hz, 1H), 3.56-3.47 (m, 1H), 3.14 (t, J = 9.0 Hz, 1H), 3.07 (dd, J = 11.2, 4.9 Hz, 1H), 2.96 (t, J = 9.0 Hz, 1H), 2.93 -2.77 (m, 4H), 2.39 (t, J = 10.9 Hz, 1H), 2.35-2.26 (m, 1H), 1.26 (d, J = 6.2 Hz, 3H); ESI MS m / z 270.15 [M + H] + .
[0256] Example 39 (2R,3R,4R,5S)-1-(2-chlorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] DIPEA (0.15 mL, 0.88 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (45 mg, 0.11 mmol) and 1-(2-bromoethyl)-2-chlorobenzene (118 mg, 0.55 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h and cooled to ambient temperature. The reaction mixture was poured into ice-water (30 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel flash chromatography to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-chlorophenethyl)-2-methylpiperidine as a white solid (29 mg, 48%). ESI MS m / z 556.26 [M+H] + .
[0257] To a stirred solution of the above material (28 mg, 0.050 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.50 mL, 0.50 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 h and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 min. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2-chlorophenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (10 mg, 70%). 1H NMR (400 MHz, CD3OD) δ 7.37 (dd, J = 7.7, 1.6 Hz, 1H), 7.31 (dd, J = 7.5, 2.0 Hz, 1H), 7.28-7.18 (m, 2H), 3.58-3.49 (m, 1H), 3.15 (t, J = 9.0 Hz, 1H), 3.10 (dd, J = 11.2, 4.9 Hz, 1H), 3.00-2.79 (m, 5H), 2.42 (t, J = 10.9 Hz, 1H), 2.37 -2.28 (m, 1H), 1.28 (d, J = 6.2 Hz, 3H); ESI MS m / z 286.12 [M + H] + .
[0258] Example 40 (2R,3R,4R,5S)-1-(2,3-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a cooled (0 °C) solution of 2-(2,3-difluorophenyl)acetic acid (1.0 g, 5.8 mmol) in 15 mL of anhydrous THF was added LAH (0.6 g, 17.4 mmol) in small portions with stirring under Ar. Once effervescence ceased, the mixture was heated to reflux for 5 h until the starting material disappeared. The mixture was diluted with EtOAc and washed with 1.0 M HCl, water, and brine. The organics were dried over anhydrous NaSO and concentrated to afford 2-(2,3-difluorophenyl)ethanol (0.98 g, 98%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 7.09-6.94 (m, 3H), 3.83 (m, 2H), 2.92 (m, 2H), 2.28-2.05 (m, 1H).
[0259] The above material (0.4 g, 2.5 mmol) and CBr (1.0 g, 3.0 mmol) were dissolved in DCM (15 mL), the mixture was cooled to 0 °C, and PhP (0.8 g, 3.0 mmol) was added portionwise. The reaction mixture was warmed to room temperature and stirred for 2 h, after which the solvent was removed in vacuo. Flash chromatography (EtOAc / hexane, 1:4) afforded 1-(2-bromoethyl)-2,3-difluorobenzene (0.5 g, 89%). 1 H NMR (400 MHz, CDCl3) δ 7.12-6.95 (m, 3H), 3.58 (t, J = 7.3 Hz, 2H), 3.24 (td, J = 7.3, 1.3 Hz, 2H).
[0260] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.1 g, 0.24 mmol) in DMF (4 mL) and DIPEA (0.32 mL, 1.84 mmol) was added 1-(2-bromoethyl)-2,3-difluorobenzene (0.2 g, 1.0 mmol). The reaction mixture was heated at 85 °C overnight and then diluted with EtOAc (30 mL). The organics were washed with brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,3-difluorophenethyl)-2-methylpiperidine (0.049 g, 36.7%) as a gummy solid. 1H NMR (400 MHz, CDCl3) δ 7.40-7.24 (m, 15H), 7.06-6.94 (m, 2H), 6.89 (dt, J = 8.8, 3.4 Hz, 1H), 4.97 (t, J = 10.7 Hz, 2H), 4.84 (d, J = 11.0 Hz, 1H), 4.77-4.65 (m, 2H), 4.61 (d, J = 10.8 Hz, 1H), 3.67-3.57 (m, 1H), 3.51 (t, J = 9.0 Hz, 1H), 3.17-3.03 (m, 2H), 2.94-2.71 (m, 4H), 2.49-2.32 (m, 2H), 1.22 (d, J = 6.1 Hz, 3H); ESI MS m / z 558.267 [M + H] + .
[0261] To a solution of the above material (0.049 g, 0.087 mmol) in DCM (5 mL) under Ar at −78° C., BCl (1.0 M in DCM, 0.87 mL, 0.87 mmol) was added, and the mixture was stirred for 2 h, during which the bath temperature was allowed to warm to 0° C. The mixture was stirred at 0° C. for the next 2 h and then quenched by the slow addition of MeOH (2 mL). After stirring at room temperature for 30 min, the mixture was concentrated under reduced pressure. The resulting residue was neutralized with NHOH (0.5 mL) and concentrated again under reduced pressure. The crude residue was purified by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-(2,3-difluorophenethyl)-2-methylpiperidine-3,4,5-triol (0.021 g, 87%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 7.15-7.04 (m, 3H), 3.51 (ddd, J = 10.5, 9.0, 4.9 Hz, 1H), 3.14 (t, J = 9.0 Hz, 1H), 3.07 (dd, J = 11.2, 4.9 Hz, ESI MS m / z 288.137 [M+H] + .
[0262] Example 41 (2R,3R,4R,5S)-1-(2,4-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] DIPEA (0.50 mL, 2.87 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (18 mg, 0.043 mmol) and 1-(2-bromoethyl)-2,4-difluorobenzene (200 mg, 0.91 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 hours and cooled to ambient temperature. The reaction mixture was poured into ice-water (30 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,4-difluorophenethyl)-2-methylpiperidine as an oil (13 mg, 54%).
[0263] To a stirred solution of the above material (13 mg, 0.023 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.50 mL, 0.50 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2,4-difluorophenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (5 mg, 75%). 1 H NMR (400 MHz, CD3OD) δ 7.33-7.25 (m, 1H), 6.95-6.86 (m, 2H), 3.55-3.47 (m, 1H), 3.13 (t, J = 9.0 Hz, 1H), 3.06 (dd, J = 11.2, 4.9 Hz, ESI MS m / z 288.14 [M+H] + .
[0264] Example 42 (2R,3R,4R,5S)-1-(2,5-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a cooled (0 °C) solution of 2-(2,5-difluorophenyl)acetic acid (1.0 g, 5.8 mmol) in 15 mL of anhydrous THF was added LAH (0.6 g, 17.4 mmol) in small portions with stirring under Ar. Once effervescence ceased, the mixture was heated to reflux for 5 h until the starting material disappeared. The mixture was diluted with EtOAc and washed with 1.0 M HCl, water, and brine. The organics were dried over anhydrous NaSO and concentrated to afford 2-(2,5-difluorophenyl)ethanol (0.9 g, 98%) as an oil. 1 H NMR (500 MHz, CDCl3) δ 7.00-6.91 (m, 2H), 6.87 (ddd, J = 8.9, 7.5, 3.5 Hz, 1H), 3.83 m, 2H), 2.86 (m, 2H), 2.28-2.10 (bs, 1H).
[0265] The above material (0.4 g, 2.5 mmol) and CBr (1.0 g, 3.0 mmol) were dissolved in DCM (15 mL), the mixture was cooled to 0 °C, and PhP (0.8 g, 3.0 mmol) was added portionwise. The reaction mixture was warmed to room temperature and stirred for 2 h, after which the solvent was removed in vacuo. Flash chromatography (EtOAc / hexane, 1:4) afforded 2-(2-bromoethyl)-1,4-difluorobenzene (0.45 g, 81%). 1 H NMR (400 MHz, CDCl3) δ 7.04-6.87 (m, 3H), 3.57 (t, J = 7.3 Hz, 2H), 3.18 (td, J = 7.3, 1.2 Hz, 2H).
[0266] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.06 g, 0.14 mmol) in DMF (5 mL) and DIPEA (0.32 mL, 1.84 mmol) was added 2-(2-bromoethyl)-1,4-difluorobenzene (0.15 g, 0.71 mmol). The reaction mixture was heated at 85 °C overnight, after which it was diluted with EtOAc (30 mL). The organics were washed with brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,5-difluorophenethyl)-2-methylpiperidine (0.044 g, 55%) as a gummy solid. 1 H NMR (400 MHz, CDCl3) δ 7.39-7.27 (m, 15H), 7.00-6.92 (m, 1H), 6.86 (td, J = 8.1, 7.6, 4.3 Hz, 2H), 4.97 (t, J = 10.6 Hz, 2H), 4.84 (d, J = 11.0 Hz, 1H), 4.76-4.66 (m, 2H), 4.61 (d, J = 10.9 Hz, 1H), 3.62 (bs, 1H), 3.50 (t, J = 9.0 Hz, 1H), 3.17-3.03 (m, 2H), 2.92-2.78 (m, 2H), 2.70 (t, J = ESI MS m / z 558.27 [M + H] + .
[0267] To a solution of the above material (0.044 g, 0.078 mmol) in DCM (5 mL) under Ar at −78° C., BCl (1.0 M in DCM, 0.78 mL, 0.78 mmol) was added, and the mixture was stirred for 2 h, during which the bath temperature was warmed to 0° C. The mixture was stirred at 0° C. for the next 2 h and then quenched by the slow addition of MeOH (2 mL). After stirring at room temperature for 30 min, the mixture was concentrated under reduced pressure. The resulting residue was neutralized with NHOH (0.5 mL) and concentrated again under reduced pressure. The crude residue was purified by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-(2,5-difluorophenethyl)-2-methylpiperidine-3,4,5-triol (0.018 g, 81.6%) as a white solid. 1 H NMR (400 MHz, CD3OD) δ 7.11-7.01 (m, 2H), 6.96 (ddd, J = 8.6, 6.4, 3.7 Hz, 1H), 3.51 (ddd, J = 10.5, 9.0, 4.9 Hz, 1H), 3.14 (t, J = 9.0 Hz, 1H), 3.06 (dd, J = 11.2, 4.9 Hz, 1H), 2.98-2.86 (m, 2H), 2.87-2.77 (m, 3H), 2.36 (t, J = 10.9 Hz, 1H), 2.28 (dt, J = 9.1, 6.1 Hz, 1H), 1.24 (d, J = 6.1 Hz, 3H); ESI MS m / z 288.13 [M + H] + .
[0268] Example 43 (2R,3R,4R,5S)-1-(3,4-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)piperidin-2-yl)methanol (0.2 g, 0.46 mmol) in DMF (4 mL) and DIPEA (0.64 mL, 3.68 mmol) was added 4-(2-bromoethyl)-1,2-difluorobenzene (0.5 g, 2.4 mmol). The reaction mixture was heated at 85 °C overnight, after which it was diluted with EtOAc (30 mL). The organics were washed with brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give ((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(3,4-difluorophenethyl)piperidin-2-yl)methanol (0.2 g, 68%) as a gummy solid. ESI MS m / z 574.272[M+H] + .
[0269] To a stirred solution of the above material (0.2 g, 0.39 mmol) in dry DCM (15 mL) at 0 °C, PhP (0.20 g, 0.78 mmol) was added, followed by CBr (0.26 g, 0.78 mmol). After stirring at 0 °C for 2 h, the reaction mixture was diluted with DCM (30 mL) and washed with saturated aqueous NaHCO. The organics were dried over anhydrous NaSO and concentrated. The crude residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-(bromomethyl)-1-(3,4-difluorophenethyl)piperidine (0.05 g, 21%) as a yellow solid. ESI MS m / z 638.179 [M+H] + .
[0270] A mixture of the above material (0.087 g, 0.13 mmol) and Raney Ni (0.050 g) in EtOH was stirred overnight under 50 psi hydrogen pressure. The mixture was then filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The crude material was dissolved in DCM (5 mL), and BCl (1.0 M in DCM, 0.8 mL, 0.8 mmol) was added dropwise under Ar at −78° C. The mixture was stirred for 2 hours, during which the bath temperature was warmed to 0° C. The mixture was stirred at 0° C. for the next 2 hours and then quenched by the slow addition of MeOH (2 mL). After stirring at room temperature for 30 minutes, the mixture was concentrated under reduced pressure. The resulting residue was neutralized with NHOH (0.5 mL) and concentrated again under reduced pressure. The crude residue was purified by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-(3,4-difluorophenethyl)-2-methylpiperidine-3,4,5-triol (0.017 g, 74%) as a white solid. 1 H NMR (400 MHz, CD3OD) δ 7.25-7.16 (m, 2H), 7.08 (ddd, J = 8.9, 4.4, 2.2 Hz, 1H), 3.60 (td, J = 9.6, 4.5 Hz, 1H), 3.30-3.21 (m, 2H), 3.21-3.07 (m, 2H), 3.06-2.96 (m, 1H), 2.96-2.85 (m, 2H), 2.66-2.56 (m, 2H), 1.35 (d, J = 6.2 Hz, 3H); ESI MS m / z 288.13s [M + H] + .
[0271] Example 44 (2R,3R,4R,5S)-1-(2-fluoro-4-methoxyphenethyl)-2-methylpiperidine-3,4,5-triol [ka] DIPEA (0.12 mL, 0.7 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (43 mg, 0.10 mmol) and 1-(2-bromoethyl)-2-fluoro-4-methoxybenzene (121 mg, 0.52 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 hours and cooled to ambient temperature. The reaction mixture was poured into ice-water (30 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel flash chromatography to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2-fluoro-4-methoxyphenethyl)-2-methylpiperidine as a white solid (35 mg, 61%). ESI MS m / z 570.30 [M+H] + .
[0272] To a solution of the above material (23 mg, 0.04 mmol) in EtOH (10 mL) was added Pd(OH)2 / C (20% by weight, 8.6 mg, 0.012 mmol) and 6 N HCl (0.1 mL). The mixture was treated with hydrogen (1 atmosphere) for 18 hours. The catalyst was filtered off through Celite, and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2-fluoro-4-methoxyphenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (9 mg, 75%). 1H NMR (400 MHz, CD3OD) δ 7.15 (t, J = 8.6 Hz, 1H), 6.74-6.61 (m, 2H), 3.78 (s, 3H), 3.56-3.47 (m, 1H), 3.14 (t, J = 9.0 Hz, 1H), 3.06 (dd, J = 11.2, 4.9 Hz, 1H), 2.96 (t, J = 9.1 Hz, 1H), 2.92-2.67 (m, 4H), 2.37 (t, J = 10.9 Hz, 1H), 2.33-2.26 (m, 1H), 1.25 (d, J = 6.2 Hz, 3H); ESI MS m / z 300.16 [M + H] + .
[0273] Example 45 (2R,3R,4R,5S)-1-(3-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a cooled (0 °C) solution of 2-(3-chloro-2-fluorophenyl)acetic acid (0.5 g, 2.6 mmol) in 15 mL of anhydrous THF was added LAH (0.3 g, 8.7 mmol) in small portions with stirring under Ar. Once effervescence ceased, the mixture was heated to reflux for 5 h until the starting material disappeared. The mixture was diluted with EtOAc and washed with 1.0 M HCl, water, and brine. The organics were dried over anhydrous NaSO and concentrated to afford 2-(3-chloro-2-fluorophenyl)ethanol (0.4 g, 90%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 7.29-6.98 (m, 3H), 3.87-3.79 (m, 2H), 2.91 (td, J = 6.4, 4.1 Hz, 2H), 1.99-1.88 (m, 1H).
[0274] The above material (0.20 g, 1.16 mmol) and CBr (0.5 g, 1.5 mmol) were dissolved in DCM (15 mL), the mixture was cooled to 0 °C, and PhP (0.4 g, 1.5 mmol) was added portionwise. The reaction mixture was warmed to room temperature and stirred for 2 h, after which the solvent was removed in vacuo. Flash chromatography (EtOAc / hexane, 1:4) afforded 1-(2-bromoethyl)-3-chloro-2-fluorobenzene (0.23 g, 82.7%). 1 H NMR (400 MHz, CDCl3) δ 7.79-7.62 (m, 1H), 7.60-7.44 (m, 2H), 4.02 (td, J = 7.4, 1.2 Hz, 2H), 3.70-3.62 (m, 2H).
[0275] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.06 g, 0.14 mmol) in DMF (5 mL) and DIPEA (0.32 mL, 1.84 mmol) was added 2-(2-bromoethyl)-1,4-difluorobenzene (0.16 g, 0.70 mmol). The reaction mixture was heated at 85 °C overnight and then diluted with EtOAc (30 mL). The organics were washed with brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(3-chloro-2-fluorophenethyl)-2-methylpiperidine (0.032 g, 55%) as a gummy solid. ESI MS m / z 574.23[M+H] + .
[0276] To a solution of the above material (0.032 g, 0.055 mmol) in DCM (5 mL) under Ar at −78° C., BCl (1.0 M in DCM, 0.55 mL, 0.55 mmol) was added, and the mixture was stirred for 2 h, during which the bath temperature was warmed to 0° C. The mixture was stirred at 0° C. for the next 2 h and then quenched by the slow addition of MeOH (2 mL). After stirring at room temperature for 30 min, the mixture was concentrated under reduced pressure. The resulting residue was neutralized with NHOH (0.5 mL) and concentrated again under reduced pressure. The crude residue was purified by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-(3-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol (0.014 g, 83.7%) as a white solid. 1 H NMR (400 MHz, CD3OD) δ 7.33 (m, 1H), 7.23 (m, 1H), 7.10 (m, 1H), 3.51 (td, J = 9.8, 4.9 Hz, 1H), 3.14 (t, J = 9.0 Hz, 1H), 3.07 (dd, J = 11.2, 4.9 Hz, 1H), 2.98-2.89 (m, 2H), 2.88-2.79 (m, 3H), 2.36 (t, J = 10.8 Hz, 1H), 2.32-2.25 (m, 1H), 1.24 (d, J = 6.2 Hz, 3H); ESI MS m / z 304.11 [M + H] + .
[0277] Example 46 (2R,3R,4R,5S)-1-(4-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] K2CO3 (121 mg, 0.88 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (45 mg, 0.11 mmol) and 1-(2-bromoethyl)-4-chloro-2-fluorobenzene (130 mg, 0.55 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80 °C for 18 h and cooled to ambient temperature. The reaction mixture was poured into ice-water (30 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by silica gel flash chromatography to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(4-chloro-2-fluorophenethyl)-2-methylpiperidine as a white solid (15 mg, 24%). ESI MS m / z 574.25 [M+H] + .
[0278] To a stirred solution of the above material (15 mg, 0.026 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.50 mL, 0.50 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(4-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (6 mg, 76%). 1H NMR (400 MHz, CD3OD) δ 7.28 (t, J = 8.3 Hz, 1H), 7.19-7.12 (m, 2H), 3.55-3.45 (m, 1H), 3.13 (t, J = 9.0 Hz, 1H), 3.06 (dd, J = 11.2, 4.9 ESI MS m / z 304.11 [M + H] + .
[0279] Example 47 (2R,3R,4R,5S)-1-(5-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a cooled (0 °C) solution of 2-(5-chloro-2-fluorophenyl)acetic acid (0.5 g, 2.6 mmol) in 15 mL of anhydrous THF, LAH (0.3 g, 8.7 mmol) was added portionwise with stirring under Ar. Once effervescence ceased, the mixture was heated to reflux for 5 h until the starting material disappeared. The mixture was diluted with EtOAc and washed with 1.0 M HCl, water, and brine. The organics were dried over anhydrous Na2SO4 and concentrated to 2-(5-chloro-2-fluorophenyl)ethanol (0.46 g, 99%) as an oil. 1 H NMR (400 MHz, CDCl3) δ 7.22 (dd, J = 6.5, 2.7 Hz, 1H), 7.15 (dddd, J = 8.4, 4.2, 2.7, 0.9 Hz, 1H), 6.99-6.92 (m, 1H), 3.81 (td, J = 6.6, 2.4 Hz, 2H), 2.84 (td, J = 6.6, 3.2 Hz, 2H), 2.26 (bs, 1H).
[0280] The above material (0.46 g, 2.6 mmol) and CBr (1.1 g, 3.4 mmol) were dissolved in DCM (15 mL), the mixture was cooled to 0 °C, and PhP (0.9 g, 3.4 mmol) was added portionwise. The reaction mixture was warmed to room temperature and stirred for 2 h, after which the solvent was removed in vacuo. Flash chromatography (EtOAc / hexane, 1:4) afforded 2-(2-bromoethyl)-4-chloro-1-fluorobenzene (0.99 g, 97%). 1 H NMR (400 MHz, CDCl3) δ 7.69-7.60 (m, 2H), 7.45-7.39 (m, 1H), 4.00 (t, J = 7.4 Hz, 2H), 3.64-3.58 (m, 2H).
[0281] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.06 g, 0.14 mmol) in DMF (5 mL) and DIPEA (0.32 mL, 1.84 mmol) was added 2-(2-bromoethyl)-1,4-difluorobenzene (0.16 g, 0.70 mmol). The reaction mixture was heated at 85 °C overnight and then diluted with EtOAc (30 mL). The organics were washed with brine, dried over anhydrous NaSO, and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:4) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(5-chloro-2-fluorophenethyl)-2-methylpiperidine (0.044 g, 54%) as a gummy solid. 1H NMR (400 MHz, CDCl3) δ 7.39-7.27 (m, 15H), 7.14 (dd, J = 7.8, 5.0 Hz, 2H), 6.95 (dd, J = 10.2, 7.9 Hz, 1H), 4.97 (t, J = 10.5 Hz, 2H), 4.84 (d, J = 10.9 Hz, 1H), 4.76-4.66 (m, 2H), 4.61 (d, J = 10.8 Hz, 1H), 3.62 (td, J = 9.6, 4.6 Hz, 1H), 3.50 (t, J = 9.0 Hz, 1H), 3.14-3.04 (m, 2H), 2.84 (m, ESI MS m / z 574.25 [M + H] + .
[0282] To a solution of the above material (0.044 g, 0.076 mmol) in DCM (5 mL) under Ar at −78° C., BCl (1.0 M in DCM, 0.76 mL, 0.76 mmol) was added, and the mixture was stirred for 2 h, during which time the bath temperature reached 0° C. The mixture was stirred at 0° C. for the next 2 h and then quenched by the slow addition of MeOH (2 mL). After stirring at room temperature for 30 min, the mixture was concentrated under reduced pressure. The resulting residue was neutralized with NHOH (0.5 mL) and concentrated again under reduced pressure. The crude residue was purified by flash chromatography on silica gel (MeOH / DCM, 1:9) to give (2R,3R,4R,5S)-1-(5-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol (0.021 g, 93.5%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 7.31 (dd, J = 6.5, 2.7 Hz, 1H), 7.23 (ddd, J = 8.8, 4.4, 2.7 Hz, 1H), 7.07 (t, J = 9.2 Hz, 1H), 3.50 (ddd, J = 10.5, 9.0, 4.9 Hz, 1H), 3.13 (t, J = 9.0 Hz, 1H), 3.06 (dd, J = 11.2, 4.9 Hz, 1H), 2.97-2.87 (m, 2H), 2.86-2.77 (m, 3H), 2.35 (t, J = 10.9 Hz, 1H), 2.28 (dt, J = 9.2, 6.2 Hz, 1H), 1.23 (d, J = 6.1 Hz, 3H); ESI MS m / z 304.11 [M + H] + .
[0283] Example 48 (2R,3R,4R,5S)-1-(2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] DIPEA (0.16 mL, 0.96 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (50 mg, 0.12 mmol) and 2-(2-bromoethyl)-1,3-difluorobenzene (132 mg, 0.60 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 hours and cooled to ambient temperature. The reaction mixture was poured into ice-water (30 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,6-difluorophenethyl)-2-methylpiperidine as a white solid (28 mg, 42%). ESI MS m / z 558.27 [M+H] + .
[0284] To a stirred solution of the above material (28 mg, 0.050 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.50 mL, 0.50 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (12 mg, 83%). 1 H NMR (400 MHz, CD3OD) δ 7.31-7.20 (m, 1H), 6.99-6.89 (m, 2H), 3.55-3.45 (m, 1H), 3.14 (t, J = 9.0 Hz, 1H), 3.07 (dd, J = 11.2, 4.9 Hz, ESI MS m / z 288.13 [M + H] + .
[0285] Example 49 (2R,3R,4R,5S)-1-(3-chloro-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of (methoxymethyl)triphenylphosphonium chloride (4.30 g, 12.5 mmol) in anhydrous DMF (30 mL) at 0 °C, KO tBu (1.40 g, 12.5 mmol) and 3-chloro-2,6-difluorobenzaldehyde (1.77 g, 10.0 mmol) were added, and the mixture was stirred at room temperature for 16 hours. The reaction was quenched with aqueous HCl (2N, 20 mL), and the mixture was extracted with EtOAc (3 × 30 mL). The combined extracts were washed with saturated aqueous NaHCO (50 mL), brine (50 mL), and water (50 mL), and then dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was dissolved in mixed THF (40 mL) and aqueous HCl (3N, 40 mL). After stirring at reflux for 5 hours, the mixture was cooled and extracted with EtOAc (2 × 50 mL). The combined extracts were washed with saturated aqueous NaHCO (50 mL) and dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:20 to 1:9) to give 2-(3-chloro-2,6-difluorophenyl)acetaldehyde as a pale yellow liquid (0.55 g, 28%). 1 H NMR (500 MHz, CDCl3) δ 9.76 (p, J = 1.3 Hz, 1H), 7.34 (ddd, J = 8.8, 8.3, 5.7 Hz, 1H), 6.91 (td, J = 8.8, 1.8 Hz, 1H), 3.84 (q, J = 1.3 Hz, 2H).
[0286] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.10 g, 0.24 mmol), 2-(3-chloro-2,6-difluorophenyl)acetaldehyde (0.10 g, 0.52 mmol), and NaBH(OAc) (0.17 g, 0.80 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated aqueous NaHCO (10 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:12 to 1:6) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(3-chloro-2,6-difluorophenethyl)-2-methylpiperidine as a white solid (0.13 g, 92%); ESI MS m / z 592.236 [M+H] + .
[0287] To a solution of the above material (0.13 g, 0.22 mmol) in anhydrous DCM (5 mL) at −78° C. and N was added BCl (1.0 M in DCM, 2.0 mL, 2.0 mmol), and the mixture was stirred at 0° C. for 3 hours. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash chromatography on silica gel (1 M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(3-chloro-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.058 g, 83%). 1H NMR (500 MHz, DMSO-d6) δ 7.49 (td, J = 8.8, 5.7 Hz, 1H), 7.14 (td, J = 9.0, 1.7 Hz, 1H), 4.74-4.67 (m, 3H), 3.27-3.18 (m, 1H), 2.93-2.81 (m, 2H), 2.82-2.68 (m, 3H), 2.70-2.60 (m, 2H), 2.17 (t, J = 10.6 Hz, 1H), 2.10 (dq, J = 8.9, 6.1 Hz, 1H), 1.02 (d, J = 6.1 Hz, 3H); ESI MS m / z 322.095 [M + H] + .
[0288] Example 50 (2R,3R,4R,5S)-1-(2,6-difluoro-4-(prop-1-en-2-yl)phenethyl)-2-methylpiperidine-3,4,5-triol [ka]
[0289] To a stirred solution of (methoxymethyl)triphenylphosphonium chloride (8.57 g, 25 mmol) in anhydrous THF (60 mL) was added KO tBu (2.81 g, 25 mmol) was added at 0 °C under N and stirred for 30 minutes. Then, 4-bromo-2,6-difluorobenzaldehyde (2.21 g, 10 mmol) was dissolved in 20 mL of THF and added dropwise to the mixture under N and allowed to react at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0 °C. The mixture was extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give the product as an oil with two isomers. The oil was dissolved in THF (30 mL), 2N aqueous HCl (30 mL) was added, and the mixture was stirred at 80 °C for 8 hours. The reaction mixture was cooled to room temperature and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over Na SO After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 2-(4-bromo-2,6-difluorophenyl)acetaldehyde as an oil (1.27 g, 54%). 1 H NMR (400 MHz, CDCl3) δ 9.76 (p, J = 1.2 Hz, 1H), 7.25-7.00 (m, 2H), 3.79 (q, J = 1.3 Hz, 2H).
[0290] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (600 mg, 1.44 mmol) and 2-(4-bromo-2,6-difluorophenyl)acetaldehyde (673 g, 2.88 mmol) in anhydrous MeOH (45 mL), HOAc (0.20 mL, 3.5 mmol) was added and stirred for 30 minutes. NaBHCN (181 mg, 2.88 mmol) was added, and the resulting mixture was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous NaHCO at 0°C. The mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(4-bromo-2,6-difluorophenethyl)-2-methylpiperidine as a white solid (904 mg, 99%). ESI MS m / z 636.15, 638.15 [M+H] + .
[0291] To a stirred solution of the above material (88 mg, 0.14 mmol) and 2-isopropenylboronic acid pinacol ester (47 mg, 0.28 mmol) in toluene (5 mL) was added Pd(PPh3)4 (32 mg, 0.028 mmol) followed by K2CO3 (97 mg, 0.70 mmol) and water (1 mL) under Ar. The mixture was stirred at 100 °C for 18 h, and then water was added. The mixture was extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,6-difluoro-4-(prop-1-en-2-yl)phenethyl)-2-methylpiperidine as a white solid (60 mg, 72%). ESI MS m / z 598.27 [M+H] + .
[0292] To a stirred solution of the above material (26 mg, 0.043 mmol) in anhydrous DCM (3 mL) was added BCl solution (1 M in DCM, 0.50 mL, 0.50 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2,6-difluoro-4-(prop-1-en-2-yl)phenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (11 mg, 78%). 1 H NMR (400 MHz, CD3OD) δ 7.13-7.04 (m, 2H), 5.46 (t, J = 1.0 Hz, 1H), 5.18 (t, J = 1.5 Hz, 1H), 3.55-3.47 (m, 1H), 3.13 (t, J = 9.0 Hz, 1H), 3.07 (dd, J = 11.1, 5.0 Hz, 1H), 2.96-2.77 (m, 5H), 2.40 (t, J = 10.8 Hz, 1H), 2.36-2.27 (m, 1H), 2.13 (dd, J = 1.5, 0.8 Hz, 3H), 1.23 (d, J = 6.2 Hz, 3H); ESI MS m / z 328.15 [M + H] + .
[0293] Example 51 (2R,3R,4R,5S)-1-(2,6-difluoro-4-isopropylphenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,6-difluoro-4-(prop-1-en-2-yl)phenethyl)-2-methylpiperidine (32 mg, 0.054 mmol) in EtOH (10 mL) was added Pd(OH) / C (20% by weight, 8.6 mg, 0.012 mmol) and 6 N HCl (0.1 mL). The mixture was treated with hydrogen (1 atmosphere) for 18 h. The catalyst was filtered off through Celite, and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2,6-difluoro-4-isopropylphenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (13 mg, 73%). 1 H NMR (400 MHz, CD3OD) δ 6.87-6.80 (m, 2H), 3.55-3.47 (m, 1H), 3.13 (t, J = 9.0 Hz, 1H), 3.07 (dd, J = 11.1, 5.0 Hz, 1H), 2.97-2.74 (m, ESI MS m / z 330.16 [M + H] + .
[0294] Example 52 (2R,3R,4R,5S)-1-(2,6-difluoro-3-isopropylphenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of (methoxymethyl)triphenylphosphonium chloride (8.57 g, 25.0 mmol) in anhydrous dioxane (20 mL) at 0 °C under Ar, KO tBu (2.81 g, 25.0 mmol) was added. The mixture was stirred at 0° C. for 0.5 h, and then 3-bromo-2,6-difluorobenzaldehyde (2.21 g, 10.0 mmol) was added. The reaction mixture was brought to 60° C. and stirred overnight. Saturated aqueous NH4Cl (30 mL) was added, and the mixture was extracted with EtOAc (3×10 mL). The combined organic extracts were dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, the residue was dissolved in HCl solution (30 mL, 6N), and the resulting mixture was stirred at 60° C. for an additional 2 h and cooled to room temperature. The aqueous was extracted with EtOAc (3×50 mL), and the combined organic solution was washed with saturated aqueous NaHCO3, brine, and dried over Na2SO4. Evaporation of the solvent followed by silica gel flash chromatography using 30% EtOAc in hexanes gave 2-(3-bromo-2,6-difluorophenyl)acetaldehyde as a white foam (1.66 g, 67%). 1 H NMR (400 MHz, CDCl3) δ 9.78 (t, J = 1.2 Hz, 1H), 7.52 (ddd, J = 9.1, 7.8, 5.9 Hz, 1H), 6.90 (ddd, J = 8.7, 8.7, 1.7 Hz, 1H), 3.87 (s, 2H).
[0295] To a mixture of 2-(3-bromo-2,6-difluorophenyl)acetaldehyde (368 mg, 1.48 mmol), 2-isopropenylboronic acid pinacol ester (0.55 mL, 2.90 mmol), KCO (612 mg, 4.40 mmol) in anhydrous and degassed toluene (5 mL) and water (1 mL) under Ar, Pd(PPh) (34 mg, 0.03 mmol) was added. The mixture was stirred in a sealed tube at 115 °C for 19 h and then cooled to room temperature. EtO (50 mL) was added, and the resulting precipitate was filtered off. The filtrate was concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel using 5% EtOAc in hexane to give ethyl 2-(2,6-difluoro-3-(prop-1-en-2-yl)phenyl)acetaldehyde as a white solid (238 mg, 82%).
[0296] To a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(piperidin-4-ylmethyl)piperidine (239 mg, 0.57 mmol) and 2-(2,6-difluoro-3-(prop-1-en-2-yl)phenyl)acetaldehyde (210 mg, 0.86 mmol) in anhydrous DCM (8 mL) under Ar was added NaBH(OAC) (241 mg, 1.13 mmol). The mixture was stirred at room temperature for 18 hours, saturated aqueous NaHCO (30 mL) was added, and the mixture was extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel using 20% EtOAc in hexanes to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,6-difluoro-3-(prop-1-en-2-yl)phenethyl)-2-methylpiperidine as a white foam (320 mg, 94%). 1 H NMR (400 MHz, CDCl3) δ 7.46-7.20 (m, 15H), 7.13 (td, J = 8.5, 6.4 Hz, 1H), 6.83 (t, J = 8.6 Hz, 1H), 5.28-5.13 (m, 2H), 4.98 (dd, J = 15.3, 10.9 Hz, 2H), 4.86 (d, J = 11.0 Hz, 1H), 4.73 (s, 2H), 4.63 (d, J = 10.8 Hz, 1H), 3.66-3.62 (m, 1H), 3.53 (t, J = 9.0 Hz, 1H), 3.20 (dd, J = 11.2, 4.8 Hz, 1H), 3.08 (t, J = 9.0 Hz, 1H), 2.96-2.62 (m, 4H), 2.54-2.37 (m, 2H), 2.21-2.05 (m, 3H), 1.27 (dd, J = 24.1, 6.6 Hz, 3H).
[0297] The above material (300 mg, 0.50 mmol) in EtOH (30 mL), 6 N HCl (0.7 mL) was treated with hydrogen in a balloon in the presence of Pd(OH) (catalyst) overnight. Removal of Pd(OH) by filtration and evaporation of the solvent, followed by purification by silica gel chromatography using 10% MeOH and 2% NH in DCM and dry-packing gave 2(2R,3R,4R,5S)-1-(2,6-difluoro-3-isopropylphenethyl)-2-methylpiperidine-3,4,5-triol (113 mg, 70%). 1 H NMR (400 MHz, CD3OD) δ 7.28-7.09 (m, 1H), 7.01-6.68 (m, 1H), 3.56-3.50 (m, 1H), 3.24-3.16 (m, 3H), 3.02-2.94 (m, 6H), 2.57 (bs, 1H), 1.30 (d, J = 6.1 Hz, 3H), 1.26 (d, J = 6.9 Hz, 6H); ESI MS m / z 330.19 [M + H] + .
[0298] Example 53 (2R,3R,4R,5S)-1-(4-cyclopropyl-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka]
[0299] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(4-bromo-2,6-difluorophenethyl)-2-methylpiperidine (100 mg, 0.16 mmol) and cyclopropylboronic acid (27 mg, 0.32 mmol) in toluene (5 mL) was added Pd(OAc) (7 mg, 0.032 mmol), followed by tricyclohexylphosphine (0.1 mL, 0.064 mmol) and KPO (133 mg, 0.64 mmol) and water (0.3 mL) under Ar. The mixture was stirred at 100 °C for 18 h, and then water was added. The mixture was extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with water (2 × 10 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(4-cyclopropyl-2,6-difluorophenethyl)-2-methylpiperidine as a white solid (82 mg, 86%). ESI MS m / z 598.29 [M+H] + .
[0300] To a stirred solution of the above material (80 mg, 0.13 mmol) in anhydrous DCM (5 mL) was added BCl solution (1 M in DCM, 1.0 mL, 1.0 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(4-cyclopropyl-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (30 mg, 71%). 1H NMR (400 MHz, CD3OD) δ 6.71-6.63 (m, 2H), 3.55-3.46 (m, 1H), 3.13 (t, J = 9.0 Hz, 1H), 3.05 (dd, J = 11.1, 5.0 Hz, 1H), 2.93 (t, J = 9.1 Hz, 1H), 2.89-2.73 (m, 4H), 2.39 (t, J = 10.8 Hz, 1H), 2.35-2.27 (m, 1H), 1.96-1.87 (m, 1H), 1.22 (d, J = 6.2 Hz, 3H), 1.05-0.97 (m, 2H), 0.73-0.66 (m, 2H); ESI MS m / z 328.17 [M + H] + .
[0301] Example 54 (2R,3R,4R,5S)-1-(2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl)-2-methylpiperidine-3,4,5-triol [ka] A mixture of 4-bromo-2,6-difluorobenzaldehyde (4.42 g, 20.0 mmol), 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester (38A) (4.20 g, 20.0 mmol), Pd(PPh) (1.15 g, 1.00 mmol), and aqueous KCO (4.0 M, 10.0 mL, 40 mmol) in 1,4-dioxane (60 mL) under Ar was stirred at 85 °C for 16 h and then cooled to room temperature. Brine (50 mL) was added, and the mixture was extracted with EtOAc (3 × 30 mL). The combined extracts were washed with brine (50 mL) and dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:5 to 1:4) to give 4-(3,6-dihydro-2H-pyran-4-yl)-2,6-difluorobenzaldehyde as a white solid (1.75 g, 39%). 1H NMR (400 MHz, CDCl3) δ 10.31 (s, 1H), 7.04-6.97 (m, 2H), 6.38-6.36 (m, 1H), 4.35 (q, J = 2.9 Hz, 2H), 3.93 (t, J = 5.4 Hz, 2H), 2.50-2.45 (m, 2H),
[0302] To a solution of (methoxymethyl)triphenylphosphonium chloride (3.42 g, 10.0 mmol) in anhydrous THF (40 ml) at -10°C, t Bu (1.12 g, 10.0 mmol) was added, and the mixture was stirred at −10° C. for 1 hour. 4-(3,6-Dihydro-2H-pyran-4-yl)-2,6-difluorobenzaldehyde (1.00 g, 4.46 mmol) was added, and the mixture was stirred at room temperature for 24 hours. The mixture was diluted with saturated aqueous NaHCO (50 mL) and extracted with EtOAc (3×30 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:6) to give the desired product. The product was dissolved in mixed THF (40 mL) and aqueous HCl (2.5 N, 40 mL). After stirring at reflux for 5 hours, the mixture was cooled and diluted with ice water (50 mL). After extraction with EtOAc (3 × 30 mL), the combined extracts were washed with saturated aqueous NaHCO (30 mL) and dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:6 to 1:4) to give 2-(4-(3,6-dihydro-2H-pyran-4-yl)-2,6-difluorophenyl)acetaldehyde as a pale yellow solid (0.65 g, 61%, 2 steps). 1H NMR (500 MHz, CDCl3) δ 9.75 (p, J = 1.3 Hz, 1H), 7.03-6.75 (m, 2H), 6.19 (tt, J = 3.1, 1.6 Hz, 1H), 4.32 (q, J = 2.8 Hz, 2H), 3.92 (t, J = 5.4 Hz, 2H), 3.86-3.68 (m, 2H), 2.46 (ttd, J = 5.5, 2.8, 1.6 Hz, 2H).
[0303] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.208 g, 0.500 mmol), 2-(4-(3,6-dihydro-2H-pyran-4-yl)-2,6-difluorophenyl)acetaldehyde (0.16 g, 0.67 mmol), and NaBH(OAc) (0.21 g, 1.0 mmol) in DCM (15 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (15 mL) and extracted with DCM (2 × 20 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:6 to 1:4) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(4-(3,6-dihydro-2H-pyran-4-yl)-2,6-difluorophenethyl)-2-methylpiperidine as a pale yellow solid (0.29 g, 90%). ESI MS m / z 640.3328 [M+H] + .
[0304] A mixture of the above material (0.15 g, 0.26 mmol) and Pd(OH) / C (20% Pd by mass, 0.075 g, 0.14 mmol) in MeOH / THF (15 mL / 5 mL) and 5 drops of concentrated HCl was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and then purified by flash column chromatography on silica gel (0.5 M NHMeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl)-2-methylpiperidine-3,4,5-triol (0.060 g, 70%) as a white solid. 1 H NMR (500 MHz, DMSO-d6) δ 6.99-6.94 (m, 2H), 4.75-4.61 (m, 3H), 3.98-3.90 (m, 2H), 3.39 (td, J = 11.5, 2.5 Hz, 2H) 3.29-3.21 (m, 1H), 2.90 (td, J = 8.8, 4.4 Hz, 1H), 2.84 (dd, J = 10.9, 4.9 Hz, 1H), 2.80-2.74 (m, 1H), 2.72-2.65 (m, 5H), 2.20 (t, J = 10.6 Hz, 1H), 2.12 (dq, J = 8.9, 6.1 Hz, 1H), 1.72-1.53 (m, 4H), 1.06 (d, J = 6.1 Hz, 3H); ESI MS m / z 372.1970 [M + H] + .
[0305] Example 55 (2R,3R,4R,5S)-1-(2,6-difluoro-4-(trifluoromethyl)phenethyl)-2-methylpiperidine-3,4,5-triol [ka]
[0306] To a stirred solution of 3,5-difluorobenzotrifluoride (1.50 g, 8.24 mmol) in anhydrous EtO (70 mL) was added n-BuLi solution (2.5 M in hexane, 5.0 mL, 12.5 mmol) under N at −78 °C. The mixture was stirred at −78 °C for 1 h. Anhydrous DMF (3.19 mL, 41.2 mmol) was added and stirred at −78 °C for another 1 h. The reaction was quenched with saturated aqueous NH Cl at −78 °C. The mixture was extracted with EtO (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over Na SO . After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 2,6-difluoro-4-(trifluoromethyl)benzaldehyde as a clear liquid (1.07 g, 62%). 1 H NMR (400 MHz, CDCl3) δ 10.40 (s, 1H), 7.35-7.27 (m, 2H).
[0307] To a stirred solution of (methoxymethyl)triphenylphosphonium chloride (4.08 g, 11.9 mmol) in anhydrous THF (30 mL) was added KO tBu (1.33 g, 11.9 mmol) was added at 0 °C under N2 and stirred for 30 minutes. Then, 2,6-difluoro-4-(trifluoromethyl)benzaldehyde (1.0 g, 4.76 mmol) was dissolved in 5 mL of THF and added dropwise to the mixture under N2 and allowed to react at room temperature for 4 hours. The reaction was quenched with saturated aqueous NH4Cl at 0 °C. The mixture was extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give the product as an oil with two isomers. The oil was dissolved in THF (25 mL), 2N aqueous HCl (25 mL) was added, and the mixture was stirred at 80 °C for 8 hours. The reaction mixture was cooled to room temperature and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 2-(2,6-difluoro-4-(trifluoromethyl)phenyl)acetaldehyde as a white solid (370 mg, 35%). 1 H NMR (400 MHz, CDCl3) δ 9.80 (t, J = 1.2 Hz, 1H), 7.30-7.25 (m, 2H), 3.91 (s, 2H).
[0308] To a stirred solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (260 mg, 0.62 mmol) and 2-(2,6-difluoro-4-(trifluoromethyl)phenyl)acetaldehyde (278 mg, 1.24 mmol) in anhydrous DCM (10 mL) was added HOAc (0.10 mL, 1.75 mmol) and stirred for 30 min. NaBHCN (264 mg, 1.24 mmol) was added and the resulting mixture was stirred at room temperature for 18 h. The reaction was quenched with saturated aqueous NaHCO at 0 °C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,6-difluoro-4-(trifluoromethyl)phenethyl)-2-methylpiperidine as a white solid (349 mg, 90%). 1 H NMR (400 MHz, CDCl3) δ 7.42-7.26 (m, 15H), 7.16 (d, J = 6.4 Hz, 2H), 4.98 (t, J = 11.5 Hz, 2H), 4.85 (d, J = 11.0 Hz, 1H), 4.73 (d, J = 2.5 Hz, 2H), 4.61 (d, J = 10.8 Hz, 1H), 3.66-3.57 (m, 1H), 3.52 (t, J = 9.0 Hz, 1H), 3.2-3.12 (m, 1H), 3.05 (t, J = 8.9 Hz, 1H), 2.94-2.75 (m, 4H), 2.50-2.34 (m, 2H), 1.19 (d, J = 6.1 Hz, 3H).
[0309] To a stirred solution of the above material (185 mg, 0.30 mmol) in anhydrous DCM (10 mL) was added BCl solution (1 M in DCM, 1.80 mL, 1.80 mmol) under N at −78° C. The mixture was stirred at 0° C. for 2 hours and then quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 minutes. The solvent was removed in vacuo, and the residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 minutes, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2,6-difluoro-4-(trifluoromethyl)phenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (62 mg, 58%). 1 H NMR (400 MHz, CD3OD) δ 7.39-7.30 (m, 2H), 3.53-3.44 (m, 1H), 3.13 (t, J = 9.0 Hz, 1H), 3.07 (dd, J = 11.1, 5.0 Hz, 1H), 3.01-2.76 (m, 5H), 2.36 (t, J = 10.8 Hz, 1H), 2.33-2.24 (m, 1H), 1.19 (d, J = 6.1 Hz, 3H); ESI MS m / z 356.12 [M + H] + .
[0310] Example 56 (2R,3R,4R,5S)-1-(2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl)-2-methylpiperidine-3,4,5-triol [ka] (E and Z)-5-bromo-1,3-difluoro-2-(2-methoxyvinyl)benzene (0.506 g, 2.00 mmol), pyrrolidine (0.32 g, 4.6 mmol), KO in anhydrous toluene (15 mL). tA mixture of Bu (0.45 g, 4.0 mmol), BINAP (0.18 g, 0.30 mmol), and Pd(dba) (0.092 g, 0.10 mmol) was bubbled with Ar for 10 min and then stirred at 85 °C for 16 h. The reaction mixture was cooled to room temperature and diluted with saturated aqueous NaHCO (30 mL). After extraction with EtOAc (2 × 30 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:12 to 1:9) to give (E and Z)-1-(3,5-difluoro-4-(2-methoxyvinyl)phenyl)piperidine as a pale yellow oil (0.29 g, 61%, mixture of trans and cis isomers). ESI MS m / z 240.115 [M+H] + .
[0311] To a solution of the above material (0.29 g, 1.2 mmol) in THF (20 mL) was added aqueous HCl (3.5 N, 20 mL), and the mixture was stirred at reflux for 4 hours. The reaction mixture was cooled to room temperature and diluted with saturated aqueous NaHCO (50 mL). After extraction with EtOAc (2 × 30 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:9 to 1:6) to give 2-(2,6-difluoro-4-(pyrrolidin-1-yl)phenyl)acetaldehyde as a pale yellow oil (0.17 g, 62%). 1 ESI MS m / z 226.104 [M+H] + .
[0312] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.20 g, 0.48 mmol), 2-(2,6-difluoro-4-(pyrrolidin-1-yl)phenyl)acetaldehyde (0.15 g, 0.67 mmol), and NaBH(OAc) (0.20 g, 0.94 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:8 to 1:5) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl)-2-methylpiperidine as a white solid (0.25 g, 83%). ESI MS m / z 627.331 [M+H] + .
[0313] To a solution of the above material (0.25 g, 0.40 mmol) in anhydrous DCM (8 mL) at −78° C. and N was added BCl (1.0 M in DCM, 2.0 mL, 2.0 mmol), and the mixture was stirred at 0° C. for 3 hours. The reaction mixture was cooled at −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash column chromatography on silica gel (1 M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.121 g, 85%). 1H NMR (400 MHz, DMSO-d6) δ 6.37-6.03 (m, 2H), 4.93-4.59 (m, 3H), 3.30-3.11 (m, 5H), 2.90 (td, J = 8.9, 4.4 Hz, 1H), 2.83 (dd, J = 10.9, ESI MS m / z 357.201 [M+H] + .
[0314] Example 57 (2R,3R,4R,5S)-1-(2,6-difluoro-4-(piperidin-1-yl)phenethyl)-2-methylpiperidine-3,4,5-triol [ka] To a solution of (methoxymethyl)triphenylphosphonium chloride (5.14 g, 15.0 mmol) in anhydrous DMF (35 mL) at 0 °C, KO t Bu (1.70 g, 15.0 mmol) and 4-bromo-2,6-difluorobenzaldehyde (2.21 g, 10.0 mmol) were added, and the mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (200 mL) and then extracted with EtOAc (3 × 50 mL). The combined extracts were washed with brine (2 × 50 mL) and dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:19 to 1:9) to give (E and Z)-5-bromo-1,3-difluoro-2-(2-methoxyvinyl)benzene as a pale yellow solid (2.30 g, 92%, mixture of trans and cis isomers).
[0315] The above material (0.506 g, 2.00 mmol), piperidine (0.34 g, 4.0 mmol), KO t A mixture of Bu (0.45 g, 4.0 mmol), BINAP (0.18 g, 0.30 mmol), and Pd(dba) (0.092 g, 0.10 mmol) was bubbled with Ar for 10 min and then stirred at 85 °C for 16 h. The reaction mixture was cooled to room temperature and diluted with saturated aqueous NaHCO (30 mL). After extraction with EtOAc (2 × 30 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:16 to 1:9) to give (E and Z)-1-(3,5-difluoro-4-(2-methoxyvinyl)phenyl)piperidine as a pale yellow oil (0.30 g, 59%, mixture of trans and cis isomers). ESI MS m / z 254.136 [M+H] + .
[0316] To a solution of the above material (0.30 g, 1.2 mmol) in THF (20 mL) was added aqueous HCl (2.5 N, 20 mL), and the mixture was stirred at reflux for 4 hours. The reaction mixture was cooled to room temperature and diluted with saturated aqueous NaHCO (50 mL). After extraction with EtOAc (2 × 30 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:12 to 1:8) to give 2-(2,6-difluoro-4-(piperidin-1-yl)phenyl)acetaldehyde as a pale yellow oil (0.21 g, 74%). 1 ESI MS m / z 240.120 [M+H] + .
[0317] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.25 g, 0.60 mmol), 2-(2,6-difluoro-4-(piperidin-1-yl)phenyl)acetaldehyde (0.12 g, 0.50 mmol), and NaBH(OAc) (0.18 g, 0.85 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:12 to 1:8) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(2,6-difluoro-4-(piperidin-1-yl)phenethyl)-2-methylpiperidine as a white solid (0.179 g, 56%). ESI MS m / z 641.351 [M+H] + .
[0318] To a solution of the above material (0.13 g, 0.20 mmol) in anhydrous DCM (8 mL) at −78° C. and N was added BCl (1.0 M in DCM, 1.5 mL, 1.5 mmol), and the mixture was stirred at 0° C. for 3 hours. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash chromatography on silica gel (1 M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(2,6-difluoro-4-(piperidin-1-yl)phenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.070 g, 94%). 1H NMR (400 MHz, DMSO-d6) δ 6.60-6.51 (m, 2H), 4.71-4.65 (m, 3H), 3.24 (ddd, J = 14.3, 11.2, 6.5 Hz, 1H), 3.17-3.12 (m, 4H), 2.94-2.78 (m, 2H), 2.72-2.51 (m, 5H), 2.23-2.06 (m, 2H), 1.60-1.50 (m, 6H), 1.06 (d, J = 6.1 Hz, 3H); ESI MS m / z 371.215 [M + H] + .
[0319] Example 58 (2R,3R,4R,5S)-1-(2,6-difluoro-4-morpholinophenethyl)-2-methylpiperidine-3,4,5-triol [ka] (E and Z)-5-bromo-1,3-difluoro-2-(2-methoxyvinyl)benzene (0.506 g, 2.00 mmol), morpholine (0.35 g, 4.0 mmol), KO in anhydrous toluene (15 mL). t A mixture of Bu (0.45 g, 4.0 mmol), BINAP (0.18 g, 0.30 mmol), and Pd(dba) (0.092 g, 0.10 mmol) was bubbled with Ar for 10 min and then stirred at 85 °C for 16 h. The reaction mixture was cooled to room temperature and diluted with saturated aqueous NaHCO (30 mL). After extraction with EtOAc (2 × 30 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:9 to 1:6) to give (E and Z)-4-(3,5-difluoro-4-(2-methoxyvinyl)phenyl)morpholine as a pale yellow oil (0.25 g, 49%, mixture of trans and cis isomers). ESI MS m / z 256.110 [M+H] + .
[0320] Synthesis of 2-(2,6-difluoro-4-morpholinophenyl)acetaldehyde (34B) To a solution of the above material (0.25 g, 0.98 mmol) in combined THF (15 mL) was added aqueous HCl (3.5 N, 15 mL), and the mixture was stirred at reflux for 4 h. The reaction mixture was cooled to room temperature and diluted with saturated aqueous NaHCO (50 mL). After extraction with EtOAc (2 × 30 mL), the combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:6 to 1:4) to give 2-(2,6-difluoro-4-morpholinophenyl)acetaldehyde as a pale yellow oil (0.12 g, 51%). 1 H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 6.51-6.29 (m, 2H), 3.88-3.79 (m, 4H), 3.66 (s, 2H), 3.16-3.11 (m, 4H); ESI MS m / z 242.094 [M + H] + .
[0321] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.19 g, 0.46 mmol), 2-(2,6-difluoro-4-morpholinophenyl)acetaldehyde (0.12 g, 0.50 mmol), and NaBH(OAc) (0.23 g, 1.1 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:4 to 1:3) to give 4-(3,5-difluoro-4-(2-((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidin-1-yl)ethyl)phenyl)morpholine as a white solid (0.26 g, 88%). ESI MS m / z 643.329 [M+H] + .
[0322] To a solution of the above material (0.26 g, 0.40 mmol) in anhydrous DCM (8 mL) at −78° C. and N was added BCl (1.0 M in DCM, 2.0 mL, 2.0 mmol), and the mixture was stirred at 0° C. for 3 hours. The reaction mixture was cooled to −78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash column chromatography on silica gel (1 M NH in MeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(2,6-difluoro-4-morpholinophenethyl)-2-methylpiperidine-3,4,5-triol as a white solid (0.124 g, 83%). 1 H NMR (400 MHz, DMSO-d6) δ 6.82-6.46 (m, 2H), 4.86-4.41 (m, 3H), 3.69 (dd, J = 6.0, 3.8 Hz, 4H), 3.29-3.19 (m, 1H), 3.11 (dd, J = 6.0, 3.8 Hz, 4H), 2.89 (td, J = 8.8, 4.3 Hz, 1H), 2.83 (dd, J = 10.9, 4.9 Hz, 1H), 2.73-2.54 (m, 5H), 2.18 (t, J = 10.6 Hz, 1H), 2.14-2.07 (m, 1H), 1.06 (d, J = 6.1 Hz, 3H); ESI MS m / z 373.195 [M + H] + .
[0323] Example 59 (2R,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka] A mixture of 3,5-difluorophenol (2.60 g, 20.0 mmol), 1-bromobutane (4.00 g, 29.2 mmol), and K2CO3 (5.00 g, 36.3 mmol) in DMF (25 mL) was stirred at 80 °C for 2 hours and then cooled to room temperature. The mixture was diluted with water (50 mL) and extracted with hexane (2 × 50 mL). The combined extracts were washed with brine (2 × 50 mL) and then dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (hexane) to give 1-butoxy-3,5-difluorobenzene as a clear, colorless liquid (3.50 g, 94%). 1 H NMR (400 MHz, CDCl3) δ 6.45-6.34 (m, 3H), 3.92 (t, J = 6.5 Hz, 2H), 1.80-1.71 (m, 2H), 1.55-1.41 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H).
[0324] To a solution of the above material (3.50 g, 18.8 mmol) in anhydrous THF (20 mL) under N2 at -78 °C, freshly prepared LDA (22.0 mmol) in mixed THF / hexane (20 mL / 10 mL) was added, and the mixture was stirred at -78 °C for 1 h. Anhydrous DMF (2.92 g, 40.0 mmol) was added, and the mixture was stirred at -78 °C for 30 min and then at 0 °C for 1 h. Diluted aqueous HCl (0.5 N, 50 mL) was added, and the mixture was extracted with EtOAc (2 × 50 mL). The combined extracts were washed with brine (2 × 50 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:20) to give 4-butoxy-2,6-difluorobenzaldehyde as a white solid (3.8 g, 94%). 1H NMR (500 MHz, CDCl3) δ 10.18 (s, 1H), 6.52-6.42 (m, 2H), 4.00 (t, J = 6.5 Hz, 2H), 1.83-1.73 (m, 2H), 1.52-1.42 (m, 2H), 0.97 (t, J = 7.4Hz, 3H).
[0325] To a solution of (methoxymethyl)triphenylphosphonium chloride (2.30 g, 6.50 mmol) in anhydrous DMF (30 mL) at 0 °C, KO t Bu (0.729 g, 6.50 mmol) and 4-butoxy-2,6-difluorobenzaldehyde (1.15 g, 5.37 mmol) were added, and the mixture was stirred at room temperature for 16 h. The mixture was diluted with saturated aqueous NaHCO3 (50 mL) and extracted with EtOAc (2 × 40 mL). The combined extracts were washed with brine (2 × 50 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:30 to 1:9) to give a clear liquid. The clear liquid was dissolved in mixed THF (25 mL) and aqueous HCl (2.5 N, 25 mL). After stirring at reflux for 2 h, the mixture was cooled and diluted with ice water (50 mL). After extraction with EtOAc (2 × 40 mL), the combined extracts were washed with saturated aqueous NaHCO3 (50 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:20 to 1:9) to give 2-(4-butoxy-2,6-difluorophenyl)acetaldehyde as a colorless oil (0.20 g, 16%, 2 steps). 1 H NMR (500 MHz, CDCl3) δ 9.71 (p, J = 1.3 Hz, 1H), 6.44-6.39 (m, 2H), 3.91 (t, J = 6.5 Hz, 2H), 3.69 (s, 2H), 1.80-1.69 (m, 2H), 1.50-1.43(m, 2H), 0.97 (t, J = 7.4 Hz, 3H).
[0326] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.25 g, 0.60 mmol), 2-(4-butoxy-2,6-difluorophenyl)acetaldehyde (0.20 g, 0.88 mmol), and NaBH(OAc) (0.32 g, 1.5 mmol) in DCM (15 mL) under N was stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:20 to 1:8) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(4-butoxy-2,6-difluorophenethyl)-2-methylpiperidine as a colorless oil (0.31 g, 82%). ESI MS m / z 630.335 [M+H] + .
[0327] A mixture of the above material (0.230 g, 0.365 mmol) and Pd(OH) / C (20% Pd by mass, 0.080 g, 0.15 mmol) in MeOH (20 mL) and 5 drops of concentrated HCl was stirred under H at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash chromatography on silica gel (1 M NHMeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol (0.115 g, 88%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 6.59-6.44 (m, 2H), 3.94 (t, J = 6.4 Hz, 2H), 3.52-3.45 (m, 1H), 3.11 (t, J = 9.0 Hz, 1H), 3.03 (dd, J = 11.2, 4.9 Hz, 1H), 2.91 (t, J = 9.1 Hz, 1H), 2.86-2.65 (m, 4H), 2.36 (t, J = 10.8 Hz, 1H), 2.28 (dq, J = 9.1, 6.1 Hz, 1H), 1.81-1.67 (m, 2H), 1.58-1.39 (m, 2H), 1.21 (d, J = 6.1 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H); ESI MS m / z 360.201 [M + H] + .
[0328] Example 60 (2R,3R,4R,5S)-1-(4-(cyclopropylmethoxy)-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol [ka]
[0329] A mixture of 3,5-difluorophenol (1.80 g, 13.8 mmol), (bromomethyl)cyclopropane (2.00 g, 14.8 mmol), and K2CO3 (3.00 g, 21.7 mmol) in DMF (20 mL) was stirred at 80 °C for 16 hours and then cooled to room temperature. The mixture was diluted with water (50 mL) and extracted with hexane (2 × 50 mL). The combined extracts were washed with brine (2 × 50 mL) and then dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (hexane) to give 1-(cyclopropylmethoxy)-3,5-difluorobenzene as a clear, colorless liquid (2.30 g, 90%).
[0330] To a solution of the above material (2.30 g, 12.5 mmol) in anhydrous THF (20 mL) under N2 at -78 °C, freshly prepared LDA (14.0 mmol) in mixed THF / hexane (20 ml / 10 mL) was added, and the mixture was stirred at -78 °C for 1 hour. Anhydrous DMF (1.83 g, 25.0 mmol) was added, and the mixture was stirred at -78 °C for 30 minutes and then at 0 °C for 1 hour. Diluted aqueous HCl (0.5 N, 50 mL) was added, and the mixture was extracted with EtOAc (2 × 50 mL). The combined extracts were washed with brine (2 × 50 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:10) to give 4-(cyclopropylmethoxy)-2,6-difluorobenzaldehyde as a white solid (2.35 g, 90%). 1 H NMR (400 MHz, CDCl3) δ 10.18 (s, 1H), 6.63-6.39 (m, 2H), 3.85 (d, J = 7.0 Hz, 2H), 1.37-1.08 (m, 1H), 0.73-0.59 (m, 2H), 0.39-0.35 (m, 2H).
[0331] To a solution of (methoxymethyl)triphenylphosphonium chloride (2.40 g, 7.00 mmol) in anhydrous DMF (20 ml) at 0°C, KO tBu (0.841 g, 7.50 mmol) and 4-(cyclopropylmethoxy)-2,6-difluorobenzaldehyde (1.00 g, 4.71 mmol) were added, and the mixture was stirred at room temperature for 16 h. The mixture was diluted with saturated aqueous NaHCO3 (50 mL) and extracted with EtOAc (2 × 40 mL). The combined extracts were washed with brine (2 × 50 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:30 to 1:9) to give a clear liquid. The clear liquid was dissolved in mixed THF (25 mL) and aqueous HCl (3.5 N, 25 mL). After stirring at reflux for 4 h, the mixture was cooled and diluted with ice water (50 mL). After extraction with EtOAc (2 × 40 mL), the combined extracts were washed with saturated aqueous NaHCO3 (50 mL) and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:12 to 1:7) to give 2-(4-(cyclopropylmethoxy)-2,6-difluorophenyl)acetaldehyde as a colorless oil (0.43 g, 40%, 2 steps). 1 H NMR (400 MHz, CDCl3) δ 9.71 (p, J = 1.3 Hz, 1H), 6.62-6.36 (m, 2H), 3.77 (d, J = 6.9 Hz, 2H), 3.68 (q, J = 1.3 Hz, 2H), 1.32-1.18 (m, 1H), 0.71-0.58 (m, 2H), 0.40-0.28 (m, 2H).
[0332] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.22 g, 0.53 mmol), 2-(4-(cyclopropylmethoxy)-2,6-difluorophenyl)acetaldehyde (0.20 g, 0.88 mmol), and NaBH(OAc) (0.30 g, 1.4 mmol) in DCM (10 mL) under N was stirred at room temperature for 16 h. The reaction mixture was diluted with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 15 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:10 to 1:7) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-1-(4-(cyclopropylmethoxy)-2,6-difluorophenethyl)-2-methylpiperidine as a colorless oil (0.315 g, 95%). ESI MS m / z 628.322 [M+H] + .
[0333] A mixture of the above material (0.31 g, 0.50 mmol) and Pd(OH) / C (20% Pd by mass, 0.080 g, 0.15 mmol) in MeOH (25 mL) and 6 drops of concentrated HCl was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash column chromatography on silica gel (1 M NHMeOH / DCM, 1:6) to give (2R,3R,4R,5S)-1-(4-(cyclopropylmethoxy)-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol (0.157 g, 88%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 6.59-6.46 (m, 2H), 3.78 (d, J = 6.9 Hz, 2H), 3.49 (ddd, J = 10.5, 9.0, 4.9 Hz, 1H), 3.11 (t, J = 9.0 Hz, 1H), 3.03 (dd, J = 11.1, 4.9 Hz, 1H), 2.91 (t, J = 9.1 Hz, 1H), 2.87-2.66 (m, 4H), 2.36 (t, J = 10.9 Hz, 1H), 2.27 (dt, J = 9.1, 6.1 Hz, 1H), 1.27-1.12 (m, 4H), 0.67-0.55 (m, 2H), 0.40-0.28 (m, 2H); ESI MS m / z 358.183 [M + H] + .
[0334] Example 61 (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydrofuran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol [ka] To a stirred solution of ethyl 2-(4-hydroxyphenyl)acetate (1.0 g, 5.5 mmol), PPh3 (2.18 g, 8.32 mmol), and tetrahydrofuran-3-ol (0.73 g, 8.32 mmol) in anhydrous THF (10 mL) was slowly added DIAD (1.68 g, 8.32 mmol). The resulting mixture was stirred at room temperature for 18 hours. The solvent was removed under reduced pressure, and the crude material was purified by silica gel flash chromatography to give ethyl 2-(4-((tetrahydrofuran-3-yl)oxy)phenyl)acetate as an oil (0.55 g, 40%). 1H NMR (400 MHz, CDCl3) δ 7.26-7.19 (m, 2H), 6.87-6.82 (m, 2H), 4.93 (ddt, J = 6.5, 4.5, 2.2 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 4.06-3.97 (m, 3H), 3.92 (td, J = 8.2, 4.4 Hz, 1H), 3.57 (s, 2H), 2.28-2.14 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H). To a solution of the above material (550 mg, 2.20 mmol) in anhydrous THF (10 mL) at 0° C., LAH (204 mg, 5.34 mmol) was added, and the mixture was stirred at 0° C. for 1 h. The mixture was slowly quenched with saturated aqueous NaSO and filtered. The solid was washed with EtOAc. The combined organic layers were washed with water (2×20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure to give crude 2-(4-((tetrahydrofuran-3-yl)oxy)phenyl)ethanol as an oil (490 mg).
[0335] A solution of the above material (310 mg, 1.49 mmol) and CBr (593 mg, 1.79 mmol) in DCM (10 mL) was cooled to 0 °C, and PPh (469 mg, 1.79 mmol) was added in small portions. The reaction mixture was stirred at room temperature for 1 h. The mixture was diluted with DCM and washed with saturated aqueous NaHCO, and the organic phase was separated and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 3-(4-(2-bromoethyl)phenoxy)tetrahydrofuran as an oil (311 mg, 77%). 1H NMR (400 MHz, CDCl3) δ 7.18-7.12 (m, 2H), 6.87-6.81 (m, 2H), 4.93 (ddt, J = 6.4, 4.5, 2.2 Hz, 1H), 4.05-3.97 (m, 3H), 3.92 (td, J = 8.2, 4.4 Hz, 1H), 3.56 (t, J = 7.6 Hz, 2H), 3.13 (t, J = 7.6 Hz, 2H), 2.28-2.12 (m, 2H).
[0336] DIPEA (0.16 mL, 0.96 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (50 mg, 0.12 mmol) and 3-(4-(2-bromoethyl)phenoxy)tetrahydrofuran (130 mg, 0.48 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h and cooled to ambient temperature. The reaction mixture was poured into ice-water (30 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with water (2×20 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(4-((tetrahydrofuran-3-yl)oxy)phenethyl)piperidine as a white solid (39 mg, 52%). ESI MS m / z 608.32 [M+H] + .
[0337] To a solution of the above material (35 mg, 0.058 mmol) in EtOH (10 mL) was added Pd(OH) / C (20% by weight, 8.6 mg, 0.012 mmol) and 6 N HCl (0.1 mL). The mixture was treated with hydrogen (1 atm) for 18 h. The catalyst was filtered off through Celite, and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH in MeOH (10 mL) and stirred for another 10 min, after which the solvent was removed in vacuo. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydrofuran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol as a white solid (14 mg, 72%). 1 H NMR (400 MHz, CD3OD) δ 7.20-7.13 (m, 2H), 6.89-6.83 (m, 2H), 5.03-4.97 (m, 1H), 4.05-3.80 (m, 4H), 3.63-3.52 (m, 1H), 3.21 (t, J = 8.7 Hz, 2H), 3.13-3.00 (m, 2H), 2.99-2.87 (m, 1H), 2.87-2.71 (m, 2H), 2.61-2.41 (br, 2H), 2.31-2.18 (m, 1H), 2.15-2.06 (m, 1H), 1.33 (d, J = 6.2 Hz, 3H); ESI MS m / z 338.19 [M + H] + .
[0338] Example 62 (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol [ka] To a solution of (2S,3R,4S,5S)-3,4,5-tris(benzyloxy)-2-methoxy-6-methylenetetrahydro-2H-pyran (24.4 g, 54.6 mmol) (Heterocycles, 2007, 73, C, 165-168) in THF (400 mL) was added aqueous HCl (2.5 N, 200 mL), and the mixture was stirred at 50 °C for 2 hours. The reaction mixture was diluted with ice water (400 mL) and extracted with EtOAc (3 × 300 mL). The combined extracts were washed with saturated aqueous NaHCO (500 mL) and dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure at room temperature to give (2R,3R,4S)-2,3,4-tris(benzyloxy)-5-oxohexanal as a white solid. This material was dissolved in a mixed solvent of anhydrous DCM (50 mL) and anhydrous MeOH (450 mL), and NHOAc (75.0 g, 973 mmol), NaSO (50.0 g, 352 mmol), and NaBHCN (20.0 g, 318 mmol) were added at 0 °C under N. After stirring at room temperature for 16 h, the mixture was diluted with saturated aqueous NaHCO (1 L) and extracted with DCM (3 × 500 mL). The combined extracts were dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 3:7, then 1 M NH in MeOH / DCM, 1:20) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine as a white solid (20.3 g, 89%, 2 steps). 1H NMR (400 MHz, DMSO-d6) δ 7.43-7.15 (m, 15H), 4.86 (d, J = 11.2 Hz, 1H), 4.77 (d, J = 11.2 Hz, 1H), 4.72 (d, J = 11.2 Hz, 1H), 4.65 (d, J = 12.0 Hz, 1H), 4.62-4.53 (m, 2H), 3.43-3.34 (m, 2H), 3.14 (dd, J = 11.9, 4.4 Hz, 1H), 2.89 (t, J = 8.8 Hz, 1H), 2.41 (dd, J = 9.4, 6.3 Hz, 1H), 2.28 (dd, J = 11.9, 9.4 Hz, 1H), 2.08 (s, br., 1H), 1.05 (d, J = 6.2 Hz, 3H); ESI MS m / z 418.235 [M + H] + .
[0339] To a solution of ethyl 2-(4-hydroxyphenyl)acetate (2.00 g, 11.1 mmol), PPh3 (4.50 g, 17.2 mmol), and tetrahydro-2H-pyran-3-ol (1.70 g, 16.6 mmol) in anhydrous THF (30 mL) at 0° C., DIAD (3.40 g, 16.8 mmol) was slowly added, and the mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure at room temperature, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:7 to 1:3) to give ethyl 2-(4-((tetrahydro-2H-pyran-3-yl)oxy)phenyl)acetate as a pale yellow oil (1.50 g, 51%).
[0340] To a solution of the above material (0.650 g, 2.46 mmol) in anhydrous THF (20 mL) at 0° C. and under N2, LAH (0.152 g, 4.00 mmol) was added, and the mixture was stirred at 0° C. for 1 h. Wet sodium sulfate heptahydrate (50 g) was added to quench the reaction, and the suspension was stirred at room temperature for 30 min. After filtration, the solvent was evaporated to give 2-(4-((tetrahydro-2H-pyran-3-yl)oxy)phenyl)ethanol as a clear oil.
[0341] To a solution of the above material in anhydrous DCM (30 mL) at 0° C., PPh (0.84 g, 3.2 mmol) and CBr (1.0 g, 3.0 mmol) were added, and the mixture was stirred at room temperature for 16 h. The solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel (EtOAc / hexane, 1:9 to 1:7) to give 3-(4-(2-bromoethyl)phenoxy)tetrahydro-2H-pyran as a clear oil (0.61 g, 87%, 2 steps). 1 H NMR (500 MHz, CDCl3) δ 7.14-7.08 (m, 2H), 6.92-6.80 (m, 2H), 4.28 (tt, J = 7.6, 3.6 Hz, 1H), 3.95 (ddd, J = 11.5, 3.6, 1.6 Hz, 1H), 3.80-3.72 (m, 1H), 3.60-3.53 (m, 2H), 3.52 (t, J = 7.7 Hz, 2H), 3.09 (t, J = 7.7 Hz, 2H), 2.14-2.03 (m, 1H), 1.94-1.83 (m, 1H), 1.81-1.74 (m, 1H), 1.68-1.59 (m, 1H).
[0342] A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (0.10 g, 0.24 mmol), 3-(4-(2-bromoethyl)phenoxy)tetrahydro-2H-pyran (0.20 g, 0.70 mmol), and DIPEA (0.20 g, 2.3 mmol) in anhydrous DMF (5 mL) in a sealed tube was stirred at 85 °C for 16 h. The reaction mixture was cooled to room temperature and diluted with saturated aqueous NaHCO (20 mL). After extraction with EtOAc (3 × 20 mL), the combined extracts were washed with brine (2 × 20 mL) and dried over anhydrous NaSO. After filtration, the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel (EtOAc / hexanes, 1:7 to 1:3) to give (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methyl-1-(4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl)piperidine as a pale yellow oil (0.11 g, 74%); ESI MS m / z 622.342 [M+H] + .
[0343] A mixture of the above material (0.10 g, 0.16 mmol) and Pd(OH) / C (20% Pd by mass, 0.075 g, 0.14 mmol) and 2 drops of concentrated HCl in MeOH (20 mL) was stirred under hydrogen at 1 atmosphere overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH in MeOH and purified by flash chromatography on silica gel (1 M NHMeOH / DCM, 1:8) to give (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol (0.042 g, 75%) as a white foam. 1H NMR (400 MHz, DMSO-d6) δ 7.08 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 4.71-4.64 (m, 3H), 4.29 (tt, J = 7.0, 3.5 Hz, 1H), 3.82-3.76 (m, 1H), 3.66-3.58 (m, 1H), 3.53-3.39 (m, 2H), 3.28-3.16 (m, 1H), 2.93-3.84 (m, 2H), 2.79-2.65 (m, 2H), 2.64-2.54 (m, 3H), 2.15-1.96 (m, 3H), 1.78-1.71 (m, 1H), 1.68-1.60 (m, 1H), 1.55-1.47 (m, 1H), 1.09 (d, J = 6.1 Hz, 3H); ESI MS m / z 352.207 [M + H] + .
[0344] Example 63 (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl)piperidine-3,4,5-triol [ka] To a stirred solution of ethyl 2-(4-hydroxyphenyl)acetate (2.0 g, 11.1 mmol), PPh3 (4.36 g, 16.6 mmol), and tetrahydro-2H-pyran-4-ol (1.70 g, 16.6 mmol) in anhydrous THF (20 mL) was slowly added DIAD (3.36 g, 16.6 mmol). The resulting mixture was stirred at room temperature for 18 hours. The solvent was removed under reduced pressure, and the crude material was purified by silica gel flash chromatography to give ethyl 2-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)acetate as an oil (1.45 g, 54%). 1H NMR (400 MHz, CDCl3) δ 7.25-7.17 (m, 2H), 6.97-6.85 (m, 2H), 4.48 (tt, J = 7.8, 3.8 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 4.00 (ddd, J = 11.7, 6.1, 3.8 Hz, 2H), 3.64-3.55 (m, 4H), 2.08-1.96 (m, 2H), 1.81 (dtd, J = 12.4, 8.1, 3.8 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H).
[0345] To a solution of the above material (1.0 g, 3.79 mmol) in anhydrous THF (20 mL) at 0° C., LAH (431 mg, 11.4 mmol) was added, and the mixture was stirred at 0° C. for 1 h. The mixture was slowly quenched with saturated aqueous NaSO and filtered. The solid was washed with EtOAc. The combined organic layers were washed with water (2×20 mL), separated, and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure to give crude 2-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)ethanol as an oil (890 mg, 100%).
[0346] A solution of the above material (540 mg, 2.43 mmol) and CBr (967 mg, 2.92 mmol) in DCM (20 mL) was cooled to 0 °C, and PPh (766 mg, 2.92 mmol) was added in small portions. The reaction mixture was stirred at room temperature for 1 h. The mixture was diluted with DCM and washed with saturated aqueous NaHCO, and the organic phase was separated and dried over NaSO. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give 4-(4-(2-bromoethyl)phenoxy)tetrahydro-2H-pyran as an oil (568 mg, 82%). 1H NMR (400 MHz, CDCl3) δ 7.17-7.09 (m, 2H), 6.94-6.84 (m, 2H), 4.48 (tt, J = 7.8, 3.9 Hz, 1H), 4.01 (ddd, J = 10.7, 6.0, 3.8 Hz, 2H), 3.67-3.45 (m, 4H), 3.12 (t, J = 7.6 Hz, 2H), 2.08-1.97 (m, 2H), 1.81 (dtd, J = 12.4, 8.1, 3.8 Hz, 2H).
[0347] DIPEA (0.16 mL, 0.96 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-methylpiperidine (50 mg, 0.12 mmol) and 4...
Claims
1. A compound of formula (I) or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (I) (In the formula, R 1 is H, and R 2 is CH 3 , C.H. 2 F or CHF 2 or R 1 is CH 3 Or CH 2 F and R 2 is H, R 3 (CH 2 ) n R 4 n is 1 or 2; R 4 are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)methyl, ([1,1′-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which is selected from one or more of F, Cl, C. 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 Alkoxy and / or CF 3 or R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 Alkyl, cyclopropyl, propen-2-yl, OCH 3 , and / or C.F. 3 or phenylethyl, optionally substituted with one to a maximum of the following substituents: R 3 is one or more of F, C 1-6 Alkyl, OCH 3 , and / or C.F. 3 C, each of which may be substituted with one to a maximum number of substituents 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth, 【Chemistry 2】 and R 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 Alkoxyl, OCF 3 , and / or C.F. 3 (iii) is selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each of which may be substituted with one to a maximum number of substituents selected from the group consisting of
2. R 1 is H, R 2 But, CH 3 or CH 2 F, R 3 cyclohexylmethyl, (4,4-dimethylcyclohexyl)methyl, (4,4-difluorocyclohexyl)methyl, (4,4-dichlorocyclohexyl)methyl, (4-ethylcyclohexyl)methyl, ((1s,4S)-4-vinylcyclohexyl)methyl, ((1s,4S)-4-isopropylcyclohexyl)methyl, ((1r,4R)-4-isopropylcyclohexyl)methyl, 4-(tert-butyl)cyclohexyl)methyl, ((1s,4S)-4-(tert-butyl)cyclohexyl)methyl, ((1r,4R)-4-(t tert-butyl)cyclohexyl)methyl, ((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl, ((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl, ((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((trans)-3-(trifluoromethyl)cyclohexyl)methyl, ((cis)-3-(trifluoromethyl)cyclohexyl)methyl, ((1s,4S)-4-methoxycyclohexyl cyclohexyl)methyl, ((1r,4R)-4-methoxycyclohexyl)methyl, (4-(methoxymethyl)cyclohexyl)methyl, ((1s,4S)-4-cyclopropylcyclohexyl)methyl, ((1r,4R)-4-cyclopropylcyclohexyl)methyl, (4-phenylcyclohexyl)methyl, (spiro[2.5]octan-6-yl)methyl, (spiro[3.5]nonan-7-yl)methyl, (spiro[4.5]decan-8-yl)methyl, 2-cyclohexylethyl, 2-(4,4-difluorocyclohexyl)ethyl, 2-(( 1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-(adamantan-1-yl)ethyl, 3-cyclohexylpropyl, phenethyl, 2-methylphenethyl, 2-methoxyphenethyl, 2-fluorophenethyl, 2-chlorophenethyl, 2,3-difluorophenethyl, 2,4-difluorophenethyl, 2,5-difluorophenethyl, 3,4-difluorophenethyl, 2-fluoro-4-methoxyphenethyl, 3-chloro-2-fluorophenethyl,4-chloro-2-fluorophenethyl, 5-chloro-2-fluorophenethyl, 2,6-difluorophenethyl, 3-chloro-2,6-difluorophenethyl, 2,6-difluoro-4-(prop-1-en-2-yl)phenethyl, 2,6-difluoro-4-isopropylphenethyl, 2,6-difluoro-3-isopropylphenethyl, 4-cyclopropyl-2,6-difluorophenethyl, 2,6-difluoro-4-(trifluoromethyl)phenethyl, 2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl, 2,6- Difluoro-4-(piperidin-1-yl)phenethyl, 2,6-difluoro-4-morpholinophenethyl, 4-butoxy-2,6-difluorophenethyl, 4-(cyclopropylmethoxy)-2,6-difluorophenethyl, 4-((tetrahydrofuran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl, 4-phenoxyphenethyl, 4-((tetrahydrofuran-3-yl)methoxy)phenethyl, ( R)-2-phenylpropyl, (S)-2-phenylpropyl, 2-([1,1'-biphenyl]-4-yl)ethyl, 2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl, 2-(benzo[d][1,3]dioxol-5-yl)ethyl, 2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl, 2-(thiophene-2 -yl)ethyl, 2-(thiophen-3-yl)ethyl, 2-(pyridin-2-yl)ethyl, 3-phenylpropyl, 3-(2-fluorophenyl)propyl, 3-(4-fluorophenyl)propyl, 3-(thiophen-2-yl)propyl, 3-(thiophen-3-yl)propyl, (1-phenylpiperidin-4-yl)methyl, (1-(2-fluorophenyl)piperidin-4-yl)methyl, (1-(3-fluorophenyl)piperidin-4-yl)methyl, (1-(4-fluorophenyl)piperidin-4-yl)methyl,(1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl, (4-methyl-1-phenylpiperidin-4-yl)methyl, (4-fluoro-1-phenylpiperidin-4-yl)methyl, 2-(1-phenylpiperidin-4-yl)ethyl, (1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl, (1-isobutyrylpiperidin-4-yl)methyl, (1-pivaloylpiperidin-4-yl)methyl, (1-butyrylpiperidin-4-yl)methyl, (1-(3-methylbutanoyl)piperidin-4-yl) Methyl, (1-(3,3-dimethylbutanoyl)piperidin-4-yl)methyl, (1-(2-cyclopentylacetyl)piperidin-4-yl)methyl, (1-(cyclopropanecarbonyl)piperidin-4-yl)methyl, (1-(cyclobutanecarbonyl)piperidin-4-yl)methyl, (1-(cyclopentanecarbonyl)piperidin-4-yl)methyl, (1-(cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-((1s,4s)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl , (1-((1r,4r)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-methoxycyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-benzoylpiperidin-4-yl)methyl, (1-(3-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl, (1-(2-phenylacetyl)piperidin-4-yl)methyl, (1-(thiophene-3-carbonyl)piperidin 1-(cyclohexylcarbamoyl)piperidin-4-yl)methyl, ((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl, (1,2,3,4-tetrahydronaphthalen-2-yl)methyl, (2,3-dihydro-1H-inden-2-yl)methyl, 2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl, (1-(pyridin-3-yl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamoyl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamothioyl)piperidin-4-yl)methyl,(1-((1S,2R)-2-(trifluoromethyl)cyclohexyl)azetidin-3-yl)methyl, ((R)-1-phenylpyrrolidin-3-yl)methyl, ((R)-1-(o-tolyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, (R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl, (R)-1-(3-fluorophenyl)pyrrolidin-3-yl 1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-methylpyridin (R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl chiral, ((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl, (S)-(1-(4-(trifluoromethyl)benzoyl)pyrrolidin-3-yl)methyl, ((R)-1-(o-tolyl)piperidin-3-yl)methyl, ((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl,((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 3-fluorophenethyl, 4-fluorophenethyl, 3,4-dichlorophenethyl, 3-(trifluoromethyl)phenethyl, 4-(trifluoromethyl)phenethyl, ((R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 4-(3,5-dimethylisoxazol-4-yl) 4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,6-difluorophenethyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]oxazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-isopropylthiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl, (R)-1-(benzo[d]thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)piperidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-5-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, -(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl or ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl. The compound of claim 1.
3. (2R,3R,4R,5S)-1-(cyclohexylmethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4,4-dimethylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4,4-difluorocyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4,4-dichlorocyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4-ethylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((1s,4S)-4-vinylcyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((trans)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((cis)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-methoxycyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-methoxycyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4-(methoxymethyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((4-phenylcyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(spiro[2.5]octan-6-ylmethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(spiro[3.5]nonan-7-ylmethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(spiro[4.5]decan-8-ylmethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1,2,3,4-tetrahydronaphthalen-2-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((2,3-dihydro-1H-inden-2-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-cyclohexylethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(4,4-difluorocyclohexyl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((2-adamantan-1-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-cyclohexylpropyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-phenethylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-methylphenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-methoxyphenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-chlorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,3-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,4-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,5-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3,4-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-fluoro-4-methoxyphenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(5-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-chloro-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(prop-1-en-2-yl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-isopropylphenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-3-isopropylphenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-cyclopropyl-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(trifluoromethyl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(piperidin-1-yl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-morpholinophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-(cyclopropylmethoxy)-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydrofuran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-phenoxyphenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydrofuran-3-yl)methoxy)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((R)-2-phenylpropyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((S)-2-phenylpropyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-([1,1'-biphenyl]-4-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-(thiophen-2-yl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-(thiophen-3-yl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-(pyridin-2-yl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(3-phenylpropyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-(2-fluorophenyl)propyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-(4-fluorophenyl)propyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(3-(thiophen-2-yl)propyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(3-(thiophen-3-yl)propyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((1-(2-fluorophenyl)piperidin-4-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((1-(3-fluorophenyl)piperidin-4-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((1-(4-fluorophenyl)piperidin-4-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((4-methyl-1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4-fluoro-1-phenylpiperidin-4-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-(1-phenylpiperidin-4-yl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1-(pyridin-3-yl)piperidin-4-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol; 2-methyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)propan-1-one; 2,2-dimethyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)propan-1-one; 1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one; 3-methyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one; 3,3-dimethyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one; 2-cyclopentyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)ethanone; Cyclopropyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; Cyclobutyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; Cyclopentyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; Cyclohexyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; ((1s,4S)-4-(tert-butyl)cyclohexyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; ((1r,4R)-4-(tert-butyl)cyclohexyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; (4-Methoxycyclohexyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; (4-(trifluoromethyl)cyclohexyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; Phenyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; (3-(trifluoromethyl)phenyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; 2-Phenyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)ethanone; Thiophen-3-yl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; N-cyclohexyl-4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidine-1-carboxamide; N-cyclohexyl-4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidine-1-carbothioamide; (2R,3R,4R,5S)-2-methyl-1-((1-((1S,2R)-2-(trifluoromethyl)cyclohexyl)azetidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-phenylpyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(o-tolyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(3-fluorophenyl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-methylpyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (4-(trifluoromethyl)phenyl)((R)-3-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)pyrrolidin-1-yl)methanone; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(o-tolyl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-((4-isopropylcyclohexyl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-((4-(tert-butyl)cyclohexyl)methyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-phenethylpiperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-(2-fluorophenethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2,6-difluoro-4-isopropylphenethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-((1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-((1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(difluoromethyl)-1-phenethylpiperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-(fluoromethyl)-1-(2-fluorophenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3,4-dichlorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(3-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-(3,5-dimethylisoxazol-4-yl)-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]oxazol-2-yl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(5-isopropylthiazol-2-yl)piperidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]thiazol-2-yl)piperidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]thiazol-4-yl)piperidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; or a pharma- ceutically acceptable salt of any one of the preceding compounds.
4. A compound according to any one of claims 1 to 3, which inhibits non-lysosomal glucosylceramidase (GBA2).
5. The compound according to any one of claims 1 to 4, which specifically binds to GBA2.
6. A compound according to any one of claims 1 to 5 which reduces the enzyme activity level of GBA2.
7. The compound according to any one of claims 4 to 6, wherein the GBA2 is a mammalian GBA2.
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, in combination with a pharma- ceutically acceptable carrier.
9. A pharmaceutical composition for inhibiting GBA2 in a subject in need thereof, said pharmaceutical composition comprising an effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt thereof. 【Chemistry 3】 (I) (In the formula, R 1 is H, and R 2 is CH 3 , C.H. 2 F or CHF 2 or R 1 is CH 3 Or CH 2 F and R 2 is H, R 3 (CH 2 ) n R 4 n is 1 or 2; R 4 are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)methyl, ([1,1′-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which is selected from one or more of F, Cl, C. 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 Alkoxy and / or CF 3 or R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 Alkyl, cyclopropyl, propen-2-yl, OCH 3 , and / or C.F. 3 or phenylethyl, optionally substituted with one to a maximum of the following substituents: R 3 is one or more of F, C 1-6 Alkyl, OCH 3 , and / or C.F. 3 C, each of which may be substituted with one to a maximum number of substituents 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth, 【Chemistry 4】 and R 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 Alkoxyl, OCF 3 , and / or C.F. 3 and benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each of which may be substituted with one to a maximum of the following substituents:
10. A pharmaceutical composition for reducing GBA2 enzyme activity in a subject in need thereof, comprising an effective amount of a compound of formula (I), or a pharma- ceutically acceptable salt thereof. 【Chemistry 5】 (I) (In the formula, R 1 is H, and R 2 is CH 3 , C.H. 2 F or CHF 2 or R 1 is CH 3 Or CH 2 F and R 2 is H, R 3 (CH 2 ) n R 4 n is 1 or 2; R 4 are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)methyl, ([1,1′-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which is selected from one or more of F, Cl, C. 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 Alkoxy and / or CF 3 or R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 Alkyl, cyclopropyl, propen-2-yl, OCH 3 , and / or C.F. 3 or phenylethyl, optionally substituted with one to a maximum of the following substituents: R 3 is one or more of F, C 1-6 Alkyl, OCH 3 , and / or C.F. 3 C, each of which may be substituted with one to a maximum number of substituents 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth, 【Chemistry 6】 and R 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 Alkoxyl, OCF 3 , and / or C.F. 3 and benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each of which may be substituted with one to a maximum of the following substituents:
11. A pharmaceutical composition for treating a condition regulated by GBA2 in a subject in need of such treatment, comprising an effective amount of a compound of formula (I) or a pharma- ceutical acceptable salt thereof. 【Chemistry 7】 (I) (In the formula, R 1 is H, and R 2 is CH 3 , C.H. 2 F or CHF 2 or R 1 is CH 3 Or CH 2 F and R 2 is H, R 3 (CH 2 ) n R 4 n is 1 or 2; R 4 are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)methyl, ([1,1′-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which is selected from one or more of F, Cl, C. 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 Alkoxy and / or CF 3 or R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 Alkyl, cyclopropyl, propen-2-yl, OCH 3 , and / or C.F. 3 or phenylethyl, optionally substituted with one to a maximum of the following substituents: R 3 is one or more of F, C 1-6 Alkyl, OCH 3 , and / or C.F. 3 C, each of which may be substituted with one to a maximum number of substituents 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth, 【Chemistry 8】 and R 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 Alkoxyl, OCF 3 , and / or C.F. 3 and benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each of which may be substituted with one to a maximum of the following substituents:
12. A pharmaceutical composition for treating a condition selected from a neurological disease, a lysosomal storage disease, and a hepatic disease in a subject in need of treatment for such a condition, comprising an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. 【Chemistry 9】 (I) (In the formula, R 1 is H, and R 2 is CH 3 , C.H. 2 F or CHF 2 or R 1 is CH 3 Or CH 2 F and R 2 is H, R 3 (CH 2 ) n R 4 n is 1 or 2; R 4 are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)methyl, ([1,1′-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which is selected from one or more of F, Cl, C. 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 Alkoxy and / or CF 3 or R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 Alkyl, cyclopropyl, propen-2-yl, OCH 3 , and / or C.F. 3 or phenylethyl, optionally substituted with one to a maximum of the following substituents: R 3 is one or more of F, C 1-6 Alkyl, OCH 3 , and / or C.F. 3 C, each of which may be substituted with one to a maximum number of substituents 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth, 【Chemistry 10】 and R 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 Alkoxyl, OCF 3 , and / or C.F. 3 and benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each of which may be substituted with one to a maximum of the following substituents:
13. The condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), addiction, anxiety, argyrophilic grain dementia, ataxia-telangiectasia (AT), attention-deficit / hyperactivity disorder (ADHD), autism spectrum disorder (ASD), Becker muscular dystrophy (BMD), bipolar disorder (BD), vascular murmurs, Sexual disorders, cerebellar ataxia, Charcot-Marie-Tooth disease (CMT), chronic fatigue syndrome, corticobasal degeneration (CBD), dementia pugilistica, dementia with Lewy bodies (DLB), Dejerine-Sottas disease, diffuse neurofibrillary tangles with calcifications, Down syndrome, Duchenne muscular dystrophy (DMD), epilepsy, essential tremor (ET), familial British dementia, familial Danish dementia, fibromyalgia, frontotemporal dementia linked to chromosome 17 and parkinsonism (FTDP-17), Friedreich's ataxia, Gerstmann-Sträussler-Scheinker disease, glaucoma, Guadeloupe parkinsonism, Guillain-Barré syndrome, Hallervorden-Spatz syndrome (neurodegenerative disease with cerebral iron accumulation type 1), insomnia, Lambert-Eaton myasthenic syndrome (LEMS), major depressive disorder ( MDD), migraine, mild cognitive impairment (MCI), multi-infarct dementia, multiple system atrophy (MSA), myasthenia gravis, myotonic dystrophy (including DM1 and DM2), neuronal ceroid lipofuscinosis (including types 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10), neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), oculopharyngeal muscular dystrophy, pain, pons pallidus Cerebral substantia nigra degeneration, Parkinson-Dementia Complex of Guam, Pick's disease (PiD), Postencephalitic Parkinsonism (PEP), Primary Lateral Sclerosis (PLS), Prion diseases (including Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD), fatal familial insomnia, and kuru), progressive transcortical gliosis, progressive supranuclear palsy (PSP), Richardson syndrome, schizophrenia, seizures, spinal cord injury, spinal muscular atrophy (SMA), spinocerebellar ataxia (including types 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, and 29), stroke, subacute sclerosing panencephalitis, fibrillary tangle-predominant dementia, tardive dyskinesia, Tourette's syndrome (TS), vascular dementia, Wilson's disease, Gaucher disease (including types I, II, and III), Niemann-Pick disease (including types A, B, and C), mucolipidoses (I, II, III, IV, VI, and and VII), cerebrotendinous xanthomatosis, Fabry disease, Farber disease, GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy (MLD), multiple sulfatase deficiency, Pompe disease, Sandhoff disease, Tay-Sachs disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), Alagille syndrome, alcohol-related liver disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, autoimmune cholangitis, benign liver tumors, biliary atresia, cirrhosis, The pharmaceutical composition according to claim 11 or 12, wherein the condition is Rigler-Najjar syndrome, drug-induced liver injury (DILI), galactosemia, Gilbert syndrome, hemochromatosis, hepatic encephalopathy, hepatocellular carcinoma (HCC), intrahepatic cholestasis of pregnancy (ICP), lysosomal acid lipase deficiency (LAL-D), liver cyst, liver cancer, neonatal jaundice, primary sclerosing cholangitis (PBC), primary biliary cholangitis (PSC), Reye's syndrome, glycogen storage disease type I, or viral hepatitis (including types A, B, C, D, and E).
14. 13. The pharmaceutical composition of claim 11 or 12, wherein the condition is Parkinson's disease.
15. 13. The pharmaceutical composition of claim 11 or 12, wherein the condition is Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.
16. 13. The pharmaceutical composition of claim 11 or 12, wherein the condition is Niemann-Pick disease type C.
17. 13. The pharmaceutical composition of claim 11 or 12, wherein the condition is Gaucher disease, mucolipidosis type IV, or Sandhoff disease.
18. 13. The pharmaceutical composition of claim 11 or 12, wherein the condition is non-alcoholic steatohepatitis (NASH).
19. The pharmaceutical composition of any one of claims 9 to 18, wherein the compound is any of the following or a pharma- ceutically acceptable salt thereof: (2R,3R,4R,5S)-1-(cyclohexylmethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4,4-dimethylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4,4-difluorocyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4,4-dichlorocyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4-ethylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((1s,4S)-4-vinylcyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-isopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-(tert-butyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((1s,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((trans)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((cis)-3-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-methoxycyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-methoxycyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4-(methoxymethyl)cyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1s,4S)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((1r,4R)-4-cyclopropylcyclohexyl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((4-phenylcyclohexyl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(spiro[2.5]octan-6-ylmethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(spiro[3.5]nonan-7-ylmethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(spiro[4.5]decan-8-ylmethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1,2,3,4-tetrahydronaphthalen-2-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((2,3-dihydro-1H-inden-2-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-cyclohexylethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(4,4-difluorocyclohexyl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-((1s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-((1r,4R)-4-(trifluoromethyl)cyclohexyl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((2-adamantan-1-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-cyclohexylpropyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-phenethylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-methylphenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-methoxyphenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-chlorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,3-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,4-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,5-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3,4-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-fluoro-4-methoxyphenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(5-chloro-2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-chloro-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(prop-1-en-2-yl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-isopropylphenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-3-isopropylphenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-cyclopropyl-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(trifluoromethyl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-(piperidin-1-yl)phenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2,6-difluoro-4-morpholinophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-(cyclopropylmethoxy)-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydrofuran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-phenoxyphenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-((tetrahydrofuran-3-yl)methoxy)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((R)-2-phenylpropyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((S)-2-phenylpropyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-([1,1'-biphenyl]-4-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-(thiophen-2-yl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-(thiophen-3-yl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-(pyridin-2-yl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(3-phenylpropyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-(2-fluorophenyl)propyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-(4-fluorophenyl)propyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(3-(thiophen-2-yl)propyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(3-(thiophen-3-yl)propyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((1-(2-fluorophenyl)piperidin-4-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((1-(3-fluorophenyl)piperidin-4-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((1-(4-fluorophenyl)piperidin-4-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((4-methyl-1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-((4-fluoro-1-phenylpiperidin-4-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(2-(1-phenylpiperidin-4-yl)ethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1-(pyridin-3-yl)piperidin-4-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-((1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol; 2-Methyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)propan-1-one; 2,2-Dimethyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)propan-1-one; 1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one; 3-Methyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one; 3,3-Dimethyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)butan-1-one; 2-Cyclopentyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)ethanone; Cyclopropyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; Cyclobutyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; Cyclopentyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; Cyclohexyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; ((1s,4S)-4-(tert-butyl)cyclohexyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; ((1r,4R)-4-(tert-butyl)cyclohexyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; (4-Methoxycyclohexyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; (4-(trifluoromethyl)cyclohexyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; Phenyl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; (3-(trifluoromethyl)phenyl)(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; 2-Phenyl-1-(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)ethanone; Thiophen-3-yl(4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidin-1-yl)methanone; N-cyclohexyl-4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidine-1-carboxamide; N-cyclohexyl-4-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)piperidine-1-carbothioamide; (2R,3R,4R,5S)-2-methyl-1-((1-((1S,2R)-2-(trifluoromethyl)cyclohexyl)azetidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-phenylpyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(o-tolyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(3-fluorophenyl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-methylpyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (4-(trifluoromethyl)phenyl)((R)-3-(((2R,3R,4R,5S)-3,4,5-trihydroxy-2-methylpiperidin-1-yl)methyl)pyrrolidin-1-yl)methanone; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(o-tolyl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-((4-isopropylcyclohexyl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-((4-(tert-butyl)cyclohexyl)methyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-phenethylpiperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-(2-fluorophenethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2,6-difluoro-4-isopropylphenethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2-(3,5-difluoro-[1,1'-biphenyl]-4-yl)ethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-((1-phenylpiperidin-4-yl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(fluoromethyl)-1-((1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)piperidine-3,4,5-triol; (2S,3R,4R,5S)-2-(difluoromethyl)-1-phenethylpiperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(2-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2S,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-(fluoromethyl)-1-(2-fluorophenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-(fluoromethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-fluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(3,4-dichlorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(3-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(4-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-(3,5-dimethylisoxazol-4-yl)-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,6-difluorophenethyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]oxazol-2-yl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(5-isopropylthiazol-2-yl)piperidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-methyl-1-(((R)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]thiazol-2-yl)piperidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol; (2R,3R,4R,5S)-1-(((R)-1-(benzo[d]thiazol-4-yl)piperidin-3-yl)methyl)-2-methylpiperidine-3,4,5-triol
20. The pharmaceutical composition of any one of claims 9 to 19, wherein the compound reduces the level of GBA2 enzyme activity in the subject.
21. The pharmaceutical composition according to any one of claims 9 to 20, wherein the subject is a human.
22. Use of an effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof in the preparation of a medicament. 【Chemistry 11】 (I) (In the formula, R 1 is H, and R 2 is CH 3 , C.H. 2 F or CHF 2 or R 1 is CH 3 Or CH 2 F and R 2 is H, R 3 (CH 2 ) n R 4 n is 1 or 2; R 4 are cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridin-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)methyl, ([1,1′-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each of which is selected from one or more of F, Cl, C. 1-6 Alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C 1-6 Alkoxy and / or CF 3 or R 3 is one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C 1-6 Alkyl, cyclopropyl, propen-2-yl, OCH 3 , and / or C.F. 3 or phenylethyl, optionally substituted with one to a maximum of the following substituents: R 3 is one or more of F, C 1-6 Alkyl, OCH 3 , and / or C.F. 3 C, each of which may be substituted with one to a maximum number of substituents 1-6 Alkyl, C 3-7 (1-formylpiperidin-4-yl)methyl substituted in the formyl group by one of cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl; or R 3 teeth, 【Chemistry 12】 and R 5 is one or more of F, Cl, C 1-6 Alkyl, C 1-6 Alkoxyl, OCF 3 , and / or C.F. 3 and benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each of which may be substituted with one to a maximum of the following substituents:
23. The use described in claim 22, wherein the medicament is for inhibiting GBA2, for reducing the level of GBA2 enzyme activity, for treating a condition regulated by GBA2, for treating a neurological disease, for treating a lysosomal storage disease, or for treating a liver disease.
Citation Information
Patent Citations
N-alkylated 1,6-bideoxyazaglucide compound, its synthesis method and uses
CN1951949A
Pharmaceutically active piperidine derivatives
JP2004517869A
Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010015816A2
N-(5-((ARYL or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
WO2015147639A1
